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Advisor: Richard G. Moran, Ph.D.
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Several classes of antimetabolites have been developed for the treatment of cancer, including
numerous inhibitors of nucleotide biosynthesis.

N-(phosphonacetyl)-L-aspartate (PALA) and

hydroxyurea (HU) are two antimetabolites that inhibit nucleotide biosynthesis; PALA inhibits de novo
pyrimidine

synthesis

and

HU

inhibits

the

conversion

of

ribonucleotide

diphosphates

to

deoxyribonucleotide diphosphates. Due to the similar mechanisms, it was thought that cancer cells would
respond similarly to HU and PALA treatment. However, studies in this dissertation revealed strikingly
different responses to either HU or PALA treatment in HCT116 cells. A cytoprotective S-phase arrest
was activated upon HU treatment while PALA treatment failed to activate the S-phase checkpoint,

resulting in p53-dependent apoptosis.

The checkpoint effector kinase, Chk1, was not significantly

phosphorylated during PALA treatment due to a failure to recruit ATR, the upstream kinase, to chromatin
sites. The post-translational modifications of p53, phosphorylation of serines 46 and 392, suggested that
PALA treatment promotes the accumulation of a transcriptionally active p53 while HU does not. ChIP
analysis showed that p53 bound to pro-apoptotic promoters, therefore activating p53-dependent apoptosis
during PALA treatment. To gain more insight into these differential cellular responses, we developed a
tandem-affinity purification (TAP) tagged p53 cell line in which a TAP tag was inserted into the Cterminus of the endogenous p53 genetic locus through homologous recombination. This technology
allows purification of p53 with its protein binding partners at endogenous expression levels. The tagged
p53 accumulated and bound to promoters in response to DNA damage similar to the untagged p53,
suggesting that the TAP tag did not interfere with the normal cellular functions of p53. Using mass
spectrometry, we can identify the different p53 protein binding partners in response to PALA or HU
treatment. We can also determine the variable pattern of post-translational modifications on different
drug-stabilized p53 and determine which modifications are responsible for promoting apoptosis versus
cytoprotective arrest. We can then exploit the identified proteins and post-translational modifications in
the development of new chemotherapeutic agents.

Chapter 1: Overview and Introduction

Development of Cancer Chemotherapy
The origin of cancer chemotherapy dates back to World War I, when soldiers whom were
exposed to mustard gases experienced dramatic symptoms, including significant bone marrow
depression (Krumbhaar and Krumbhaar, 1919). Many years after this initial observation the
biological action of mustard gases was investigated and it was found that proliferating cells are
selectively vulnerable to mustard gases (Gilman and Philips, 1946). An initial clinical trial with a
patient with non-Hodgkin lymphoma resulted in a dramatic anti-tumor effect with the use of
mustard gas (Gilman, 1963).

This experience with mustard gas was instrumental in the

development of the concept that drugs could be administered systemically to induce tumor
regression.
The next major advance in cancer chemotherapy was the development of antifolates.
Syndey Farber made the discovery that administering folic acid to children with acute
lymphoblastic leukemia (ALL) stimulated the proliferation of the cancer cells (Farber et al.,
1947).

This observation led to the development of aminopterin, a folic acid antagonist.

Aminopterin induced remission in children suffering from ALL, the first time that induction of a
temporary remission from cancer by drug was observed (Farber and Diamond, 1948). The
concept of targeted therapeutics designed to inhibit cellular division led to the beginning of
modern chemotherapy.
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Antimetabolite development began to focus on DNA and RNA precursors in the early
1950‟s with the development of the purine analog 6-mercaptopurine (Hitchings and Elion, 1954),
which was shown to have anti-cancer activity in mice with acute leukemia (Hitchings and Elion,
1954; Skipper et al., 1954). Pyrimidine analogs were also developed, the first being 5fluorouracil, which was shown to inhibit the growth of transplanted tumors in mice
(Heidelberger et al., 1957; Heidelberger et al., 1958).

5-FU is one of the oldest

chemotherapeutic agents that is still in use for the treatment of several human cancers including
colorectal, breast, stomach and pancreatic cancers, suggesting that this field of chemotherapy
drugs is still very much alive.

A novel inhibitor of de novo pyrimidine synthesis
N-(phosphonaceytl)-L-aspartate (PALA) was synthesized in the search for specific
inhibitors of nucleotide synthesis. Unlike 5-FU which requires cellular metabolism to convert it
to its active form, 5-fluorodeoxyuridine monophosphate (FdUMP), which inhibits thymidylate
synthase, PALA directly binds to and inhibits the second enzyme in de novo pyrimidine
synthesis, aspartate transcarbamylase (Fig 1-1) (Collins and Stark, 1971). This enzyme consists
of five subunits, two catalytic subunits and three regulatory subunits (Kantrowitz and Lipscomb,
1988).

The end product of pyrimidine synthesis, cytidine triphosphate, interacts with the

regulatory subunit decreasing the catalytic activity through negative feedback.

Adenosine

triphosphate also interacts with the regulatory subunit exerting the opposing effect, stimulating
the catalytic activity of the enzyme (Gerhart and Pardee, 1962; Pardee and Yates, 1956). These
feedback mechanisms maintain balanced levels of purines and pyrimidines in the cell for

1

Figure 1-1. De novo pyrimidine and purine nucleotide synthesis pathway. Inhibition of the
enzymes in this pathway by HU and PALA is indicated by red T-bars. AT, aspartate
transcarbamylase and RR, ribonucleotide reductase.
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nucleotide synthesis. The catalytic subunit binds L-aspartate and carbamyl-phosphate catalyzing
the formation of carbamyl-L-aspartate, the first precursor committed exclusively to the
biosynthesis of pyrimidines (Fig 1-2) (Reichard and Hanshoff, 1956).
Ultraviolet difference spectroscopy of the catalytic of subunit of E. coli aspartate
transcarbamylase with various substrates demonstrated that the enzyme binds the transition state
of the reaction more tightly than the substrates (Collins and Stark, 1969). The enzyme-carbamyl
phosphate complex binds the inhibitor succinate more tightly than the natural substrate Laspartate because it allows the conformational shift required for the reaction to occur without
colliding with the carbamyl-phosphate.

A model of the transition state of the aspartate

transcarbamylase reaction was created on the basis of these observations in which the enzyme
converts a portion of the electrostatic binding energy of L-aspartate into energy needed to force
the two substrates together (Fig 1-2) (Collins and Stark, 1969). Using this model, PALA was
synthesized as a transition state analog designed by combining structural features of the
substrates (carbamyl phosphate and L-aspartate) and of the product (carbamyl-L-aspartate) of the
aspartate transcarbamylase reaction (Fig 1-2) (Collins and Stark, 1971).
PALA simultaneously interacts with aspartate transcarbamylase at the binding sites for
carbamyl-phosphate and L-aspartate with a Ki of 0.162 M (Cohen and Schachman, 1986;
Collins and Stark, 1971). It is a competitive inhibitor with carbamyl-phosphate at the catalytic
subunit of the enzyme. Due to the ordered sequence of the reaction, carbamyl phosphate must
first be bound to aspartate transcarbamylase in order for L-aspartate to bind; an excess of Laspartate does not relieve PALA inhibition (Collins and Stark, 1971). Ultraviolet difference
spectroscopy of PALA and aspartate transcarbamylase produced the same spectrum as was
observed with carbamyl-phosphate and succinate, thus indicating that PALA inhibits the enzyme

3

Figure 1-2. The chemical reaction catalyzed by aspartate transcarbamylase.

4

in a conformation closely resembling that associated with the transition state (Collins and Stark,
1971).
Initial studies with PALA in mammalian cells showed that PALA blocked proliferation
and was cytotoxic. These effects were completely reversed with the addition of the nucleoside
uridine indicating that PALA specially inhibits de novo pyrimidine synthesis (Swyryd et al.,
1974). These initial studies suggested that PALA might have a clinical use in inhibiting cellular
proliferation. In mice bearing transplanted tumors, PALA treatment delayed tumor growth and
caused a partial regression. The most sensitive of these tumors was the Lewis lung carcinoma, a
tumor that is refractory to most antiproliferative agents (Johnson et al., 1976). Doses of PALA
which delayed the growth of Lewis lung carcinoma depleted the uracil and cytosine levels in the
tumor without having an effect on the pyrimidine pools of liver, spleen or lung, indicating the
specificity of PALA for rapidly proliferating cancer cells (Moyer and Handschumacher, 1979).
This specificity was strictly found for solid tumors, including Lewis lung carcinoma, B16
melanoma and colon carcinoma 26, while L1210 and P388 leukemia are virtually insensitive to
PALA (Johnson et al., 1976; Tsuboi et al., 1977). The spectrum of sensitivity of PALA to
several experimental cancers inversely correlated with the cellular content of aspartate
transcarbamylase.

Interestingly, slow growing solid tumors in culture had lower levels of

aspartate transcarbamylase than the fast growing leukemic cells (Johnson et al., 1978). This
implies that PALA would potentially be an important drug for the slow growing, often drug
refractory, solid human carcinomas.
The depletion of pyrimidine pools by PALA is considered to be essential for its antitumor
activity. After 5 hours of PALA treatment in L1210 cells, UTP and CTP pools decreased to 10%
of the control while ATP pools increased to 120% of control and GTP pools remain unchanged
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(Moyer et al., 1982). Subsequently, DNA synthesis was 80% inhibited as measured by pulse
labeling with 3H-guanosine. Mice bearing transplanted tumors from L1210 cells were treated
with PALA for 24 hours and showed similar trends and mirrored what was observed in Lewis
lung carcinoma (described above); there were large decreases in CTP and GTP pools to 30-40%
of the control, while ATP pools increased and GTP did not change (Moyer and
Handschumacher, 1979; Moyer et al., 1982).

Clinical Evaluations of PALA
As a result of the promising preclinical antitumor effects of PALA, Phase I clinical trials
were conducted in the late 1970‟s. In the first clinical trial, thirty-six patients were included, the
majority of whom had either colon or lung cancer (Erlichman et al., 1979). All patients received
a daily 15 minute intravenous infusion for a total of five consecutive days repeated every three
weeks due to the rapid renal excretion of PALA with a plasma elimination t1/2 of 4.6 hours.
Dose limiting skin and gastrointestinal toxicities were observed at the highest doses. Only one
patient with metastatic colon carcinoma showed signs of a clinical response to PALA after 8
months of treatment; in this patient, lung metastases decreased by more than 50% and several
liver lesions also decreased in size (Erlichman et al., 1979). Phase II trials conducted in patients
with colon, rectal or non-small cell lung cancer did not demonstrate significant antitumor
activity, preventing further trials with PALA as a single agent (Carroll et al., 1980; Casper et al.,
1980; Van Echo et al., 1980).
Experiments focusing on a possible combination therapy with PALA and other drugs
began shortly after the completion of Phase II trials with PALA alone. When thymidylate
synthetase is inhibited with 5-FU the conversion of dUMP to thymidylate is blocked causing an
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accumulation of dUMP, which may interfere with FdUMP further binding and inhibiting
thymidylate synthetase (Moran et al., 1979). If dUMP accumulation after 5-FU treatment could
be prevented with the use of PALA, the inhibition of FdUMP on thymidylate synthetase might
be enhanced. This hypothesis was tested; a 12-18 hour pretreatment with PALA followed by a
two hour incubation with 5-FU increased FdUMP levels more than two fold and decreased
dUMP levels three fold when compared to 5-FU alone in sarcoma cells (Liang et al., 1982).
Encouraging experimental data led to a Phase I clinical trial consisting of 16 patients who
received a 24-hour transfusion of PALA followed by an IV bolus of 5-FU daily for 5 days. This
cycle was repeated every 28 days.

Side effects included hair loss, diarrhea, skin rash,

myelosuppression and dose-limiting gut toxicity (Meshad et al., 1981). One patient who was
previously resistant to 5-FU responded to the combination treatment. A subsequent Phase II
clinical trial with 57 patients treated with the same regimen concluded that 14% of the patients
with the diseases responded to the drug combination. Of the responding patients, one with colon
cancer and two with breast cancer had previously failed to respond to 5-FU alone. Although the
outcome of the trials showed some promise, it was concluded that there was minimal advantage
of PALA treatment in combination with 5-FU (Weiss et al., 1982).
Other drug combinations attempted to augment the incorporation of FUTP into RNA
after administration of 5-FU, an alternative mechanism of the drug. When thymidine was
administered before 5-FU in humans, it was shown to increase the half life of 5-FU by more than
five-fold, an effect due to competition between 5-FU and thymidine at dihydropyrimidine
dehydrogenase, the rate limiting process for 5-FU elimination (Woodcock et al., 1980).
Subsequently, a Phase II clinical trial of the combination of FU, PALA, and thymidine was
conducted in 37 patients with colorectal cancer. The dosing regimen consisted of an IV infusion
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of PALA administered on day 1 followed by an IV infusion of thymidine 24 hours later on day 2
directly followed by an IV infusion of 5-FU.

Treatment was repeated every four weeks

(O'Connell et al., 1984). Although primary toxicities of leucopenia and ataxia were noted, there
was a 27% response rate to this combination therapy over the historical response rate of 17%
obtained after therapy with 5-FU alone. The dose-limiting leucopenia toxicity of the regimen
prevented increasing the dosage of 5-FU.
Clinical trials using PALA in combination with other drugs, including methotrexate, araC and dipyridamole, continued until the mid 1990‟s but none resulted in any appreciable
advantage in the treatment of cancer (Grem et al., 1988; Kemeny et al., 1989; Markman et al.,
1987).

Hydroxyurea, a classic inhibitor of deoxynucleotide synthesis
Hydroxyurea, HU, was first synthesized in Germany by Dresler and Stein in 1869 (Fig 13) (Dresler and Stein, 1869). One hundred years after its original synthesis, it was discovered
that HU inhibits ribonucleotide reductase, inhibiting the conversion of the four ribonucleotide
diphosphates into deoxyribonucleotide diphosphates, the rate limiting step in the biosynthesis of
DNA (Fig 1-1) (Krakoff et al., 1968). Mammalian and Escherichia coli ribonucleotide reductase
consists of four subunits, two pairs of dimers, R1 and R2 (Reichard and Ehrenberg, 1983). Two
active sites are formed at the interface between the R1 and R2 subunits. Each active site contains
two sulfhydryl groups from the R1 subunit and a stable tyrosyl radical and two nonheme irons
from the R2 subunit. Ribonucleotides bind to the R1 subunit and the sulfhydryl groups, tyrosyl
radicals and nonheme irons participate in the reduction of the ribonucleotides (Atkin et al., 1973;
Brown et al., 1969; Reichard, 1993). There are multiple levels of regulation of ribonucleotide
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Figure 1-3. The chemical structure of hydroxyurea
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reductase activity in place to obtain a balanced supply of dNTPS. Each R1 subunit contains two
regulatory sites; one binds ATP activating the enzyme or dATP inactivating it, while the other
binds effector molecules (ATP, dATP, dTTP or dGTP) altering the substrate specificity (Brown
and Reichard, 1969; Reichard, 1987). HU scavenges the tyrosyl free radical, reducing it to a
normal tyrosine residue, inhibiting the enzymatic activity of ribonucleotide reductase (Reichard
and Ehrenberg, 1983). The –NH-OH segment of HU was shown to be essential for inhibition as
detected in human recombinant holoenzyme-based in vitro assays (Shao et al., 2005). Using
electron paramagnetic resonance, the inhibitory reaction between HU and purified R2 subunit of
ribonucleotide reductase from mouse and E. coli was determined to be a one-electron transfer
from HU to the tyrosyl radical (Lassmann et al., 1992). Studies with ribonucleotide reductase
purified from Chinese hamster ovary cells demonstrated that HU noncompetitively inhibits the
enzyme with a Ki of 0.08 mM for CDP reduction, 0.13 mM for ADP reduction and 0.07 mM for
GDP reduction (Lewis and Wright, 1978). There are several other types of ribonucleotide
reductase inhibitors (Reviewed in (Shao et al., 2006)). Other inhibitors that also scavenge the
tyrosyl free radical include trimidox, nitric oxide and didox. Triapine chelates the iron groups in
the R2 subunit inhibiting the enzyme. The R1 subunit is also a drug target. Caracemide and
cisplatin inactivate the sulfhydryl groups and there are also several nucleoside analogs that bind
to and inhibit the R1 subunit including, gemcitabine, tezacitabine and cytarabine.
The mechanism of action of HU was first linked to decreased nucleotide pools in E. coli
(Neuhard, 1967). Further analysis in mouse embryonic fibroblast 3T6 cells showed that, after 10
minutes of HU treatment, dCTP, dGTP and dATP pools had decreased to 40% of the control
while dTTP pools increased to 150% of the control (Bianchi et al., 1986).

Thymidine

incorporation into DNA was inhibited after 10 minutes of HU treatment indicating that the
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decreases in nucleotide pools effectively inhibited DNA synthesis. When HU was given to
animals, a marked leukopenia and anemia resulted, suggesting that HU might be active against
leukemia (Rosenthal et al., 1928). Similar results were obtained when U251 human glioblastoma
cells were treated with HU; after 2 hours dATP, dGTP and dCTP pools decreased while dTTP
pools increased (Ostruszka and Shewach, 2003). Interestingly, after 24 hours of HU treatment,
dATP pools remain decreased to 1% of the control while dGTP were 40% of control and both
dCTP and dTTP pools increased to 175% of control.

In 1963, HU was found to be active in

L1210 mouse leukemia, doubling the life span of the treated mice (Stearns et al., 1963). This
study resulted in clinical trials on patients with various types of cancer.

Clinical Evaluations of HU
Initial clinical trials of HU began in the 1960s in patients with a range of tumors. Patients
with solid tumors experienced minimal improvement, while patients with chronic myelogenous
leukemia, CML, experienced a decrease in leukocyte counts, a decrease in splenomegaly and an
improvement in anemia (Fishbein et al., 1964; Thurman et al., 1963). A clinical trial focused on
patients with CML administered a dose of 50 mg/kg/day of HU in two divided doses until the
white blood cell count was 40% of the pretreated value, with the average length of treatment
being ten days. The treatment of HU effectively controlled all nine patients with CML, but
continuous therapy was required to maintain remission.

Four of the nine patients were

previously not responsive to busulfan, which led to the Federal Food and Drug Administration
approving HU for the use in CML refractory to busulfan therapy (Kennedy and Yarbro, 1966).
Subsequent trials proved that HU can be used as a primary therapy for CML and is currently
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used in crises to rapidly reduce the number of white blood cells (Kennedy, 1972; von Bubnoff
and Duyster, 2010).
When Chinese hamster ovary cells were treated with HU prior to or after IR treatment,
the effects of radiation were more cytotoxic when compared to IR alone as measured by colony
formation assays, implying HU is a radiosensitizing agent (Sinclair, 1968). Clinical trials began
in 1969 for the combination treatment of head and neck carcinoma with IR and HU. Twenty
patients received HU every third day with simultaneous treatment with IR over a period from
three to ten weeks, while another 20 patients received IR with a placebo.

Following the

treatment with irradiation, patients continued receiving HU for six to eight weeks. Excluding the
patients that underwent surgery, 6 out of the remaining 11 patients who received the combination
therapy went into complete remission, while 2 out of the 11 patients who received placebo went
into remission (Richards and Chambers, 1969). Several other clinical trials all demonstrated HU
in combination with IR treatment is more beneficial than IR treatment alone in the treatment of
head and neck carcinoma; HU and IR is clinically used to treat such cancers.
Other combination treatments with HU have been investigated but are currently not in
clinical use. HU in combination with ara-C has been shown to enhance the cellular metabolism
to the active metabolite ara-CTP (Robichaud and Fram, 1987). A phase II clinical trial in which
21 patients with non-Hodgkin‟s lymphoma treated with HU for six days followed by a three day
infusion of ara-C resulted in 43% treated patients going into partial or complete remission
(Schilsky et al., 1987). In combination with 5-FU, HU improved the survival of mice with
L1210 mouse leukemia compared with treatment of either alone, although a clinical trial on
patients with colon cancer showed only modest improvement (Lokich et al., 1975; Moran et al.,
1982).
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Currently, HU is also approved for the treatment of melanoma and inoperable, metastatic
or recurrent ovarian cancer. Interestingly, HU is also used to treat the painful crises of sickle cell
anemia, decreasing the need for blood transfusions (Platt et al., 1984). HU has been shown to
increase fetal hemoglobin in patients with sickle cell anemia. The increased level of fetal
hemoglobin limits sickle-cell hemoglobin polymerization, which is responsible for the painful
episodes (Rodgers, 1992).

Cellular events induced by nucleotide synthesis inhibitors
Although PALA is not clinically used due to limiting efficacy at maximal tolerated doses,
HU and PALA were shown to efficiently reduce tumor growth and in some cases even induce
remission. The cellular and molecular mechanisms responsible for growth arrest and kill by
nucleotide synthesis inhibitors have been investigated. This section will summarize what is
presently known and how this dissertation research adds to the current understanding of the
cytotoxicity induced by this class of antimetabolites.
Previous studies demonstrated that when fibroblasts with a functional p53 are treated
with PALA, a G1 arrest results whereas cells lacking p53 were able to progress into S-phase after
treatment, therefore indicating that p53 contributes to the G1 checkpoint (Yin et al., 1992). In
contrast to the p53-dependence of the PALA-induced cell cycle arrest, HU caused arrest in early
S-phase regardless of the p53 status, suggesting that fibroblasts respond differently to various
types of nucleotide synthesis inhibitors (Linke et al., 1996). This concept raised a question
which was central to this dissertation, namely, how do cancer cells molecularly respond to
treatment with different nucleotide synthesis inhibitors? The data suggesting p53 is not required
for the apparent S-phase checkpoint activated by inhibitors of dNTP synthesis also raises the
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question of whether p53 is involved in the cellular response to HU. The molecular events of the
G1 arrest induced by PALA treatment were shown to include p53 accumulation, p21 activation
and hypophosphorylation of Rb (Linke et al., 2003). Analysis of metaphase chromosomes
demonstrated that PALA treatment did not cause chromosomal aberrations and did not cause
DNA damage, yet p53 still accumulated. This led to the idea that p53 could detect levels of
nucleotide pools, activating the G1 checkpoint when pools become unbalanced (Linke et al.,
2003). If this is true, how does this explain the observation that regardless of p53 status, HU
treated cells arrest in early S-phase? Can p53 only detect nucleotide pools imbalances when
pyrimidine or purine synthesis is inhibited and not when all dNTP synthesis is inhibited? The
observed arrest induced by PALA treatment was not universal across all cell lines; out of five
fibroblast cell lines studied that had wild-type p53, two arrested in S-phase while the other three
underwent a functional G1 arrest (Agarwal et al., 1998). Those cells that arrested in S-phase
exhibited reduced BrdU staining and a three-fold decrease in thymidine incorporation, both
suggesting that the arrested cells are not efficiently synthesizing DNA. This was not observed in
fibroblasts lacking a functional p53; these cells continued synthesizing DNA and entered mitosis,
suggesting p53 is inhibiting DNA synthesis during an arrested S-phase (Taylor et al., 1999).
Synthesizing DNA in the presence of limited pyrimidine pools resulted in apoptosis as observed
from positive staining in the TUNEL assay, DNA laddering, cytochrome c release, and cleavage
of caspases 3 and 9 (Agarwal et al., 2006). Cells containing a wild-type p53 that arrested in Sphase appeared to be protected from cellular death by MIC-1 (macrophage inhibitory cytokine
1), a member of the TGF- superfamily. A follow-up study addressed how p53 is stabilized
during PALA treatment and suggested that when normal actively dividing fibroblasts are treated
with PALA, reversible DNA damage occurs activating ATR and subsequent phosphorylation of
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Chk1 and p53, leading to p53 accumulation, MIC-1 induction and S-phase arrest (Hastak et al.,
2008).

There appear to be contradictions on what checkpoint, if any, is activated in p53

competent cells treated with PALA. Some studies indicate p53 activates the G1 checkpoint
(Linke et al., 1996) while others suggest p53 activates the S-phase checkpoint (Agarwal et al.,
1998). The reason for this discrepancy is not clear. This dissertation work is aimed at clarifying
this field and understanding the molecular activities of p53 during PALA and HU treatment.
HU was identified to be an S-phase specific drug when Chinese hamster ovary cells
traversing through S-phase were killed during HU treatment while the non-S-phase cells
accumulate at the G1-S boundary of the cell cycle and survived (Sinclair, 1965). Flow cytometry
analysis of G1 synchronized Chinese hamster ovary cells released into HU for 10 hours
demonstrated that cells accumulated at the G1/S border, with approximately 10% cells entering
S-phase as compared to the control (Tobey and Crissman, 1972). After HU was removed, the
cells entered S-phase synchronously and divided 6 hours later. These experiments led to the use
of HU as a synchronization agent that has been a very valuable approach for generating an Sphase enriched cell population. In the early characterization of cell-cycle checkpoints, HU was
often used for this reason, as well as to understand how incomplete DNA replication is detected
by cellular mechanisms. A screen for Schizosaccharomyces pombe mutants that failed to arrest
in the cell-cycle, and therefore initiated mitosis when DNA replication was blocked by HU,
identified five genes named hus (hydroxyurea sensitive) 1-5, (Enoch et al., 1992). The analyses
of these mutants in yeast have led to the discovery of what is now known as the S-phase
checkpoint. It is now understood that HU activates the protective S-phase checkpoint and this
compound is commonly used as a tool to study this cell cycle checkpoint, raising the question of
whether other drugs that inhibit the synthesis of nucleotides will also activate this checkpoint,
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which has been almost exclusively characterized with the use of HU. The S-phase checkpoint is
described in detail in the introduction of the next chapter.

Focus of this Dissertation
Through the course of this dissertation, we investigated the cellular responses resulting
from treatment with nucleotide synthesis inhibitors. The precedent literature suggested that
PALA and HU treatment would activate the same molecular event within the cell, the protective
ATR activated S-phase arrest. As described in Chapter 2, we determined that when human colon
carcinoma HCT116 cells are treated with PALA or HU, both of which inhibited enzymes within
the nucleotide synthesis pathways and thus, slowing the progress of the replication fork, the
cancer cells respond differently at the molecular level. PALA is cytotoxic to the tumor cells,
while HU is cytoprotective, preventing further tumor cell growth with little immediate
cytotoxicity. The cellular signaling resulting from drug treatment is strikingly different, although
both drugs cause a slowed S-phase and robust accumulation of p53. The differences in the
molecular response of HCT116 cells to HU and PALA will be described. During these studies,
we have developed a HCT116 cell line in which one allele of the p53 gene has been
endogenously modified with a tandem affinity purification (TAP) tag. This cell line will be very
useful in investigating the role of p53 in the cellular events leading to the cytotoxic versus
cytoprotective response after treatment with these nucleotide synthesis inhibitors.

The

development and functional characterization of this cell line is detailed in Chapter 3. The
implications of the results presented here will be discussed in Chapter 4.
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Chapter 2: Differential Cellular Responses to Nucleotide Synthesis Inhibitors

Introduction
This Chapter will investigate the cellular and molecular responses of human colon cancer
cells to different inhibitors of nucleotide synthesis. The role of p53 in the signaling pathways
activated by the drugs as well as the possible mechanisms causing the observed responses will
also be addressed. The following introduces the tumor suppressor p53, its cellular functions and
the molecular events involved in the S-phase checkpoint.

The Tumor Suppressor p53
Structure of p53
p53 was discovered in 1979 as a phosphoprotein that co-immunoprecipitated with the
simian virus large T antigen after SV40 infection and traveled at 53,000 Daltons on sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Lane and Crawford, 1979).
p53 was originally hypothesized to have oncogenic properties after a temperature sensitive
mutant of the SV40 large T-antigen gene was found to cause p53 accumulation after a
temperature shift suggesting that p53 was involved in SV40-mediated transformation (Linzer et
al., 1979).

It is now know that the accumulation of p53 under these conditions reflects

inactivation of p53 function by binding to the large T-antigen. p53 was later identified as a
tumor suppressor after the loss of p53 was found to promote cancer. This was first reported in
1984 when p53 was inactivated by a retroviral insertion into a leukemia virus-transformed mouse
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cell line (Wolf and Rotter, 1984). p53 was cloned shortly afterwards, allowing experimental
manipulation of the gene and investigation of the consequences of such manipulations (Oren and
Levine, 1983).
The p53 gene is located on the short arm of human chromosome 17 (17p13) and consists
of 11 exons spanning approximately 20 kb of DNA (Benchimol et al., 1985; Lamb and
Crawford, 1986). The p53 protein consists of 393 amino acids organized into four functional
domains (Fig 2-1). The amino terminus of p53 contains two acidic transactivation domains,
amino acids 1-42 and 43-60 (Fields and Jang, 1990). Activation of gene transcription by p53 is
facilitated through the binding of several transcription factors at the amino terminus of p53
including the TATA binding protein (TBP) and TBP associated factors (TAFs) (Seto et al., 1992;
Thut et al., 1995). One nuclear export sequence is located within the transactivation domain at
amino acids 12-27 containing two serine residues (serine 15 and serine 20), which are known to
be phosphorylated after DNA damage, resulting in nuclear retention of p53 (Zhang and Xiong,
2001). Downstream from the transactivation domain there is a proline rich domain (amino acids
64-92), which contains five repeats of the src homology 3 (SH3) binding motif PXXP where P
represents proline and X any other amino acid (Walker and Levine, 1996). This region has been
linked to p53-mediated apoptosis and appears to be dispensable for transactivation and cell
growth arrest (Sakamuro et al., 1997). Amino acids 102-292 constitute the DNA binding domain
that enables p53 to bind to specific DNA sequences (Kern et al., 1991). This domain of p53
specifically binds to the consensus binding sequence (p53 response element, p53RE) within gene
promoters that contains two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′
separated by 10-13 bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry et al.,
1992). There are four conserved regions within the DNA binding domain responsible for
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Figure 2-1. Structure of the p53 protein. Map of the functional domains of the p53 protein,
the amino-acid residues spanning each domain are indicated below the domain name. p53
consists of two amino terminal acidic transactivation domains (TAD), a proline rich (PRD), a
central DNA binding domain (DBD), a flexible linker (L), a tetramerization domain (4DE)
followed by the C-terminal regulatory domain (CTRD). The nuclear export sequence (NES) and
nuclear localization signals (NLS) are also noted.
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contacting the minor and major grooves of the DNA within the p53-binding site. The DNA
binding domain contains the majority of mutation hotspots in human cancer; the most frequently
occurring mutations are in the peptides that make the closest contacts with DNA, explaining why
many p53 mutants are unable to bind DNA (Cho et al., 1994).
The C-terminal region of p53 contains a flexible linker connecting the central core
domain to the oligomerization domain, a 32 amino acid peptide required for the formation of
tetramers, which are the form of p53 that bind to DNA (Fig 2-1) (Kraiss et al., 1988). Each
monomer contains a turn, a -strand, a second turn and an -helix. Two monomers form a dimer
in which the -helix is anti-parallel to the -strand in the corresponding monomer. Tetramers
are formed by two dimers interacting through their -helices and therefore the p53 tetramer is
known as a dimer of dimers (Jeffrey et al., 1995). This tetramerization is required for efficient
p53 transactivation in vivo and subsequent growth suppression (Pietenpol et al., 1994). A
nuclear export sequence (NES) is located at amino acids 340-351 within the oligomerization
domain and tetramerization masks the NES resulting in nuclear retention of p53 (Stommel et al.,
1999). The extreme C-terminal basic domain, amino acids 363-393, was initially thought to be a
negative regulator of sequence specific binding (Hupp and Lane, 1995). It was shown that DNA
binding increased when the C-terminus of p53 was blocked with an antibody. This view has
recently changed with the discovery that p53 binds nonspecifically to DNA via the C-terminal
domain (CTD) and then slides along the DNA searching for p53 consensus sequences and
therefore the CTD promotes DNA binding (McKinney et al., 2004). There are three known
nuclear localization signals within p53, one located in the flexible linker sequence and the other
two within the CTD (Addison et al., 1990; Shaulsky et al., 1990).
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Accumulation and Stabilization of p53 by Post Translational Modifications
p53 is rapidly turned over in unstressed cells through its interaction with MDM2, a RING
family type E3 ligase, which promotes poly-ubiquitination and proteasomal degradation (Honda
et al., 1997).

After the genotoxic stress of IR-induced DNA damage, p53 protein levels

increased, apparently due to a post-translational mechanism.

(Kastan et al., 1991).

Post-

translational modifications (PTMs) of p53 play a role in p53 accumulation by uncoupling the
interaction between MDM2 and p53 thereby inhibiting its degradation (Shieh et al., 1997).
PTMs of p53 have been extensively investigated; modifications can include phosphorylation,
acetylation, methylation, ubiquitination, neddylation and/or sumoylation (Reviewed in (Toledo
and Wahl, 2006)). After different cellular stresses, PTMs are thought to act as a barcode
dictating the multiple cellular functions of p53. This section will address the phosphorylation
sites which were investigated in this dissertation work. Figure 2.2 summarizes the known PTMs
of p53.

Serine 15
The role of serine 15 phosphorylation in p53 biology appears to be complex.
Phosphorylation of serine 15 is not required for p53 accumulation or transcriptional activation
but enhances subsequent phosphorylations on neighboring residues (Fuchs et al., 1995).
Nonetheless, MDM2 interacts with amino acids 18-23 of p53, therefore phosphorylation at serine
15 undoubtedly promotes p53 accumulation by alleviating this inhibitory interaction (Shieh et
al., 1997). This residue lies within a nuclear export signal and when phosphorylated, results in
nuclear retention of p53 (Zhang and Xiong, 2001). After IR, phosphorylation of serine 15
increases the ability of p53 to recruit and associate with the transcriptional coactivator proteins
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Figure 2-2. Post-translational modifications of p53. A map of the post translational
modifications of p53 where each residue known to be modified is shown. Phosphorylation (P)
sites are indicated in yellow, acetylations (A) in pink, ubiquitination (U) in grey, methylation
(M) in as blue and neddylation (N) in green.
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CBP and p300 (Lambert et al., 1998). The acetyltransferase activity of p300 recognizes the Cterminal domain of p53 as a substrate and acetylates it at lysines 373 and 382 enhancing the
sequence-specificity of p53 binding to DNA (Gu and Roeder, 1997). Several kinases have been
linked to phosphorylation of serine 15, including ATM, ATR, AMPK, DNA-PK, ERK, p38 and
CDK9 (Reviewed in (Toledo and Wahl, 2006)). In this dissertation we are most interested in the
activity of ATR, which is known to phosphorylate serine 15 after IR and UV treatment and is
involved in the S-phase checkpoint (see below) (Tibbetts et al., 1999).

Serine 20
Phosphorylation of serine 20 also aids in p53 accumulation and nuclear retention in a
similar fashion as was described for serine 15 phosphorylation. It is also not required for p53
stabilization and activation (Chehab et al., 1999). Chk1, among several other kinases, have been
identified to be capable of phosphorylating serine 20 and, rather surprisingly, other than
facilitating p53 stabilization, no further functions of this modification have been elucidated
(Shieh et al., 2000).

Serine 37
Phosphorylation at serine 37 after UV and IR treatment appears to be important in p53dependent transcription. Mutating this serine residue to an alanine significantly impairs the
transactivating ability of p53 in a MDM2-luciferase reporter assay (Dohoney et al., 2004).
Sequence-specific DNA binding of p53 is also enhanced when serine 37 is phosphorylated. The
phosphorylation of serine 37 was shown to stimulate the interaction between p53 and the
transcriptional coactivators p300 and PCAF which acetylate p53 at lysine 382 and lysine 320,
respectively, activating the sequence-specific DNA-binding of p53 (Sakaguchi et al., 1998).
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Serine 46
Phosphorylation of serine 46 has been implicated in p53 dependent apoptosis. When this
residue is mutated to an alanine, cells have a reduced ability to induce apoptosis after UV
treatment when compared to cells containing wild-type p53. Phosphorylation of p53 at serine 46
by the kinase HIPK2 induces the p53 dependent transcription of p53AIP1, a protein known to
induce apoptosis by disrupting the mitochondrial membrane potential (D'Orazi et al., 2002; Oda
et al., 2000). One study demonstrated that the phosphorylation status of serine 46 dictates the
promoter selection of p53 (Mayo et al., 2005). Thus, during mild VP16-induced DNA damage,
serine 46 is not phosphorylated and p53 thereby activates the transcription of MDM2 inducing
the autoregulatory feedback loop. After extensive VP16-induced DNA damage, serine 46 is
phosphorylated and the transcriptional activation by p53 becomes more extensive, for instance,
PTEN transcription is activated favoring apoptosis (Mayo et al., 2005).

Serine 392
Thermodynamic studies demonstrated that phosphorylation of serine 392 significantly
enhanced tetramer stability, possibly through hydrogen bonds between the phosphorylated
residue and the N-terminal region of p53 (Sakaguchi et al., 1997).

DNA binding and

transcription activation of p53 is also enhanced after phosphorylation of serine 392 during UV
treatment (Hupp et al., 1992; Keller et al., 2001).

All of these effects of phosphorylation of

serine 392 appear to be important for the anti-proliferative activity of p53. When SV3T3 mouse
cells were transfected with p53 containing an alanine at this residue, this mutant p53 was unable
to suppress colony formation as compared to cells transfected with wild-type p53 (Milne et al.,
1992).
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Transcriptional Regulation by p53
As described in the previous section, p53 contains a DNA binding domain which
specifically binds the p53 response element (p53RE) within promoter regions of various genes,
and a C-terminal domain, which has been shown to non-specifically bind DNA and then
coordinate the linear search of DNA for p53REs (el-Deiry et al., 1992; McKinney et al., 2004).
This section will further explain how p53 regulates gene transcription from binding to the p53RE
to transcriptional elongation.

p53 Response Element
The p53RE contains two copies of the 10 bp motif 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′
separated by 10-13 bps where Pu is a purine base and Py is a pyrimidine base (el-Deiry et al.,
1992). However, p53 is somewhat promiscuous when binding to promoters. It has been shown
that tetrameric p53 is able to recognize, bind and transactivate genes from noncanonical
consensus sequences containing only half of the consensus sequence (Jordan et al., 2008).
Overall, the literature suggests that different p53RE have different binding affinities for p53. A
study using a red-white p53 reporter system in Saccharomyces cerevisiae measured the ability of
p53 to transactivate the reporter gene from various p53REs. It was shown that there is as much
as a 1000-fold difference between the transactivation from weaker p53RE to stronger p53RE.
The upstream p21 p53RE had the highest affinity, while the p53RE within the BAX promoter
had the weakest affinity (Inga et al., 2002). In vitro thermodynamic studies using fluorescence
anisotropy to measure the ability of purified p53 to bind to fluorescein labeled p53RE
oligonucleotides agreed with the yeast model, demonstrating that the upstream p21 p53RE has
greatest affinity and the promoters of other p53-regulated cell cycle genes, cyclin G, 14-3-3 and
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GADD45 also have higher binding affinity than the proapoptotic genes PUMA, BAX and
p53AIP (Weinberg et al., 2005).

Post translational modifications of p53 and p53 binding

partners also contribute to the diversity of the transcriptional response.

For instance, the

phosphorylation of serine 46 discussed above has been shown to selectively induce p53 to
transactivate the pro-apoptotic gene p53AIP (Oda et al., 2000). The ASPP family of proteins
bind to p53 and promote transactivation of the pro-apoptotic gene bax; this is not observed with
the cell cycle regulator p21 (Samuels-Lev et al., 2001). The control of genes transactivated by
p53 is an enormously complex process for which multiple p53 post translational modifications
and protein interactions with binding partners effect promoter selectivity.

Transcriptional Initiation
Prior to transcriptional initiation the chromatin around a promoter must be modified to
open the chromatin structure allowing the general transcriptional initiation machinery to bind to
the DNA. The role of p53 in this process is intricate. After p53 has bound to the p53RE, histone
acetyltransferases (HATs) are recruited to acetylate the histones surrounding p53 (Lill et al.,
1997). One such HAT that is recruited to promoters is p300/CBP following the interaction of
CBP with the transactivation domain of p53. Not only does p300/CBP acetylate the histones
bound to DNA in the vicinity of p53, it also acetylates the CTD of p53 increasing the activation
of gene transcription (Gu and Roeder, 1997). After the opening of chromatin, the general
transcription machinery can be recruited to form the preinitiation complex (PIC). p53 is known
to act with several components of the PIC to initiate transcription. The assembly of complexes
containing p53, TBP, the TBP associating factors (TAF), TAFII60, TAFII40 and TAFII250 can
activate transcription. When leucine 22 and tryptophan 23 residues of p53 that have been shown
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to interact with the transcriptional machinery, were mutated to alanine, the transcriptional
activity of the complex decreased (Thut et al., 1995).
The composition of the PIC required for transcriptional activation differs between gene
loci as well as the stress stimuli. Two examples of this are the p21 and FAS promoters. Prior to
any cellular stress, p53 is poised at the p21 promoter along with components of the PIC, TBP
and paused RNA polymerase (Espinosa et al., 2003). After UV stress, increased levels of p53
leads to completion of the transactivation process by p53-dependent recruitment of TAFII250 and
stimulating the phosphorylation of serine 2 in the C terminal domain (CTD) of the paused RNA
polymerase, converting it to the elongation form. In contrast, the FAS promoter does not contain
a TATA box. Prior to any stress, p53 is also poised but the levels of paused RNA polymerase
are significantly lower than found at the p21 promoter (Espinosa et al., 2003). After UV
treatment, p53 levels increase recruiting HATs and TAFII250 to the promoter. There is no net
loss of paused RNA polymerase at the promoter after the appearance of the elongation form,
suggesting that the initiation and elongation rates were similar. The difference between these
two promoters demonstrate that cell cycle genes, such as p21, are poised for rapid transcriptional
activation after cellular stress while the transcriptional activation of the proapoptotic gene Fas is
slower due to the lower levels of RNA polymerase poised at the promoter.

Once RNA

polymerase is loaded onto the promoter and transcription is initiated, transcription of FAS
remained constant because there is no net loss of paused RNA polymerase while p21
transcription fluctuates due to varying levels of loaded RNA polymerase (Espinosa et al., 2003).

Transcriptional Elongation
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After RNA polymerase is cleared from the promoter, its processivity is facilitated by
several elongation factors, some of which interact with p53. The phosphorylation of serine 392
of p53 is often implicated in complexes with elongation factors and, as described above, this
phosphorylation promotes oligomerization of p53 and subsequent DNA binding (Hupp et al.,
1992; Sakaguchi et al., 1997). During the discovery that casein kinase 2 (CK2) is able to
phosphorylate serine 392 of p53 after UV treatment, p53 was found to be in a complex with
subunits from the FACT (facilitated chromatin transcription) complex, a known elongation factor
(Keller et al., 2001). The human p-TEF (positive transcription elongation factor) is responsible
for converting the paused RNA polymerase to elongating polymerase through phosphorylation at
serine 2 in the carboxy terminal domain (Marshall et al., 1996). The Cdk9 kinase is the
component of p-TEF responsible for phosphorylating serine 5 of the CTD of RNA polymerase
(Ramanathan et al., 2001; Zhu et al., 1997).

Cdk9 is known to interact with p53 and

phosphorylate it at serine 392; the stabilized p53 then promotes transcription of Cdk9, thereby
promoting transcriptional elongation in a feed-forward system (Claudio et al., 2006).

Transcriptional Repression
A less studied role of p53 is transcriptional repression.

After binding to certain

promoters, p53 interacts with mSin3a recruiting HDAC1 (histone deactetylase), which removes
the acetyl moieties from the chromatin causing the chromatin to close around the promoter,
repressing transcription (Murphy et al., 1999). The physical binding of p53 to promoters may
occlude the binding of other transcription factors required for transcriptional activation. This is
observed during hypoxic stress: under these conditions p53 binds to the alpha-fetoprotein
promoter, inhibiting the binding of the transcriptional activator HNF3 and, hence, repressing
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transcription (Lee et al., 1999). Although the mechanism of transcriptional repression is not
understood yet, p53 binds to the Rad51 promoter repressing transcription of this protein critical
to homologous recombination during DNA damage (Arias-Lopez et al., 2006). As will be
discussed below, this repression is of interest for this dissertation.

p53 Dependent Apoptosis
It was first shown that p53 was involved in the apoptosis pathway when tumor cells null
for p53 underwent spontaneous cell death after the introduction of a wild-type p53 by
transfection (Yonish-Rouach et al., 1991). Bax was found to be a direct transcriptional target of
p53 and the first example of a proapoptotic gene directly regulated by p53 (Miyashita and Reed,
1995). The restoration of p53 in murine leukemia cells caused an increase of Bax mRNA and
protein levels (Selvakumaran et al., 1994). Since then several other pro-apoptotic genes have
been identified that are regulated by p53, including p53AIP1, APAF1, Caspases 1, 6 and 10,
FAS, PUMA, DR4 and DR5. Upon binding to the promoters of these genes, p53 activates
transcription, thereby promoting the downstream components of the apoptosis cascade
(Reviewed in (Riley et al., 2008)).
Evidence for a role of p53 in the regulation of apoptosis that was independent of
transcription was first hypothesized after transcriptionally inactive mutants of p53 were found to
induce cell death (Haupt et al., 1995). After DNA damage, p53 translocates to the surface of
mitochondria prior to the release of cytochrome c from the mitochondrial intramembrane space
and caspase 3 cleavage in the cytosol, suggesting that p53 has a direct role in the intrinsic
pathway of apoptotic signaling (Marchenko et al., 2000). Once at mitochondria, p53 specifically
binds to the Bcl-2 family proteins. The interaction between p53 and Bak releases the anti-
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apoptotic inhibitory protein Mcl-1 from complexes with Bak, allowing oligomerization of Bak
and subsequent cytochrome c release from the mitochondria (Leu et al., 2004). Similarly, p53
also interacts with Bax releasing the anti-apoptotic protein Bcl-xl from Bax-Bcl-xl complexes
and promoting Bax oligomerization and cytochrome c release (Chipuk et al., 2004). The antiapoptotic proteins Bcl-xl and Bcl-2 are also modulated by p53 within mitochondria. The DNA
binding domain of p53 binds to Bcl-xl and Bcl-2 inhibiting their anti-apoptotic activity, again
facilitating the release of the central mediator of the intrinsic pathway, causing cytochrome c
release (Mihara et al., 2003; Tomita et al., 2006).

p53 senses cellular stresses induced by chemotherapeutic agents
Due to the several roles of p53 in response to chemotherapeutic agents, the question arose
as to what cellular changes p53 could detect after such treatments. Most cellular responses have
been studied in response to IR or UV; much less is known about the p53 response to nucleotide
pool deprivations. Ionizing radiation, camptothecin and bleomycin directly and rapidly induce
DNA strand breaks, promoting the accumulation of significant levels of p53 within one hour of
treatment. Cells electroporated with DNaseI or the restriction enzyme AluI also accumulated
p53, leading to the conclusion that DNA strand breaks initiate p53-dependent signaling pathways
(Nelson and Kastan, 1994). Further analyses showed that only one single DNA strand break per
cell was sufficient to induce a p53 dependent growth arrest (Huang et al., 1996).
The concept that p53 could sense nucleotide levels and then would become stabilized was
first proposed by Linke et al. (Linke et al., 1996). In their experiment, treating WS1 embryonic
skin cells containing a wild-type p53 with antimetabolites inhibiting different parts of de novo
pyrimidine and purine synthesis resulted in a G1 cell cycle arrest. In cells null for p53 the effect

30

did not occur and cells slipped into early S-phase and then arrested.

Interestingly, dNTP

biosynthesis inhibitors caused arrest in early S-phase regardless of p53 status. This dissertation
addresses the question of what role, if any, does p53 have in the S-phase checkpoint. In the
studies of Linke and colleagues, the G1 arrest was reversed upon the addition of the limiting
nucleotides and no apparent DNA damage was detected by metaphase chromosome analysis,
therefore, the p53 dependent arrest was not caused by DNA damage. This was a central paper to
this dissertation in that it demonstrated the accumulation of p53 in response to deoxynucleotide
deficiencies promoted cell cycle arrest. This unique p53 dependent cell cycle arrest caused by
nucleotide depletion is of substantial importance because if cells are allowed to divide in the
presence of limiting nucleotides, chromosome breakages could arise due to incomplete DNA
replication, putting the genome at risk of becoming highly unstable and tumorigenic (Linke et
al., 1996).

p53 mutations and cancer
In approximately 50% of human cancers p53 is mutated, making it the most commonly
mutated gene in human malignancies (Vogelstein, 1990). As described above, p53 is capable of
triggering apoptosis or growth arrest, both of which aid in maintaining genome stability. Due to
the involvement of p53 in these pathways protecting the cell from tumorigenesis, extensive
research has been done to further understand mutant p53 and its cellular effects. The majority of
p53 mutations in human cancers disrupt the ability of p53 to bind to DNA (Kato et al., 2003). In
a study including 280 tumors containing p53 with somatic base substitution mutations, 98% of
the mutations fell within a 600 base pair region of p53 encompassing exons 5 through 8 (amino
acids 110-307). Out of the 280 analyzed, 227 were from solid tumors. Colon, esophagus, breast
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and non-small cell lung cancer containing the most mutations (Hollstein et al., 1991).

In

heterozygous cells, a mutant p53 allele can alter the function of the wild-type p53 allele, have a
dominant negative effect on wild-type p53, or results in gaining new oncogenic properties
independent of the wild-type p53 (Baker et al., 1989). Analysis of tumors containing allelic
deletions in the short arm of chromosome 17, specifically the region encoding p53, showed that
the remaining allele contained point mutations indicative of loss of heterozygosity (Baker et al.,
1989).

Upon co-translation of mutant p53 and wild-type p53, mutant p53 was found to

oligomerize with wild-type p53, driving it to a mutant phenotype characteristic of a dominant
negative effect (Milner and Medcalf, 1991). Transfection of mutant p53 into p53 null tumors
resulted in lethal tumors, demonstrating that mutant p53 may gain oncogenic properties (Wolf et
al., 1984).

DNA Replication
DNA replication in eukaryotic cells is an intricate process; this section will serve as a
brief overview of the main proteins that are present at replication forks during an unperturbed Sphase (See Figure 2-3). Replication is initiated at multiple origins along the DNA in mammalian
cells as was shown by audioradiography of chromosomal DNA fibers isolated from Chinese
hamster fibroblasts (Huberman and Riggs, 1966). The origins are marked by the formation of
pre-replicative complexes (preRC) in G1. The origin recognition complex (ORC) binds to the
preRC as well as the additional replication factors, including Cdc6, Cdt1 and minichromosome
maintenance helicase complex (MCM2-7) (Bell and Stillman, 1992).

Initiation of DNA

synthesis is regulated by two protein kinases: S-phase specific cyclin-dependent kinase (S-CDK)
and Cdc7-Dbf4 (DDK). The exact mechanisms of how these kinases enhance the initiation of
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Figure 2-3. Model of eukaryotic DNA synthesis. Modifications of the origin of replication
complex (ORC) by S-CDK and DDK initiates DNA replication. MCM helicase unwinds the
DNA allowing access to replisome proteins. Replication protein A (RPA) binds to and stabilizes
the ssDNA during DNA synthesis. The replication clamp PCNA is loaded onto the complex by
RCF forming a complex with pol. The leading strand is indicated by the continuous arrow
while the lagging strand is indicated by the discontinuous arrows.
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replication in eukaryotes remain to be elucidated but it is thought that they are involved in
promoting the assembly of the active helicase CMG complex, consisting of Cdc45, MCM and
GINS (Moyer et al., 2006). DDK was shown to phosphorylate the N-terminus of MCM4 in
Saccharomyces cerevisiae (Sheu and Stillman, 2006). A mutant of MCM4 with the N-terminus
removed was able to progress through S-phase in the absence of DDK indicating that the
phosphorylation of MCM4 by DDK relieves an inhibitory activity (Sheu and Stillman, 2010).
During S-phase, fired origins consist of two replication forks moving away from the origin in
opposing directions as the DNA is unwound by the MCM helicase allowing access to replisome
proteins including DNA polymerase- primase, replicative DNA polymerase- and polymeraseewhich elongate the primers, and Cdc45 (Aparicio et al., 1997; Aparicio et al., 1999). As the
DNA is unwound by MCM2-7 helicase and DNA is replicated by the components of the
replisome, the replication protein A (RPA) binds and stabilizes the ssDNA as was observed by
colocalization of the RPA subunits with newly synthesized DNA (Dimitrova and Gilbert, 2000).

The S-phase Checkpoint
The accurate completion of DNA replication is of utmost importance for maintaining
genomic stability and preventing carcinogenesis. Although DNA damage can occur throughout
all phases of the cell cycle, cells are most susceptible to genotoxic stress during S-phase and Mphase. The S-phase checkpoint is in place to inhibit progress through S-phase and the subsequent
mitosis when the conditions for accurate DNA replication have not been met. This checkpoint
would then allow time for DNA repair, recombination or apoptosis (Kastan and Bartek, 2004;
Zhou and Bartek, 2004).
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Function of the S-phase Checkpoint
The function of the S-phase checkpoint is to maintain functional replication forks in
times of replication perturbations, to ensure successful chromosome replication. This was shown
in yeast when kinase dead mutants of the yeast homolog to mammalian ATR (Ataxia
telangiectasia mutated and Rad3 Related), mec1, had a significant increase in the rate of
replication fork breakdown during HU treatment which led to replication fork collapse and
generation of lethal double strand breaks. When the yeast effector kinase homologous to human
checkpoint effector kinase, Chk1, was put under the control of a Gal promoter allowing
induction by galactose, non-induced cells were unable to recover from HU treatment, resulting in
a decrease in viability. This suggests that DNA damage is caused by stalled replication forks
which are not stabilized through Chk1 signaling and this is catastrophic for the cell (Tercero et
al., 2003). The RecQ helicase BLM and the homologous recombination protein Rad51 are
proteins within the ATR-Chk1 signaling cascade that have both been implicated in the restart of
stalled replication forks after the removal of HU (Davies et al., 2007; Petermann et al., 2010).
The S-phase checkpoint regulates BLM and Rad51 so that stalled replication forks are not
restarted in the presence of replicative stress, which could possibly lead to replication fork
collapse (see below) and subsequent catastrophic DNA damage.
In order to explain the mechanisms in which the S-phase checkpoint stabilizes stalled
replication forks, it is necessary to discuss the remodeling of the stalled replication fork
structures prior to the restart of S-phase events, which remain largely speculative (summarized in
Fig 2-4). One central model is that when a replication fork encounters a lesion in the template
DNA, the leading and lagging strand unwind and pair with the newly replicated sister strand,

35

Single strand
Interruption

1

A

2

Rad51

3

Lesion

B

G

BLM

F

E

D

C

Rad51

BLM

4

BLM

Figure 2-4. Pathways for restart of stalled replication forks. Consequences of a collision of a
replication fork with a single strand interruption (1) or a lesion (A) are shown. After collision
with a lesion, the stalled replication fork can become stabilized by pairing with the newly
synthesized strand forming a Holliday Junction (AB) Pathway F, E, D and C all show
possible outcomes of the Holliday junction. Pathway E resolves the lesion through Rad51mediated homologous recombination and BLM-mediated resolution of double Holliday
junctions. The other pathways stabilize the stalled replication without repair of the lesion and F
results in a double strand break due to collapse of the replication fork by DNA junctionprocessing enzymes (G). Collision with a single strand interruption also results in double strand
break due to replication fork collapse. Rad51-mediated homologous recombination and
resolution of the Holliday junction by BLM repairs the damage allowing replication restart.
Leading strand is represented in blue and lagging strand is represented in red. DNA junctionprocessing enzymes are represented by black triangles and exonucleases are represented as a .
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creating a four-stranded DNA structure, termed fork regression. This resembles a Holliday
junction commonly found during recombination (AB). The fork regression can be reversed by
branch migration (ABC), or can undergo exonuclease degradation (ABD) and the
replication fork will be restored to its original conformation. The newly paired sister strand can
also be used as a substrate for homologous recombination to repair the lesion (ABE). If a
replication fork encounters a single strand interruption in the template DNA, the fork collapses,
generating a double strand break (12). A similar structure results if the regressed fork is
resolved by DNA junction-processing enzymes which ultimately breaks the fork into a double
strand break ((ABFG)). These structures can be repaired by strand invasion of the
double-strand end into the corresponding sister chromatid followed by homologous
recombination (234).

(Reviewed in (Atkinson and McGlynn, 2009; Budzowska and

Kanaar, 2009; Petermann and Helleday, 2010; Weinert et al., 2009)). The proteins involved in
the current model of replication fork recovery are part of the S-phase checkpoint and will be
discussed in detail below. The phosphorylation and recruitment of the majority of the proteins
during the S-phase checkpoint efficiently recruit and modulate the functions of BLM and Rad51
at the stalled replication fork.

Activation of the S-phase Checkpoint
The initial groundbreaking research that defined the S-phase checkpoint was done in the
yeast Saccharomyces cerevisiae in the presence of hydroxyurea (HU). Human homologs of the
checkpoint proteins discovered in yeast have since been identified and the area of research has
expanded into mammalian cells. HU is an important tool in studying the S-phase checkpoint in
both mammalian and yeast systems.

ATM (Ataxia telangiectasia mutated) and ATR are
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members of the phosphatidylinositol kinase-related protein family and are essential for cell cycle
checkpoint signaling in the presence of DNA damage or of stalled replication forks (Reviewed in
Durocher and Jackson, 2001; Shiloh, 2001). The overexpression of kinase-inactive ATR in
fibroblasts from Ataxia Telangiectasia (AT) patients sensitizes cells to UV, IR and HU treatment
and abolishes the activation of the checkpoint, thus implicating ATR in the S-phase checkpoint
(Cliby et al., 1998; Wright et al., 1998). ATR exists in a complex with ATR-interacting protein
(ATRIP) and colocalizes to nuclei after UV and HU treatment. ATRIP and ATR are mutually
dependent on each other in human cells, that is, if one is deleted or knocked-down, expression of
the other diminishes and cell cycle checkpoint control is lost (Cortez et al., 2001).
Electron microscopy analyses of the DNA structures accumulating during HU treatment
in S. cerevisiae demonstrated that cells exhibit normal replication forks when treated with HU
but sustain very slow DNA synthesis at a rate of 50 base pairs per a minute. Interestingly, there
is an increase of about 100 nucleotides of single stranded DNA (ssDNA) present at replication
forks during HU, a substantially larger ssDNA fragment when compared to those in untreated
cells, a fact that has led to the suggestion that the increase of ssDNA may activate the S-phase
checkpoint (Sogo et al., 2002). Replication protein A (RPA) has been known to coat ssDNA
within mammalian and yeast cells; when RPA was mutated in S. cerevisiae, the S-phase cell
cycle checkpoint was defective allowing progression through S-phase into G2 after UV treatment
(Longhese et al., 1996; Wold, 1997). Recruitment of ATR and ATRIP to nuclear foci depends
on the presence of RPA which stimulates ATRIP binding to ssDNA (Zou and Elledge, 2003). A
substrate of ATR is Chk1, which is phosphorylated in response to UV and HU treatment (Liu et
al., 2000). Interestingly, this phosphorylation was shown to be dependent on the presence of
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RPA lending evidence to the concept that RPA-coated ssDNA is the molecular trigger initiating
the S-phase checkpoint (Zou and Elledge, 2003).

S-phase Checkpoint Signaling
After nuclear localization of ATR and ATRIP and binding of this complex to RPAcoated ssDNA, ATR phosphorylates a series of proteins and recruits them to the stalled
replication fork in mammalian cells (Fig 2-5). Activation of the checkpoint is thought to require
the recruitment of the Rad9-Rad1-Hus1 (9-1-1) complex and the Rad17-replication factor C
complex (RCF)-dependent loading of Rad9 onto the chromatin (Weiss et al., 2003; Zou et al.,
2002). The 9-1-1 complex is a PCNA-related complex that is thought to sense DNA damage and
the recruitment of the 9-1-1 complex to sites of DNA damage is independent of ATR, suggesting
that it may enable ATR to recognize the damaged DNA (Volkmer and Karnitz, 1999; Zou et al.,
2002). TopBP1 (Topoisomerase II beta binding protein 1) is recruited to stalled replication forks
by Rad9 (Greer et al., 2003). ATR kinase activity is activated through the interaction of TopBP1
and ATRIP and the direct contact between TopBP1 and the PRD (PIKK phosphoinositide 3kinase related kinase Regulatory Domain) of ATR (Mordes et al., 2008).

ATRIP further

stimulates the kinase activity of ATR resulting in autophosphorylation of ATR, phosphorylation
of ATRIP and the RPA32 subunit (Cortez et al., 2001; Unsal-Kacmaz and Sancar, 2004). Rad9
and Rad17 are also phosphorylated by ATR (Furuya et al., 2004; Zou et al., 2002). The abovementioned series of localization and phosphorylation events are the current standing model of
ATR activation.
Like ATR, the main S-phase checkpoint effector kinase Chk1 is an essential gene and
deletion of either results in an embryonic lethal phenotype in mice, indicating an irreplaceable
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Figure 2-5. The signaling involved in the S-phase checkpoint. Long lengths of RPA-coated
single-stranded DNA activates the checkpoint signaling. RPA-dependent binding of ATRIP to
DNA and interaction with TopBP1 activates ATR kinase activity. ATR phosphorylates several
key checkpoint proteins, including Chk1 which is dependent on the presence of Claspin.
Phosphorylated and activated Chk1 is the central kinase in the S-phase checkpoint.
Phosphorylation of signaling proteins by Chk1 leads to recruitment of these proteins to the
stalled replication fork and subsequent replication fork stabilization.
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role for both kinases in development (Brown and Baltimore, 2000; Takai et al., 2000). Activated
ATR phosphorylates Chk1 at serines 317 and 345 in response to HU and subsequently activates
Chk1 as detected by the phosphorylation of the known Chk1 substrate Cdc25C (Zhao and
Piwnica-Worms, 2001). Phosphorylation of serine 345 is required for Chk1 activation and is
dependent on phosphorylation of serine 317 (Lopez-Girona et al., 2001; Walker et al., 2009).
Phosphorylation of Chk1 also requires other nuclear proteins, for instance through the interaction
of Tipin and RPA, Timeless binds to Tipin recruiting the adaptor molecule Claspin which then
facilitates the phosphorylation of Chk1 by ATR (Kemp et al., 2010). Claspin is required for
ATR-dependent Chk1 phosphorylation (Chini and Chen, 2003; Kumagai and Dunphy, 2000).
Activated Chk1 phosphorylates downstream proteins including p53 at serine 20, BRCA2, Rad51,
Cdc25C, 53BP1 and FANCE (Bahassi et al., 2008; Sanchez et al., 1997; Shieh et al., 2000;
Sorensen et al., 2005; Tripathi et al., 2008; Wang et al., 2007). The implications of these
phosphorylations will be discussed in the next section.
Chk1 is not the only substrate of ATR in the S-phase checkpoint. ATR phosphorylates
BLM at threonines 99 and 122 during HU-induced stalled replication forks (Davies et al., 2004).
Mutant forms of BLM transfected into BLM -/- cells in which these residues have been changed
to alanine fail to recover from the replication blockade following HU and arrest in G 2/M,
demonstrating that the phosphorylation of BLM by ATR is required for proper recovery from Sphase arrest.

BRCA1 is phosphorylated by ATR during HU or UV treatment and this

phosphorylation is independent of ATM (Chen, 2000; Gatei et al., 2001). Serine 15 of p53 is
phosphorylated by ATR after IR, UV or HU treatment.

Kinase inactive mutants of ATR

interfere with phosphorylation of p53 in late S-phase during IR treatment and completely
suppress p53 phosphorylation after UV treatment, supporting the obligatory role of ATR in the
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S-phase checkpoint (Tibbetts et al., 1999). During replication-mediated double strand DNA
breaks induced by camptothecin, ATR phosphorylates H2AX (H2AX) an event required to
recruit DNA repair proteins Mre11, Rad50 and NSB1 (MRN) (Furuta et al., 2003).

It is now

known that although ATM and ATR have overlapping targets, ATM is the kinase involved in the
G1/S and G2/M checkpoint signaling after IR treatment while ATR is activated after UV
treatment and is involved in the S-phase checkpoint (Reviewed in (Cimprich and Cortez, 2008;
Kastan and Bartek, 2004)).

BLM and p53
Plasmid based assays in E. coli show that when a replication fork encounters a lesion and
stalls, the leading and lagging strand of DNA replication uncouple and DNA synthesis continues
on the lagging strand, generating ssDNA gaps which may activate homologous recombination
(Pages and Fuchs, 2003). In 1990, prior to the identification of BLM in mammalian cells, RecQ
was characterized as a 3′ to 5′ DNA helicase in E. coli. It was shown to initiate homologous
recombination and unwind a broad range of DNA substrates representative of structures
generated during recombination or replication including 3′ and 5′ ssDNA overhangs, 4-way
junctions and 3-way junctions, thus implicating RecQ in repair of stalled replication forks
(Harmon and Kowalczykowski, 1998; Umezu et al., 1990). The mammalian homolog of RecQ
is BLM, which is the gene product mutated in and causative of Bloom‟s syndrome. Cells from
Bloom Syndrome patients exhibit chromosomal instability due to an elevated rate of sisterchromatid exchange suggesting that a protein involved in recombination is mutated in these cells
(Chaganti et al., 1974).

BLM selectively recognizes Holliday junctions, a four-way DNA

junction, and promotes the branch migration of these junctions, thereby preventing homologous
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recombination of the regressed fork from occurring (Karow et al., 2000).

It has been

hypothesized that, when replication forks stall, Holliday junctions may arise and resolution of
these structures would result in a double-strand DNA break that is repaired by homologous
recombination returning the replication fork to its original structure (Sharples et al., 1999). p53
has been shown to bind to BLM modulating the associated helicase activity (Yang et al., 2002).
By inhibiting the resolution of the Holliday junctions at stalled replication forks, modulation of
BLM by p53 prevents the collapse of the replication fork, further DNA damage, and the threat of
tumorigenesis.

Interestingly, BLM is required for efficient localization of p53 to stalled

replication forks during HU (Sengupta et al., 2003). Once recruited, p53 is found to bind to and
inhibit the pro-recombinogenic protein Rad51 as well as inhibiting BLM helicase activity. This
inhibition is thought to stabilize stalled replication forks by inhibiting unnecessary
recombination. It is also thought that the presence of p53 recruits other proteins to the stalled
replication fork, so that the necessary homologous recombination can occur after the replication
stress has been resolved to reinitiate the replication fork, allowing for an accurate S-phase to
continue (Sengupta et al., 2003).

Rad51
The double strand breaks resulting from replication fork collapse and resolution of the
fork regression are a lethal form of DNA damage that can be repaired error-free by homologous
recombination using the undamaged sister chromatid as a template (Johnson and Jasin, 2000; van
Gent et al., 2001). Homologous recombination is tightly regulated in the S-phase checkpoint to
prevent further DNA damage during replicative stress. Expression of Rad51 is induced in late Sphase and G2 and binds to single stranded DNA during the initial steps of homologous
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recombination (Benson et al., 1994; Flygare et al., 1996). Rad51 possesses DNA-dependent
ATPase activity which catalyzes the homologous pairing and strand exchange of the sister
chromatid during homologous recombination leading to the formation of a Holliday junction as a
DNA intermediate (Baumann et al., 1996). When Chk1 was inhibited with either UCN-01 or
caffeine during HU treatment, an increase in double strand breaks and Rad51 nuclear DNA foci
formation resulted, suggesting that Chk1 modulates Rad51 function (Sorensen et al., 2005).
Chk1 phosphorylates Rad51 at threonine 309 during HU treatment.

When this residue is

mutated to alanine, cells are more sensitive to HU treatment, indicating that phosphorylation of
Rad51 by Chk1 is required for survival after replication stress. Importantly, less than 1% of
Chk1 was found to immunoprecipitate with Rad51 during HU treatment in cells containing a
Chk1 mutant where serines 317 and 345 are mutated, preventing ATR phosphorylation and
activation of Chk1. That is, if Chk1 phosphorylation is blocked it cannot form a complex with
Rad51. Therefore the ATR dependent activation of Chk1 and subsequent nuclear localization
and phosphorylation of Rad51 is important for survival after replication–stress induced DNA
damage (Sorensen et al., 2005).
When p53 was transfected into normal human fibroblast cells along with wild-type
Rad51, the homologous recombination frequency decreased compared to cells containing only
Rad51, suggesting that the direct binding of p53 to Rad51 inhibits the homologous
recombination activity of Rad51 (Linke et al., 2003; Sturzbecher et al., 1996). Rad51 and p53
both co-localize to stalled replication forks induced by HU and their interaction inhibits the
Rad51-driven homologous recombination at the stalled replication fork, maintaining genome
integrity by stabilizing the stalled replication fork (Sengupta et al., 2003; Yoon et al., 2004).
During VP16-induced DNA damage, p53 binds to the Rad51 promoter, repressing transcription
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of Rad51, indicating that p53 controls homologous recombination when the genome integrity is
compromised at two levels; through protein-protein interactions and through transcriptional
repression (Arias-Lopez et al., 2006).

BRCA2
In vitro kinase assays demonstrated that Chk1 phosphorylates BRCA2 at threonine 3387
(Bahassi et al., 2008). This phosphorylation was found to be required for the nuclear localization
of Rad51 after DNA damage. Interestingly, when the Chk1 phosphorylation site of BRCA2 is
mutated, there is a significant increase in Rad51 binding to BRCA2 after IR treatment
comparable to the levels observed in untreated cells with wild-type BRCA2. After cells were
cotransfected with BRCA2 and either a wild-type Rad51 or mutated Rad51 at the residue
phosphorylated by Chk1, the mutant form associated with BRCA2 after UV treatment while the
wild-type form did not. Together these studies suggest a model of Rad51 control by Chk1 where
BRCA2 binds Rad51 under normal cellular conditions and upon the generation of DNA damage,
Chk1 phosphorylates BRCA2 and Rad51 releasing Rad51 allowing for Rad51 to localize to sites
of DNA damage within the nucleus (Bahassi et al., 2008).

53BP1
53BP1 was identified as a p53 binding partner in a two-hybrid yeast screen and was later
found to rapidly localize to the nucleus after exposure to DNA DSB-inducing agents, implicating
53BP1 in the cellular response to DSBs (Iwabuchi et al., 1994; Schultz et al., 2000). Initially,
53BP1 was found to be required for the nuclear localization of BLM and p53 during HU
treatment in an ATR-Chk1 dependent fashion (Sengupta et al., 2004). Co-immunoprecipitation
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studies demonstrated that, during HU treatment, 53BP1 forms a complex with Rad51 and BLM
(Tripathi et al., 2008).

Phosphorylation of 53BP1 by Chk1 enhanced the interaction between

53BP1 and Rad51. In a study on defects in cells lacking BLM, it was shown that BLM enhances
the localization and interaction of 53BP1 and Rad51 during HU-induced replication stress. The
heterotrimeric complex ultimately inhibits Rad51 as was shown by a decrease in homologous
recombination as measured by fluorimetric assay where a homologous recombination substrate is
transfected and homologous recombination results in an emission of green fluorescence. This
assay also included a mutated BLM where the residue that ATR phosphorylates is mutated to an
alanine and the homologous recombination frequency increases, indicating that this
phosphorylation is required for the anti-recombinogenic activity of BLM (Tripathi et al., 2008).

Reversal of the S-phase Checkpoint
After DNA damage has been repaired or the replication stressor is resolved, the S-phase
checkpoint must be turned off to allow cells to continue replication for an accurate completion of
S-phase. The serine/threonine phosphatase Wip1, also called PPM1D, is the protein responsible
for dephosphorylating Chk1, attenuating the S-phase checkpoint (Lu et al., 2005). Wip1 was first
identified in a screen for genes induced by IR treatment in WBM Burkitt lymphoma cells. While
comparing mRNA Wip1 transcript levels between the WBM cells containing a wild-type p53 to
several cell lines with varying p53 status from null to mutated, a clear correlation was observed
between p53 status and induction of Wip1 mRNA. Thus, the newly discovered gene was name
Wip1, wild-type p53-induced phosphatase (Fiscella et al., 1997). More than ten years later p53
was found to bind to the Wip1 promoter, transactivating the transcription of Wip1 after UV
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IR treatment. Transcription of Wip1 is p53 dependent; in cells without p53 there are very low
levels of Wip1 mRNA (Rossi et al., 2008).
Wip1 is a member of the PP2C phosphatase family. The Wip1 sequence shows regionspecific homology at the three conserved regions among the PP2C family of phosphatase and is
dependent on Mg2+ and insensitive to the inhibitor okadaic acid, all characteristics of the PP2C
family (Fiscella et al., 1997). Phosphatase assays demonstrated that Wip1 dephosphorylates
Chk1 at serine 345 but not at serine 317 and that this dephosphorylation decreases Chk1 kinase
activity by more than two fold (Lu et al., 2005). Similarly, Wip1 was found to dephosphorylate
p53 at serine 15. Wip1 was knocked down with siRNA in U2OS cells: Wip1-tet on cells, or
overexpressed following tetracycline induction and then treated with UV and the percentage of
3

H-thymidine incorporated in DNA was measured. In the absence of Wip1 there was 70%

reduction of incorporation, while cells overexpressing Wip1 incorporated more 3H-thymidine
than the control cells, indicating Wip1 attenuates the S-phase checkpoint as observed by an
increase in DNA synthesis in the presence of Wip1 (Lu et al., 2005).

Focus of this Chapter
The experiments presented in this chapter address the molecular and cellular response of
human colon cancer HCT116 cells to nucleotide pool deficiencies induced by nucleotide
synthesis inhibitors. Treatment with PALA and HU resulted in slowed S-phase progression and
p53 accumulation, yet the cellular consequences of pyrimidine deficiencies versus dNTP
deficiencies were very different. For example, ATR was not recruited to the chromatin during
PALA treatment, resulting in a deficient S-phase checkpoint, and cells subsequently underwent
p53-dependent apoptosis. During HU treatment the S-phase checkpoint was found to be intact

47

and as a result, cells were protected from the nucleotide deficiencies. The observations that the
PTMs of p53 were asymmetrically opposed during the two treatments and that p53 was bound to
pro-apoptotic promoters during PALA treatment, led us to hypothesize that p53 has a central role
in determining the cytotoxic versus cytoprotective response to nucleotide pool deficiencies.

Materials & Methods
Drug Solutions
Solutions of HU (Sigma) and PALA (National Cancer Institute) were made by dissolving
the drug in phosphate-buffered saline (PBS) containing 1.06 mM KH2PO4, 155.17 mM NaCl,
2.97 mM Na2HPO4-7H2O, pH 7.4. VP16 (Sigma) was dissolved in DMSO then diluted in PBS
prior to use. DDATHF (Eli Lilly) was dissolved in 0.2 M Tris-Cl, pH 8.9. HU was made fresh
prior to every use and PALA and DDATHF stocks were made and stored at -80ºC until use.

Cell Culture
Human colon carcinoma HCT116 p53 +/+ and p53 -/- cells were generously provided by
Dr. Bert Vogelstein (John Hopkins University).

They were grown in RPMI 1640

(Invitrogen/Life Technologies) supplemented with 10% dialyzed fetal bovine serum (dFBS) in a
humidified atmosphere of 5% CO2 at 37ºC. Go/G1 synchrony was achieved by plating cells at a
high density of 2.5 x 106 cells/T-25 flask, allowing them to reach confluency (approximately 72
hours) feeding once after 48 hours, and holding them at confluence for an additional 48 hours.
Cells were released from postconfluent synchrony by replating at low density of 2 x 106 cells/10
cm dish.

Western Blotting
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Cellular Lysate preparation
HCT116 cells were plated at 8 x 105 cells/10 cm dishes and allowed to adhere for 24
hours prior to drug treatment. Stock solutions of drug were made as previously described, filter
sterilized through a 0.22 M syringe filter, and added to the appropriate volume of RPMI 1640
containing 10% dFBS to achieve the working drug concentrations. After the time point was
reached, cells were washed with cold PBS once and scraped into PBS containing 1x protease
inhibitor complete mixture (Roche). Cells were pelleted by centrifugation at 4,000 x g for 5
minutes at 4ºC and lysed in 10x volumes of lysis buffer containing 62.5 mM Tris, pH 6.8, 5%
glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.2 mM Na3VO4, 10 mM NaF, and 1x protease
inhibitor complete mixture (Roche Applied Science). The samples were passed through a 22
gauge needle ten times and debris was pelleted by centrifugation at 10,000 x g for 10 minutes at
4ºC. Protein concentrations were determined using the Bradford assay against a standard of
bovine serum albumin (BSA) according to manufacturer‟s (Bio-Rad) instructions. Lysates were
aliquoted and stored at -80ºC.

SDS PAGE and Immunoblotting
Laemmli sample buffer (Bio-rad) was added to 25 g of total cellular protein and the
solution was boiled for 5 minutes. Proteins were resolved by electrophoresis on 5%, 7.5%, 10%
or 15% SDS-polyacrylamide gels, at 150 V in running buffer containing 25 mM Tris base, 250
mM glycine and 0.1% SDS. Immobilon-P polyvinylidene fluoride membrane (PVDF) was
activated in 100% methanol for 2 minutes prior to use. The gel and PVDF membrane were
equilibrated in cold transfer buffer containing 25 mM Tris base and 192 mM glycine for 15
minutes. Proteins were transferred to the PVDF membrane for one hour at 100 V using a wet
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transfer. Following transfer the membrane was immersed into 100% ethanol for 15 seconds and
dried for 15 minutes. Non-specific protein binding was blocked in either Starting Block Buffer
(Pierce) or a Blotto solution containing 5% milk, 0.1% Tween 20, 0.01 M Tris, pH 7.4, 0.15 M
NaCl for 1 hour at 25ºC with gentle rocking. Blots were washed three times for five minutes
each with TBS-T containing 0.5 M Tris pH 7.5, 0.14 M NaCl, 2.7 mM KCl, 0.05% Tween 20 at
25ºC with vigorous rocking then incubated with primary antibody diluted in Starting Block
Buffer or 5% milk and TBS-T for 16 hours at 4ºC with gentle rocking. Primary antibodies were
polyclonal phospho-Chk1 (S317, S345) both at 1:1000 (Cell Signaling Technology, #2344,
#2341), polyclonal Chk1 at 1:1000 (Cell Signaling, #2345), monoclonal p21 at 1:100
(Calbiochem Ab-1, OP64) monoclonal beta Actin at 1:5000 (Abcam, #8226), monoclonal p53 at
1:100 (Calbiochem Ab-6, OP43), polyclonal Wip1 at 1:1000 (Santa Cruz H-300, sc-20712),
polyclonal BLM at 1:500 (Santa Cruz C-18, sc-7790), polyclonal ATR at 1:1000 (Santa Cruz H300, sc-28901), polyclonal trimethyl-Histone H3 (Lys4) at 1:1000 (Upstate, 07-473), polyclonal
phospho p53 (S15, S20, S37, S46, S392) all at 1:1000 (Cell Signaling, #9284, #9287, #9289,
#2521, #9281) and polyclonal PARP (Cell Signaling, #9542), cleaved PARP (Asp214) (Cell
Signaling, #9541), cleaved Caspase-9 (Asp330) (Cell Signaling, #9501), cleaved Caspase-7
(Asp198) (Cell Signaling, #9491) all at 1:1000, monoclonal phospho-H2AX (S139) at 1:1000
(Millipore JBW301, #16-193).

Following three TBS-T washes as described above, the

membranes were incubated for 1 hour at 25ºC with secondary antibodies conjugated to
horseradish peroxidase (Pierce) diluted in Starting Block Buffer or 5% milk and TBS-T and
complexes were detected by enhanced chemiluminescence using the Supersignal West Pico
Chemiluminescent Substrate Kit or SuperSignal West Dura Extended Duration Substrate Kit
(Pierce). For the p53 post-translational modification blot, 25 g of cell lysates were probed for
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p53 and the densities of the corresponding p53 signals were measured with a FluorChem SP
Imager (Alpha Innotech). The amount of protein required to be loaded for each treatment lane
was calculated from the obtained densities and a second gel was set up so that equal amounts of
p53 were present in every lane by loading different volumes of the different samples.

Chromatin Immunoprecipitation (ChIP)
Formaldehyde cross-linking and chromatin shearing
The ChIP assay was adapted from Bronder et al (Bronder and Moran, 2003).
Approximately 1 x 107 cells per condition were crosslinked at room temperature with 1%
formaldehyde for 10 minutes, the reaction was then quenched for 5 minutes by the addition of
0.125 mM glycine. Cells were washed twice with PBS, scraped, washed in buffer I containing
10 mM HEPES pH 7.5, 0.5 mM EGTA pH 7.5, 10 mM EDTA pH 8.0, 0.25% Triton X-100, then
in buffer II containing 10 mM HEPES pH 7.5, 0.5 mM EGTA pH 7.5, 1 mM EDTA pH 8.0, 200
mM NaCl.

All ChIP buffers contained 1 g/mL aprotinin, 1 g/mL leupeptin, 1 g/mL

pepstatin, 1 mM PMSF, 0.2 mM Na3VO4 and 10 mM NaF. Cells were lysed in lysis buffer
containing 25 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 0.5% Na Deoxycholate. Aliquots of 2 x 106 cells in 600 L lysis buffer were sonicated
with a Diagenode bath bioruptor for a total of 20 minutes with consecutive duty cycles of 30
seconds on, 30 seconds off at 4ºC (5 minute cycles repeated a total of 4 times). These conditions
were found to yield DNA fragments less than 1000 bp in size.

Immunoprecipitation
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Lysates corresponding to 2 x 106 cells were precleared for 1 hour at 4ºC with a 50%
slurry of protein G-Sepharose (Amersham Biosciences) beads previously blocked with 8 g of
BSA and either 5 g of sonicated lambda DNA or 6 g of sonicated salmon sperm DNA, then
incubated with 2 g p53 Ab-6 (Calbiochem) antibody or 2 g IgG (Millipore) antibody
overnight. Antibody-protein-DNA complexes were captured by the addition of 30 L of 50%
blocked protein G-Sepharose bead slurry for 1 hour at 4ºC. Beads were pelleted at 4,500 x g for
5 minutes at 4ºC and the supernatant from the IgG immunoprecipitation was saved and the DNA
contained within was referred to as input DNA. Beads were washed extensively twice with
RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 0.5% Na Deoxycholate, 1% NP40), once with High Salt Buffer (500 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% Na
Deoxycholate), once with LiCl Buffer (250 mM LiCl, 50 mM Tris pH 8.0, 0.5% Na
Deoxycholate, 1% NP-40), and twice with TE (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) for 10
minutes each at 4ºC rotating end-over-end. Protein-DNA complexes were eluted with elution
buffer (2% SDS, 10 mM DTT, 0.1 M NaHCO3) while rotating end over end at 25ºC for 15
minutes and the cross-links were reversed by the addition of 0.2 M NaCl and incubation at 65ºC
overnight. DNA was treated with 10 g of RNase for 30 minutes at 37ºC and with 20 g
Proteinase K in 10 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 0.25% SDS for 1 hour at 42ºC,
phenol-chloroform extracted, ethanol-precipitated and dissolved in 100L TE.

Quantitative PCR (Q-PCR)
Quantitative PCR was performed with 1 L of input DNA or ChIP DNA for each 25 L
reaction containing 12.5 L Quantitect SYBR Green PCR Master Mix (Qiagen) and 0.3 M of
each primer. The sequences of the primers flanking the p53 binding sites of the analyzed
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promoters can be found in Table 2-1. The amplification conditions were 95ºC for 15 minutes, 40
cycles of 95ºC for 45 seconds, for the noted Tm of each primer set in Table 2.1 for 45 seconds,
72ºC for 45 seconds with a plate read, and concluding with a 5 minute extension at 72ºC and a
melting curve from 45ºC to 100ºC. Absolute quantities were calculated using a standard curve
ranging from 100 ng to 0.8 ng of input DNA.

One Parameter Flow Cytometry
Cells were synchronized as previously described. At indicated times cells were collected
by trypsinization, centrifuged at 300 x g and washed twice in PBS. Cells were resuspended in
propidium iodide fluorochrome stain containing 50 g/mL propidium iodine, 0.1% Triton X100, 7 K-units/mL ribonuclease B in 3.2 mM sodium citrate buffer at a density of 1 x 106
cells/mL. Cell solutions were wrapped in foil and stored at 4ºC in the dark until analysis, up to
48 hours. Prior to analysis, cells were filtered through a 35 m nylon mesh to obtain a single cell
suspension. Flow cytometry was performed on a Beckman Coulter Elite XL-MCL single-laser
flow cytometer.
Growth Rescue with deoxyribonucleotides
Inosine and deoxyadenosine (AdR) (Sigma) were dissolved in PBS. Deoxyguanosine
(GdR) (Sigma) was dissolved in PBS and 10% the total volume of 1N NaOH was added to aid in
solubilization. HCT116 cells were plated in 12-well plates at 2.4 x 104 cells/well and allowed to
adhere overnight. Triplicates were plated for every drug treatment. Filter-sterilized drugs were
added to RPMI 1640 supplemented with 10% dFBS and HEPES/MOPS buffer containing 20
mM HEPES, 10 mM MOPS, pH 7.4 to obtain the working concentration and added to the plated
cells for 72 hours. Cells were fed after 48 hours with fresh drug-containing medium. Cells were
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Promoter

Sense Primer

Antisense Primer

Tm

p21 5′ RE

5′-CTTTCCACCTTTCACCATTCC-3′

5′-AAGGACAAAATAGCCACCAGC-3′

53ºC

Rad51

5′-CCTCGAACTCCTAGGCTCAGA-3′

5′-CCGCGTCGACGTAACGTAT-3′

54ºC

WIP1

5′-ACGCCTGATTTGTGTGGTGG-3′

5′-ACGCAGCCCGCCGAATCCG-3′

55ºC

PUMA

5′-TGGGGGTGTGGATCTGTG-3′

5′-AAGTCAGGACTTGCAGGCG-3′

55ºC

FAS

5′-GCGGACAGGAATTGAAGCGGAAG-3′

5′-GGACCTTTGGCTTGGCTTGTCA-3′

58ºC

PIG3

5′-CCTTTCTCTTCTCTTAGCAGCACC-3′

5′-GTGCGATTCTAGCTCTCACTTCAAGG-3′

55ºC

BAX

5′-GCTCATGCCTGTAATCCCAGCG-3′

5′-ACCTGGATCTAGCAATATAGCCCACG-3′

58ºC

AIP1

5′-ATCTCTGGATGGGTAGGAGG-3′

5′-GTTCATGTCAGGGAGGTGC-3′

53ºC

Table 2-1. Sequence of primers used in ChIP assays to quantitate the levels of p53 residence
at various promoters. The sense and antisense primers are denoted next to the specific
promoter. The melting temperature (Tm) of each primer set follows the primers.
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trypsinized and counted with the Beckman Coulter Z1 Coulter Particle Counter. For the purine
nucleotide rescue of HU treatment, the above solutions were used scaled up to 10 cm plates for
lysate preparation.

Co-immunoprecipitation
HCT116 cells were grown in RPMI 1640 supplemented with 10% dFBS.

Cells were

plated at 3 x 10 cells/15 cm dish and allowed to adhere overnight. Twenty-four hours after drug
treatment plates were washed once with PBS and then scraped in 2 mL modified RIPA buffer
containing 50 mM Tris-HCl pH 7.4, 1% NP40, 0.25% Na deoxycholate, 1mM EDTA pH 8.0.
All buffers contained 1 g/mL aprotinin, 1 g/mL leupeptin, 1 g/mL pepstatin, 1 mM PMSF,
0.2 mM Na3VO4 and 10 mM NaF. Cells were lysed through gentle rocking for 15 minutes at
4ºC. Cell debris was pelleted at 14,000 x g for 15 minutes at 4ºC. Protein concentration of the
supernatant was determined with the Bradford assay as previously described.

BLM was

immunoprecipitated from 0.75 mg of total protein with 1 g polyclonal BLM antibody (Santa
Cruz C-18, sc-7790) adding 4 M NaCl to obtain a final concentration of 100 mM NaCl. The
volume of the above solution was raised to 750 L with CO-IP buffer containing 50 mM TrisHCl pH 7.5, 15 mM EGTA pH 7.5, 100 mM NaCl, 0.1% Triton X-100 and was incubated on ice
for 90 minutes with occasional inverting.

Nonspecific aggregates were pelleted by

centrifugation at 14,000 x g for 10 minutes at 4ºC. The supernatant was incubated for 60
minutes while rotating end over end with 50 L 50% protein G bead slurry that was previously
washed three times with Co-IP buffer. Beads were pelleted by centrifugation at 4,500 x g at 4ºC
for 1 minute and washed three times with 500 L CO-IP buffer, with three tube inversions
between washes. The beads were resuspended in 25 L sample buffer containing 62.5 mM Tris55

Cl pH 6.8, 5% glycerol, 2% SDS, 5% 2-mercaptoethanol and boiled for 5 minutes. Beads were
pelleted by centrifugation at 4,500 x g at 4ºC for 1 minute and the supernatant was stored at 20ºC until further analysis by western blot, as described above.

Prior to loading on to a

polyacrylamide gel, samples were boiled for 5 minutes and 1 L 0.4% bromophenol blue was
added to each sample.

Reverse Transcriptase Quantitative PCR
Total RNA was isolated using the TRIzol reagent according to manufactures instructions
(Invitrogen). RNA (1 g) was treated with 10 units of DNase I (Invitrogen) for 15 minutes at
25ºC in a 100 L volume reaction containing 10 mM Tris HCl (pH 8.4), 2 mM MgCl2 and 5 mM
KCl. DNase I was inactivated for 10 minutes at 65ºC with 2.5 mM EDTA (pH 8). RNA was
precipitated with the addition of 1/10th the total volume of 3 M NaOAc and 2.5 times the total
volume of 100% ethanol overnight at -80ºC.

The integrity of the RNA was verified on a 1%

agarose gel containing ethidium bromide. cDNA was synthesized from 2 g RNA using random
hexamers in the Superscript III First-Strand Synthesis System according to the manufacturer‟s
instructions (Invitrogen). Quantitative PCR was performed with 1 L cDNA in a 25 L reaction
containing 12.5 L Quantitect SYBR Green PCR Master Mix (Qiagen), 0.3 M of each primer
in a three-step amplification plus melt-curve as described previously. Primers to measure the
Wip1

transcript

were

5′-TGCCGCCGCCGTTCCTCCGTG-3′

(sense)

and

5′-

GCCCCGAATGATGACCACACT-3′ (antisense); primers to measure -actin as the normalizing
control

were

5′-CACGAAACTACCTTCAACTCC-3′

TCATACTCCTGCTTGCTGATCC -3′ (antisense).
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(sense)

and

5′-

RNA Interference
HCT116 cells were plated at 1.5 x 105 cells/well in a 6-well plate, in 2 mL of RMPI 1640
with 10% dFBS and 1% pen/strep, and were allowed to adhere overnight.

siRNA (Wip1

siGENOME SMARTpools or non-targeting siRNA pool #1, Dharmacon) was resuspended to a
concentration of 20 M in 1x siRNA buffer containing 60 mM KCl, 0.2 mM MgCl2 and 6 mM
HEPES pH 7.5. siRNA was diluted to 2 M in the above mentioned 1x siRNA buffer and an
equal volume of serum free RPMI 1640 was added. Dharmafect reagent #2 was diluted down to
0.2% in serum-free RPMI 1640. Both sets of solutions were incubated at 25ºC for 5 minutes and
then mixed together and incubated for another 20 minutes at 25ºC. RPMI 1640 with 10% dFBS
was added to the transfection solutions to a final siRNA concentration of 100 nM. Each well
received 2 mL of the transfection-medium and after 24 hours the transfection medium was
removed and replaced with RPMI 1640 containing 10% dFBS and 100 U/mL of penicillin and
100 mg/mL of streptomycin replaced the transfection medium. The 24 hour drug treatment
began 48 hours after transfection.

Chromatin Fractionation
Cells were synchronized at Go/G1 as previously described and chromatin fractionation
was performed as previously described (Mendez and Stillman, 2000). Synchronized HCT116
cells were released at 2 x 106 cells/10 cm dish containing 10 mL. 24 hours after drug treatment,
cells were washed with PBS once and scraped into PBS containing 1x complete protease
inhibitor mixture (Roche). Cells were pelleted at 1000 x g for 5 minutes at 4ºC. The pellet was
resuspended in Buffer A containing 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34
M Sucrose, 10% glycerol, 1 mM DTT, and Triton X-100 was added to obtain a final
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concentration of 0.1%. All buffers contained 0.5 g/mL aprotinin, 0.5 g/mL leupeptin, 0.5
g/mL pepstatin, 0.1 mM PMSF, 2 mM Na3VO4 and 10 mM NaF. Cells were incubated on ice
for 8 minutes and nuclei were pelleted by low speed centrifugation at 1300 x g for 5 minutes at
4ºC. The supernatant was saved as the cytosolic fraction. The nuclei were washed twice with
Buffer A and lysed with 50 L for ND treatment, 40 L for HU and 30L for PALA (volumes
which were previously determined to yield equal nuclear fractions from control and drug treated
cells) of buffer B containing 3 mM EDTA pH 8.0, 0.2 mM EGTA pH 7.5, 1 mM DTT and
incubated on ice for 30 minutes. The chromatin was pelleted at 1700 x g for 5 minutes at 4ºC
and the insoluble nuclear fraction supernatant was saved. The pellet was washed twice with
buffer B and resuspended in 40 L for ND and 25 L for HU and PALA samples of 1x sample
buffer containing 62.5 mM 1 M Tris pH 6.8, 10% glycerol, 2% SDS and 10% 2-mercaptoethanol
and sonicated at 4ºC with the Diagenode bioruptor for a total of 15 minutes with consecutive
duty cycles of 30 seconds on, 30 seconds off (5 minute cycles repeated a total of 3 times). All
fractions were aliquoted and stored at -80ºC.

Clonogenic Survival
For colony formation assays, HCT116 p53 +/+ and HCT116 p53 -/- cells were plated at
150 cells/10 cm dish and allowed to adhere for 5 hours. Cells were then incubated with RPMI
medium containing 10% dFBS and a range of HU or PALA concentrations for 24 hour. Plates
were replenished with fresh RPMI with 10% dFBS medium the following day and every 2-3
days for a total of 8 days. For the adapted version of the colony formation assay, HCT116 cells
were synchronized as previously described and released into drug for 24 or 48 hours. Adherent
and floating cells were collected and plated at 100 cells/60-mm2 dish and allowed to attach
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overnight. Plates were replenished with fresh RPMI with 10% dFBS medium the following day
and every 2-3 days. After 8 days in both assays, colonies were fixed with methanol, stained with
5% Wright-Giemsa reagent and all visible colonies were counted manually.

Results
The experiments presented in Chapter 2 address the question of whether treatment of
HCT116 cells with different nucleotide synthesis inhibitors result in similar cellular responses.
Besides p53 stabilization and slowed S-phase progression, the cellular responses to HU and
PALA treatment are strikingly different.

The results presented herein suggest that PALA

treatment fails to recruit ATR to the chromatin resulting in a p53-dependent apoptosis while HUtreatment activates a S-phase checkpoint that is cytoprotective.

Cell Cycle Effects of Nucleotide Synthesis Inhibitors
Both HU and PALA stabilize p53 and minimally activate p21 transcription
Given the significant role p53 plays in a multitude of cellular responses within the cell,
the ability of nucleotide-deprived cells to promote the accumulation of p53 was investigated.
HCT116 cells were treated with HU, PALA or the positive control DNA damaging agent VP16
for 24 hours and lysates were then western blotted to determine the effect on p53 accumulation.
All three drug treatments led to the accumulation of p53. VP16 and PALA treatment resulted in
the highest accumulation of p53, but p53 levels after HU were also quite high (Fig 2-6). The
activation of p21 was investigated by immunoblotting to determine if the accumulated p53 was
promoting transcription of this critical cell cycle inhibitor. As expected VP16 caused significant
p21 activation; p21 activation by PALA treatment was very low but still clearly detectable, while
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ND

VP16

HU

PALA

p53
p21
-Actin

Figure 2-6. Nucleotide deficiencies promote p53 accumulation with minimal p21 activation.
This figure shows a western blot analysis of p53 and p21 levels in asynchronous HCT116 cells
exposed to 10 M VP16, 1.5 mM HU or 100 M PALA for 24 hours. Total cell lysate protein
(25 g) was subjected to SDS-PAGE and immunoblotted with antibodies against p53, p21 or Actin. VP16 was used as the positive control for p53 accumulation and p21 activation. Protein
loading was assessed with -Actin.
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HU treatment resulted in minimal p21 activation, even though a significant amount of p53
stabilization was seen in all three drug treatments (Fig 2.6). The poor transcriptional activation
of p21 after HU was expected from previous work in Prives‟ laboratory, but that observed after
PALA treatment was surprising but reproducible. Previously in our lab, Julie Bronder observed
a similar defect in p21 transcription during treatment of HCT116 cells with DDATHF, an
antifolate de novo purine synthesis inhibitor. In her studies, p53 was bound to p53RE sites at the
p21 promoter but, due to the lack of PTMs on p53 and the closed chromatin structure of the
promoter, transcription was not activated (Bronder and Moran, 2003). To determine if the
minimal activation of p21 transcription during HU treatment was due to failure of p53 to bind to
the p21 promoter or events downstream of binding to the p53REs in the p21 promoter, a ChIP
experiment was performed, with DDATHF included as a control for a nucleotide synthesis
inhibitor exhibiting a similar p21 defect as HU.

After DDATHF and HU treatment,

approximately threefold more p53 was detected at the upstream p53RE of the p21 promoter than
was seen in the no drug control. There was over a five-fold enrichment of p53 at the p21
promoter during PALA treatment and VP16 resulted in a four-fold enrichment of p53 bound at
this promoter (Fig 2-7).

The inability of the p53 that accumulated in HU-treated cells to

transactivate p21 in spite of binding at the p21 (Mattia et al., 2007) promoter had previously been
observed in Carol Prives‟ laboratory (Gottifredi et al., 2001), but the mechanism for this effect is
still not clear.

The post translational modifications of stabilized p53 after nucleotide synthesis inhibition
The PTMs of the p53 that accumulated in HCT116 cells during the treatments with HU,
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Figure 2-7. Nucleotide deficiencies induce p53 binding at the p21 promoter. ChIP
analysis of p53 enrichment at the p21 promoter in asynchronous HCT116 cells after 24
hours of drug treatment. p53-DNA complexes were immunoprecipitated from crosslinked
cells and p21 promoter levels were quantitated with Q-PCR. Non-specific binding was
detected by parallel immunoprecipitations with IgG. VP16 served as a positive control.
Standard error is depicted by the bars from one biological repeat with triplicate Q-PCR
samples. The same trend was observed in subsequent biological repeats. Vehicle was PBS,
VP16 was used at 10 M, HU was used at 1.5 mM, PALA was used at 100 M and
DDATHF was used at 10 M.
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PALA, and VP16 were examined by loading an equivalent amount of p53 for all conditions on a
gel and immunoblotting with phospho-specific peptide antibodies. VP16 caused robust
phosphorylation at all the serine residues examined as was expected from previous literature for
such a strong inducer of the DNA damage response. The phosphorylation profile of the p53
stabilized during HU treatment was very different to that of the p53 stabilized during PALA
treatment. Interestingly, PALA treatment did not promote significant phosphorylation at serine
20 and induced only low levels of phosphorylation at serine 15, two of the most commonly
phosphorylated serines on p53. HU promotes efficient phosphorylation of these residues. On
the other hand serines 37, 46 and 392 were significantly phosphorylated during PALA treatment
compared to that observed following HU treatment (Fig 2-8). The different pattern of post
translational phosphorylations of p53 that resulted after PALA treatment and HU treatment
suggested that the upstream regulators of p53 may differ as well was the cellular activities of the
accumulated p53.

HU and PALA-treated cells undergo a prolonged cell cycle arrest in S-phase
The observation that p21 is not being robustly activated during HU and PALA treatment
suggested that perhaps these two treatments are promoting cell cycle arrest in a different phase of
the cell cycle other than the G1/S or G2/M checkpoint. G1 synchronized HCT116 cells were
released into drug-containing medium and cells were then stained with propidium iodide after 24
hours and analyzed by flow cytometry. Under these synchronization conditions, ~97% of the
cell population was in G1 immediately after release from synchrony with the remaining ~3% in
G2 (Fig 2-9). The VP16 control caused a G2/M cell cycle arrest, which was expected from
previous literature (Smith et al., 1994). Both HU and PALA treatment bypassed the G1/S
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Figure 2-8. The post-translational modifications of the p53 that accumulate in HU- and
PALA-treated cells are substantially different. This figure shows a western blot analysis of
the post-translational modifications of p53 in asynchronous HCT116 cells after 24 hours of drug
treatment. An initial western blot was performed with 25 g of total protein to quantitate total
p53 levels and then a second gel was run with differing volumes of lysates from the different
conditions so that equivalent amounts of p53 were loaded and immunoblotted with antibodies
specific for p53 phosphorylated at serine 15, 20, 37, 46, 392. Vehicle was PBS, HU was used at
1.5 mM, PALA was used at 100 M and VP16 was used at 10 M.
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Figure 2-9. Synchronized HCT116 cells bypass the G1 checkpoint and accumulate in Sphase upon nucleotide deficiencies. HCT11 cells were synchronized in G0/G1 by holding at
confluence for 48 hours and released into drug containing medium at a low density for 24 hours.
Cells were stained with PI and cell-cycle progression was monitored by flow cytometry.
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checkpoint, an observation that was consistent with the low levels of p21 in these conditions, and
accumulated in S-phase (Fig 2-9). This suggested that the low levels of p21 activated during
PALA did not arrest the cells at the G1/S border and that this checkpoint was not active.
Compared to the vehicle, the HU and PALA treated cells moved through the cell cycle at a much
slower rate and accumulated in early to mid S-phase.

S-phase Specific Events Resulting after Nucleotide Pool Imbalance
HU and PALA treatment promote a differentially phosphorylated Chk1
The phosphorylation of Chk1 is an event commonly used as definitive of the activation of
the S-phase checkpoint (Lopez-Girona et al., 2001; Zhao and Piwnica-Worms, 2001). Since
both HU and PALA treated cells arrested in S-phase, the phosphorylation status of Chk1 was
investigated to determine if this checkpoint was being activated. VP16 and HU treatment
resulted in a robust phosphorylation of Chk1 at serine 345, while PALA treatment did not (Fig 210). This was quite surprising. Minimal phosphorylation of Chk1 was observed following
PALA treatment over that in the untreated control. A concentration-dependence study was
performed to determine whether the Chk1 phosphorylation difference observed after HU and
PALA was an artifact of the drug concentrations used. The concentration range for HU was 0.15
mM to 3 mM, 1.5 mM being the working concentration. Chk1 phosphorylation is detectable at
0.5 mM HU and was maximal at 3 mM (Fig 2-11). PALA concentrations from 10 M to 500
M did not cause appreciable Chk1 phosphorylation when compared with 1.5 mM HU or 10
M VP16. Hence, substantial Chk1 phosphorylation following any reasonable dose of PALA
was not occurring, while the phosphorylation occurring during HU treatment was robust (Fig 211).
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Figure 2-10. Chk1 is not phosphorylated at serine 345 upon PALA-induced pyrimidine
deficiencies. This figure shows a western blot analysis of phosphorylated Chk1 at serine 345
and total Chk1 levels in asynchronous HCT116 cells exposed to 10 M VP16, 1.5 mM HU or
100 M PALA for 24 hours. Total cell lysate protein (25 g) was subjected to SDS-PAGE and
immunoblotted with antibodies against phospho-Chk1 serine 345 or total Chk1. HU was used as
the positive control for stalled replication forks and VP16 served as a DNA-damage control.
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Figure 2-11. Concentration dependency of HU- or PALA-induced Chk1 phosphorylation
and p53 accumulation. This figure shows a western blot analysis of levels of accumulated p53,
total and phosphorylated Chk1 at serine 345 in asynchronous HCT116 cells treated with drug for
24 hours. Equal levels of total protein (25g) were loaded in each lane. Vehicle was PBS, HU
was used at 0.15 mM to 3 mM, PALA was used at 10 M to 500 M and VP16 was used at 10
M. HU at 1.5 mM was used as a positive control for the concentration dependency of PALA
treatment. Protein loading was assessed with-Actin.
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A time course was also performed to determine if the 24 hour time point used above
possibly missed a transient Chk1 phosphorylation during PALA treatment.

Cells were

synchronized in G1 and released into drug, then lysates were made at various time points to allow
an enriched S-phase cellular population to be studied (Fig 2-12). Interestingly, a low level and
transient phosphorylation of Chk1 was observed during PALA-induced pyrimidine imbalances.
At 24 hours, Chk1 is heavily phosphorylated at serine 345 in HU and remained phosphorylated
throughout the 48 hour time point (Fig 2-13). Throughout this period, the HU-treated cultures
were found to be in a slowed S-phase by flow cytometry (Fig 2-12). The level of transient Chk1
phosphorylation observed during PALA treatment was much lower than that observed during
HU treatment and, again, was observed only at time points corresponding to slow passage
through S-phase (Figs 2-12, 2-13). Chk1 phosphorylation was detected as early as 12 hours after
HU treatment while the low levels of Chk1 phosphorylation was first detected at 24 hours in
PALA treated cells. Another interesting difference is the amount of accumulated p53 present
during both of the drug treatments. During PALA treatment, p53 stabilization was detectable by
12 hours and was still substantial at 48 hours. During HU treatment, p53 stabilization was
undetectable at 12 hours, a lower level of p53 had accumulated at 24 hours and this level
decreased with time thereafter (Fig 2-13).

The different levels of accumulated p53 that

resulted from HU- and PALA-treatment suggested that p53 could be playing a role in the
differential Chk1 phosphorylation. To address this question the p53 isogenic HCT116 cell lines
were used to examine the possible p53 dependency of Chk1 phosphorylation. In HCT116 p53-/cells, Chk1 phosphorylation at both serines 345 and 317 was partially restored during PALA
treatment when compared to HCT116 p53 +/+ cells. The phosphorylation levels did not reach
those observed during HU, but they were significantly higher than what was observed in the
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Figure 2-12. HU and PALA treatment slow S-phase progression. HCT116 cells were
synchronized at G0/G1 and released into drug containing medium for the indicated times, stained
with PI and their DNA content was analyzed by flow cytometry. Approximately 1 x 106
synchronized cells were collected and saved for the 0 hr time point prior to releasing the
remainder into drug. Vehicle was PBS, HU was used at 1.5 mM, PALA was used at 100 M.
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Figure 2-13. The time course of Chk1 phosphorylation and p53 accumulation after HU- or
PALA-induced nucleotide deficiencies. This figure shows a western blot analysis of total and
phosphorylated Chk1 at serine 345 in G0/G1 synchronized HCT116 cells released into drug for
the indicated times. Equal levels of total protein (25 g) were loaded in each lane. Vehicle was
PBS, HU was used at 1.5 mM, PALA was used at 100 M and the VP16 control was used at 10
M for 24 hours. Protein loading was assessed with -Actin.
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presence of p53, suggesting that the presence of p53 is preventing the phosphorylation of Chk1
(Fig 2-14). HU inhibits the synthesis of both purine and pyrimidine deoxyribonucleotides and
PALA solely inhibits the synthesis of pyrimidines.

The Chk1 phosphorylation deficiency

observed during PALA treatment may be a result of the fact that the pyrimidine pools are being
affected with no effect on purines while HU is causing an overall deficiency in all of the
deoxyribonucleotide pools. To indirectly determine if the Chk1 phosphorylation deficiency in
PALA was due to the asymmetric effect on purine and pyrimidine nucleotide pools, HU treated
cells were supplemented with 2-deoxyadenosine (AdR) and 2-deoxyguanosine (GdR), precursors
of purine nucleotides. Prior to the supplementation, studies were performed with the purine
inhibitor DDATHF, and the purine deoxynucleotides, to optimize the concentrations required to
fully rescue the purine synthesis inhibition. The salvage metabolite inosine was used as a
positive control for full rescue of DDATHF treatment. DDATHF treatment alone resulted in a
90% suppression of the growth of HCT116 cells compared to the no drug control.
Supplementation of medium with 100 M inosine or by addition of both 100 M AdR and GdR
rescued the cell growth caused by 10 M DDATHF treatment (Fig 2-15A). Hence, these
concentrations of extracellular AdR and GdR allowed support for growth by salvage and they
were used to study the effect of HU suppression of deoxypyrimidine pools in the presence of
exogenously supplied deoxypurines. The level of Chk1 phosphorylation did not decrease during
HU treatment in the presence of purine deoxynucleotides, suggesting that the deficiency in Chk1
phosphorylation during PALA treatment is not due to deoxypurine/pyrimidine pool imbalances
(Fig 2-15B).

HU and PALA treatment slows S-phase progression
72
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Figure 2-14. p53 dependency of Chk1 phosphorylation. This figure shows a western blot
analysis of total and phosphorylated Chk1 at serines 317 and 345 and accumulated p53 in
asynchronous HCT116 p53 +/+ and HCT116 p53 -/- cells exposed to drug for 24 hours. Equal
levels of total protein (25 g) were loaded in each lane. Vehicle was PBS, HU was used at 1.5
mM, PALA was used at 100 M and the VP16 control was used at 10 M. Protein loading was
assessed with -Actin
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Figure 2-15. Differences in Chk1 phosphorylation is not due to the pool of nucleotides being
inhibited. A, Growth rescue of DDATHF treatment with deoxyribonucleotides or inosine to
determine concentrations for partial rescue of purine deoxyribonucleotides during HU treatment.
HCT116 cells were treated with 10 M DDATHF alone or supplemented with either 100 M
inosine or 100 M AdR and 100 M GdR for 72 hours. Cells were trypsinized and counted with
the Beckman Coulter Z1 Coulter Particle Counter. Each bar indicates the mean of three plates
within a single experiment, and standard deviation is shown. B, Western blot analysis of total,
phosphorylated Chk1 at serine 345, accumulated p53, and cleaved PARP1 in asynchronous
HCT116 cells exposed to drug for 24 hours. Purine deoxyribonucleotides were rescued during
HU treatment by supplementation with 100 M AdR and 100 M GdR. Equal levels of total
protein (25 g) were loaded in each lane. Vehicle was PBS, HU was used at 1.5 mM, PALA
was used at 100 M and the VP16 control was used at 10 M. Protein loading was assessed with
-actin.
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The differences in the time course and degree of Chk1 phosphorylation in HU and PALA
suggested that fundamentally different cellular processes were occurring during the two drug
treatments (Fig 2-13). The flow cytometry performed on the treated cells after 24 hours was
expanded to a full time course. G1-synchronized cells were immediately released into drug and
the adherent cells were collected after different time points and stained with propidium iodide.
Neither HU nor PALA-treated cell populations were blocked at the G1 checkpoint and the
majority of both populations progressed into S-phase at a slower rate than the untreated cells.
Both populations progressed into S-phase very slowly, but eventually completed transit through
S-phase. Starting at 12 hours the cells began to enter S-phase and by 48 hours they were almost
completely out of S-phase, whereas untreated HCT116 cells appeared to progress at a much
faster rate, transiting through one or more S-phases within 24 hours. PALA-treated cells
progressed through S-phase at a somewhat faster rate, approximately 12 hours ahead of HU
treated cells. At the 48 hour time point, they are completely out of S-phase while HU cells are in
the latter half of S-phase. There was a noticeable accumulation of cells in G2/M in both drug
treatments that was not observed in untreated cell populations. By 72 hours the cells are
asynchronous and the flow cytometry cell cycle histograms appeared identical (Fig 2-12).

p53 Binds to BLM during Both HU and PALA treatment
Because Chk1 phosphorylation was not observed during PALA treatment, other S-phase
specific events were investigated to define the scope of the difference in the cellular responses to
HU and PALA. Previous studies have demonstrated the interaction of BLM and p53 during the
S-phase checkpoint (Sengupta et al., 2003; Yang et al., 2002). BLM was immunoprecipitated
from HCT116 cells that were treated with either HU or PALA for 24 hours.
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This

immunoprecipitate was analyzed by western blot to determine if p53 was interacting with BLM.
Both HU and PALA treatment stimulated the binding of p53 to BLM (Fig 2-16). Equivalent
amounts of BLM were immunoprecipitated from both drug treated lysates, but slightly more p53
was found associated with BLM during PALA treatment, consistent with the higher levels of p53
in PALA-treated cells (see input lanes, Fig 2-16). Minimal BLM was pulled down in the
untreated lysates, but p53 was still found in this pellet, suggesting that BLM and p53 associate in
unstressed cells as well as in cells depleted of nucleotides. Only a small fraction of total cellular
p53 immunoprecipitated with BLM under the experimental conditions, suggesting that the
stabilized p53 has other roles besides modulating BLM function, in the cellular response to HU
and PALA treatment (Fig 2-16).

Enrichment of p53 at the Rad51 promoter is stimulated by PALA treatment
p53 has been shown to bind to the Rad51 promoter inhibiting the transcription of this
pro-recombinogenic protein during the S-phase checkpoint (Arias-Lopez et al., 2006).

The

observation that only a small fraction of total cellular p53 was binding to BLM suggested that
p53 was involved in other cellular processes, and therefore the residence of p53 at the p53RE in
the Rad51 promoter after 24 hours of HU and PALA treatment was measured by ChIP. PALA
treatment caused more than a threefold enrichment of p53 at this promoter over the no drug
treatment. HU treatment did not elevate the levels of p53 at the Rad51 promoter (Fig 2-17).
Thus, HU-stabilized p53 is not inhibiting the transcription of Rad51 while p53 that is
accumulated during PALA treatment is bound at the promoter suggesting that it is negatively
regulating the transcription of Rad51. It has been suggested that induction of apoptosis in cells
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Figure 2-16. BLM and p53 interact during HU- or PALA-induced nucleotide deficiencies.
This figure shows a western blot analysis of the interaction between p53 and BLM after 24 hours
of HU- or PALA- induced nucleotide pool deficiencies in asynchronous HCT116 cells. BLM
was immunoprecipitated from 750 g protein from whole cell lysates with the p53 antibody
(DO-1); p53 was detected in the BLM immunoprecipitate by western blotting. Input indicated
5% of the lysates used for the IP and the efficiency of the IP was verified with the BLM
antibody. PBS was added to the no drug treatment, HU was used at 1.5 mM and PALA was used
at 100 M.
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Figure 2-17. PALA treatment induces p53 binding at the Rad51 promoter. ChIP analysis of
p53 enrichment at the Rad51 promoter in asynchronous HCT116 cells after 24 hours of drug
treatment. p53-DNA complexes were immunoprecipitated from crosslinked cells and Rad51
promoter levels in the immunoprecipitate were quantitated with Q-PCR. Non-specific binding
was immunoprecipitated with IgG. Standard error is depicted by the bars from two biological
repeat with triplicate Q-PCR samples. Vehicle was PBS, HU was used at 1.5 mM and PALA
was used at 100 M.
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containing abundant DNA damage may require the repression of homologous recombination
(Ivanov et al., 2003). If this is true, it could explain that the enrichment of p53 at the Rad51
promoter is repressing transcription of the homologous recombination protein Rad51 in order to
induce apoptosis.

Mechanism of the failure of PALA to induce Chk1 phosphorylation
PALA treatment activates the transcription of the Wip1 phosphatase
Although HU and PALA treatment slowed S-phase progression, the activities of the Sphase checkpoint were found to be conflicting.

That is, HU-treatment resulted in Chk1

phosphorylation and p53 interaction with BLM, while Chk1 was not phosphorylated after
PALA-treatment, yet p53 associated with BLM and regulated Rad51 transcription. In order to
clarify the complexity of the cellular responses, we focused on the transient nature of Chk1
phosphorylation during PALA treatment. The increase in Chk1 phosphorylation in the absence
of p53 in PALA-treated HCT116 p53-/- cells suggested that p53 was preventing Chk1
phosphorylation (Fig 2-14). In combination with the p53 dependency and the transient nature of
Chk1 phosphorylation during PALA treatment, we hypothesized that the p53-dependent gene,
Wip1, was dephosphorylating Chk1. The presence of p53 at the Wip1 promoter after 24 hours of
drug treatment was investigated using ChIP. There was a massive (> eight fold) enrichment of
p53 binding to the Wip1 promoter after PALA treatment that was not observed after HU
treatment (Fig 2-18A). RT-QPCR demonstrated that the high occupancy of p53 at the Wip1
promoter after PALA treatment was strongly activating transcription as is seen by a 12-fold
increase in Wip1 transcript levels. There was about a four-fold increase in Wip1 transcript after
HU treatment. The Wip1 transcriptional activation was p53 dependent: in HCT116 cells that are
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Figure 2-18. PALA treatment activates Wip1 transcription. A, ChIP analysis of p53
enrichment at the Wip1 promoter in asynchronous HCT116 cells after 24 hours of drug
treatment. p53-DNA complexes were immunoprecipitated from crosslinked cells and Wip1
promoter levels present in the immunoprecipitate were quantitated with Q-PCR. Non-specific
binding was assessed by a parallel immunoprecipitate with IgG. Standard error is depicted by
the bars from one biological repeats with triplicate Q-PCR samples. The same trend was
observed in subsequent biological repeats. B, Wip1 transcript levels quantitated using RT-QPCR in asynchronous HCT116 p53 +/+ and HCT116 p53 -/- cells treated with drug for 24 hours.
Transcript levels were normalized to -actin. Standard error is depicted by the bars from two
biological repeat with triplicate Q-PCR samples. C, Western blot analysis of the p53-dependent
activation of Wip1 in asynchronous HCT116 p53 +/+ and HCT116 p53 -/- cells exposed to drug
for 24 hours. Equal levels of total protein (25 g) were loaded in each lane. Vehicle was PBS,
HU was used at 1.5 mM, PALA was used at 100 M and VP16 was used at 10 M. Protein
loading was assessed with-Actin.
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null for p53, the Wip1 transcript levels are down to basal (Fig 2-18B). Wip1 protein levels
correlated with the transcript levels; there is a large induction of Wip1 protein after PALA
treatment and only a small, if any, induction of Wip1 protein after HU treatment. There was no
significant Wip1 protein in HCT116 p53 null cells (Fig 2-18C).
In order to determine the functional significance of the enhanced Wip1 levels found in
PALA-treated cells, Wip1 was knocked down with pools of siRNA and the phosphorylation
status of Chk1 was investigated to determine the role of Wip1 in preventing Chk1
phosphorylation during PALA treatment. Drug treatment began 48 hours after transfection of
the Wip1 siRNA. Lysates were made 72 hours after transfection. Wip1 knock-down was
remarkably efficient; Wip1 protein was undetectable in all samples following siRNA treatment.
Chk1 phosphorylation was not restored during PALA treatment in the absence of Wip1 (Fig 219). The amount of Wip1 knockdown effectively abolished phosphatase activity as is observed
by the increase in phosphorylation at serine 15 of p53, a residue that Wip1 is known to
dephosphorylate. This suggests that Wip1 was playing a minor role in the failure to activate
Chk1 following PALA treatment and, hence, in assembling the S-phase checkpoint.
Interestingly, there was a substantial increase in the level of phosphorylation of p53 at serine 15
in all siRNA treated samples, an indication of the role of Wip1 in control of the steady-state
levels of this phosphorylation.
The protein phosphatase 2A (PP2A) has been shown to dephosphorylate Chk1 at serine
345 maintaining a hypophosphorylated Chk1 during unperturbed S-phases (Leung-Pineda et al.,
2006). To rule out the possibility that PP2A was compensating for the loss of Wip1 phosphatase
activity during these knock down experiments okadaic acid was used as a pharmacological
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Figure 2-19. Wip1 does not dephosphorylate Chk1 during PALA treatment. This figure
shows a western blot analysis of Wip1, total and phosphorylated Chk1 at serine 345 and total and
phosphorylated p53 at serine 15 in asynchronous HCT116 cells transiently transfected with Wip1
siRNA pools. Cells were exposed to drug 48 hours post transfection for 24 hours. Non-targeting
siRNA pools were used as a control. Equal levels of total protein (25 g) were loaded in each
lane. Vehicle was PBS, HU was used at 1.5 mM, PALA was used at 100 M and VP16 was used
at 10 M.
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inhibitor of the PP2A. Treatment of HCT116 cells prior to knocking down Wip1 with 50 nM
okadaic acid alone or in combination with PALA did not change Chk1 phosphorylation levels;
they were similar to what was observed with PALA treatment (Fig 2-20). In HCT116 cells in
which Wip1 was knocked down, okadaic acid treatment did not restore Chk1 phosphorylation
following PALA treatment. The phosphorylation of Chk1 was not detectable during okadaic
acid and PALA treatment suggesting PP2A is not responsible for the lack of Chk1
phosphorylation in the absence of Wip1 (Fig 2-20B).

PALA treatment fails to recruit ATR to the chromatin
The other explanation for the lack of Chk1 phosphorylation during PALA treatment could be that
ATR is not activated by recruitment to replication forks during the slowed S-phase progression. If ATR
is not present at stalled replication forks, Chk1 will not become phosphorylated and activated and, as a
result, the S-phase checkpoint will not be intact. This question of the recruitment of ATR to nucleotide
deficiency-induced stalled replication forks was addressed by fractionating chromatin away from the
soluble nuclear proteins in synchronized HCT116 cells and determining whether ATR was bound to
chromatin in HU and PALA treatment. The fractions were blotted for the presence of ATR. In whole
cell and soluble nuclear fractions the levels of ATR are relatively consistent over the treatments, ruling
out transcriptional or post-transcription effects on total cellular levels of ATR by PALA. Yet, there is no
detectable ATR accumulating in the chromatin-bound fraction during PALA treatment, while there is a
significant level of ATR recruited to the chromatin after HU treatment, indicating that Chk1 is not
phosphorylated during PALA due to the lack of ATR chromatin recruitment (Fig 2-21). Interestingly, the
S-phase checkpoint proteins phosphorylated Chk1 and BLM were also not recruited to the chromatin

during PALA treatment, yet there were equivalent levels of p53 at the chromatin during HU and
PALA treatment (Fig 2-21). The lack of S-phase proteins at the chromatin during PALA
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Figure 2-20. PP2A does not compensate for the absence of Wip1. A, This figure shows a
western blot analysis of total and phosphorylated Chk1 at serine 345 in asynchronous HCT116
cells. The arrow indicates the band specific for phosphorylated Chk1. The PBS vehicle
corresponds to the HU and PALA samples and the EtOH vehicle corresponds to the PALA with
OA and OA alone samples. B, This figure shows a western blot analysis of Wip1 and
phosphorylated Chk1 in asynchronous HCT116 cells transiently transfected with Wip1 siRNA
pools. Cells were exposed to drug 48 hours post transfection for 24 hours. Non-targeting siRNA
pools and a mock transfection were used as a control. HU was used at 1.5 mM, PALA was used
at 100 M and OA at 50 nM.
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Figure 2-21. S-phase checkpoint proteins are not recruited to the chromatin after PALA
treatment. This figure shows a western blot analysis of the assembly of S-phase checkpoint
proteins on chromatin. G0/G1 synchronized HCT116 cells were released into drug containing
medium for 24 hours and the chromatin was fractionated from whole cell lysates as described by
(Mendez and Stillman, 2000). Equal protein levels (25 g) of whole cell, nuclear soluble and
chromatin fractions were analyzed by western blot for ATR, phospho Chk1, BLM and p53.
H3K4 me3 was used to demonstrate the purity of the fractions. Vehicle was PBS, HU was used
at 1.5 mM and PALA was used at 100 M.
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treatment suggests that, due to the failure of ATR recruitment, the S-phase checkpoint is not
activated and therefore, these proteins were not being actively recruited to stalled replication
forks.

The equivalent levels of chromatin-bound p53 observed during the two treatments

suggests that, during PALA treatment, p53 is involved in other cellular processes occurring at the
chromatin, possibly at the level of transcription, i.e. binding at p53RES in promoters.

The Cellular Consequences of the Differential Chk1 Phosphorylation
PALA treatment is cytotoxic while HU treatment is cytoprotective
Colony formation assays were used to test the ability of cells to recover and survive after
HU and PALA treatment. A classical colony formation assay was performed, allowing cells to
adhere for five hours and then replacing the growth medium with medium containing increasing
concentrations of drugs for 24 hours. Both HCT116 p53 +/+ and HCT116 -/- cells lines were
used in this assay. PALA treatment had a steeper decline in cell survival over the range of
concentrations tested; this trend was observed in both cell lines. HU treatment did not decrease
cell survival as steeply as did PALA treatment, but at concentrations ≥ 3mM HU, cell survival
decreased in both cell lines. In both treatments, cells were unable to survive at a higher drug
concentration and cells without p53 were less sensitive to the cytotoxicity of both drugs.
However, the most important aspect of this analysis is that, at concentrations of HU that were
markedly inhibitory to cell progression through S-phase, i.e. 1.5 mM, HU was without
cytotoxicity whereas a concentration of PALA that impeded S-phase progression (100 M) was
grossly cytotoxic (Fig 2-22).
To determine the time course of commitment to cell death, synchronized cells were
released into either HU or PALA for various lengths of time. At each time point, adherent and
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Figure 2-22. HCT116 cells containing wild-type p53 are more sensitive to cell kill induced
by HU or PALA treatment than HCT116 null of p53. HCT116 p53 +/+ (solid symbols) and
HCT p53 -/- (open symbols) were plated and allowed to adhere for 5 hours. Medium containing
10% dFBS and various concentrations of HU (circles) or PALA (triangles) were added for 24
hours. Cells were maintained in drug free medium after the exposure for an additional 8 days
and colonies were stained and counted and plotted as survival of drug treated cells compared to
vehicle treated cells. Points indicate the mean of three plates within a single experiment and
standard error is depicted by the bars.
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floating cells were collected and counted. Both ND and HU treated cells were plated in fresh
drug-free medium at 150 cells/60 mm2 dish while PALA treated cells were plated at 150, 1,500
and 15,000 cells/60 mm2 dish and allowed to attach and grow for 7 days. HU-treated cells were
protected from nucleotide deficiencies for 36 hours, after 48 hours of drug treatment cell survival
decreased slightly. However, the cell survival observed during HU treatment never decreased
below 10% survival throughout the 72 hour time course (Fig 2-23). Conversely, the cytotoxicity
of PALA treatment was observed within 6 hours of treatment; cell survival decreased to ~10%
and continued to decrease with time. By 48 hours, PALA treatment was cytotoxic with ≤ 0.1%
cell survival (Fig 2-23). The cytotoxicity of PALA treatment can easily be seen in Fig 2-23A;
very few colonies out of the total of 15,000 plated cells survived after 12 hours of PALA
treatment, while HU and untreated cells contained a similar number of colonies at 12 hours (Fig
2-23A). The S-phase checkpoint appeared to be protecting HU-treated cells from cytotoxicity
while the lack of S-phase checkpoint resulted in cytotoxicity within 6 hours of PALA treatment.

PALA treatment promotes a p53-dependent apoptosis
The post-translational phosphorylation of p53 during PALA treatment at serine 46
suggested that these cells may be undergoing p53 dependent apoptosis (Mayo et al., 2005). This
proved to be the case: after 24 hours, PALA-treatment resulted in apoptosis as observed by
cleaved caspases 7 and 9, as well as by PARP1 (Fig 2-24). Treatment with HU did not cause
cleavage of any of these proteins crucial to the apoptotic response. The PARP1 cleavage during
PALA treatment was shown to be dependent on p53, in concordance with the data in Fig 2-14.
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Figure 2.23. The imposition of an S-phase checkpoint by HU protects HCT116 cells from
cytotoxicity for an extensive period, whereas PALA exposure is rapidly cytotoxic. G0/G1
synchronized HCT116 cells were released into drug-containing medium for the indicated times
and adherent and non-adherent cells were re-plated at 150 cells/plate in drug free medium
allowing for colony formation. B, Quantitation of the colony formation assay in HCT116 cells
after treatment with HU or PALA at the indicated times. Points indicate the mean of two
biological repeats containing two plates within a single experiment and standard error is depicted
by the bars. Colony number was plotted as survival of drug- treated cells compared to vehicletreated cells. Vehicle was PBS, HU was used at 1.5 mM, PALA was used at 100 M.
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Figure 2-24. PALA treatment induced p53 dependent apoptosis while the HU-induced Sphase checkpoint protects cells from apoptosis. This figure shows a western blot analysis of
cleaved caspases 7 and 9, PARP1 and cleaved PARP1 in asynchronous HCT116 cells treated
with drug for 24 hours. B, Lysates from asynchronous HCT116 p53 +/+ and HCT116 p53 -/cells were probed for PARP1 to determine the p53 dependency of apoptosis. Equal levels of
total protein (25 g) were loaded in each lane. Vehicle was PBS, HU was used at 1.5 mM,
PALA was used at 100 M and VP16 was used at 10M.
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Using the p53 HCT116 isogenic cell lines, PARP1 cleavage was not observed after PALA
treatment in the absence of p53. The p53 dependency of this apoptosis was further investigated
by examining the presence of p53 at a panel of known p53-dependent pro-apoptotic promoters
after 24 hours in drug. Five promoters were chosen based on their known p53RE affinities for
p53. The p53RE in the BAX, PIG3, and AIP1 promoters are known to have weaker p53 binding
affinities while that in the PUMA and FAS promoters have higher p53 promoter affinity (Inga et
al., 2002; Kaeser and Iggo, 2002; Weinberg et al., 2005). PALA treatment promoted enhanced
binding of p53 at all of these promoters at or exceeding levels seen with the highly cytotoxic
dose of VP16 used as the control, indicating that after 24 hours in drug, PALA treatment
facilitated p53 binding to pro-apoptotic promoters (Fig 2-25). This is in agreement with the
apoptosis observed by the cleavages of caspases 7, 9 and PARP1 and the cytotoxicity measured
by colony formation assays.

The species of p53 accumulating in HU-treated cells was

apparently much less active at entering the nucleus and binding at either high- or low-affinity
p53REs.
H2AX formation is a rapid cellular response for DNA double strand breaks and
therefore to determine if apoptosis resulting from PALA treatment was due to DNA damage,
levels of H2AX were measured (Rogakou et al., 1998). There were no significant differences in
the levels of H2AX between HU and PALA treatment and both were less than the positive
control for DNA damage, VP16 (Fig 2-26).
Another hypothesis was tested in the experiments that investigated rescue of HU
treatment with the addition of 2-deoxyadenosine (AdR) and 2-deoxyguanosine (GdR), the purine
deoxyribonucleotides discussed above.

The apoptosome formed by the intrinsic apoptotic

pathway responsible for cleavage of caspase 9 and initiating the downstream signaling has been
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Figure 2-25. PALA treatment induces p53 binding at promoters of pro-apoptotic proteins.
ChIP analysis of p53 enrichment at pro-apoptotic promoters in asynchronous HCT116 cells after
24 hours of drug treatment. p53-DNA complexes were immunoprecipitated from crosslinked
cells and PUMA, FAS, PIG3, BAX, AIP1 promoter levels were quantitated with Q-PCR. Nonspecific binding was immunoprecipitated with IgG. PUMA and FAS promoters correspond to
the left ordinate while PIG3, BAX and AIP1 promoters correspond to the right ordinate.
Standard error is depicted by the bars from one biological repeat with triplicate Q-PCR samples.
The same trend was observed in subsequent biological repeats. Vehicle was PBS, VP16 was
used at 10 M, HU was used at 1.5 mM and PALA was used at 100 M.
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Figure 2-26. HU and PALA-treatment induce the same level of H2AX in asynchronous
HCT116 cells. This figure shows a western blot analysis of levels of H2AX after exposure to
10 M VP16, 1.5 mM HU or 100 M PALA for 24 hours. Total cell lysate protein (25 g) was
subjected to SDS-PAGE and immunoblotted with antibodies against H2AX and -Actin. VP16
was used as the positive control. Protein loading was assessed with -Actin.
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shown to be dependent on cytochrome c and dATP (Zou et al., 1999). Since HU depletes all
dNTPS (Bianchi et al., 1986; Rosenthal et al., 1928), it was hypothesized that HU treatment
cannot promote apoptosis due to the lack of availability of dATP for apoptosome assembly.
PARP1 cleavage was immunoblotted for in these samples. There was no change in cleavage
between the HU sample alone and the HU supplemented with AdR and GdR. Therefore, the
depletion of dATP is not preventing apoptosis in HU treatment (Fig 2-15 B). Ultimately, the
supplementation experiments with AdR and GdR did not explain the differences in the cellular
responses between HU and PALA treatment.

Discussion
We have found that HCT116 cells respond very differently to two drugs that both cause
an inhibition of nucleotide synthesis pathways and a subsequent slowed progression of S-phase
and stalling of replication forks. The ribonucleotide reductase inhibitor HU activates the S-phase
checkpoint through ATR recruitment to the chromatin and Chk1 phosphorylation and is not
appreciably cytotoxic for several generation times.

PALA, an inhibitor of aspartate

transcarbamylase in the de novo pyrimidine synthesis pathway, fails to activate the S-phase
checkpoint resulting in commitment to a p53-dependent apoptosis without a lag time. One
would hypothesize that these two drugs essentially stress the cells in the same manner, by
causing an imbalance of nucleotides, and would be expected to result in similar cellular
responses. This is clearly not the case in HCT116 colon carcinoma cells.

Why does HU induce the S-phase Checkpoint and PALA does not?
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Flow cytometry analysis of G1 synchronized cells released into HU and PALA
demonstrated that the cells are slowly progressing though the S-phase (Fig 2-12). The nearly
comparable rates of S-phase progression suggested that the two drug treatments were causing
similar cell cycle signaling; this was shown to not be true. The S-phase checkpoint effector
kinase Chk1 was phosphorylated during HU treatment indicating an activated S-phase
checkpoint, while PALA treatment resulted in minimal phosphorylation of Chk1 (Fig 2-13). The
differential Chk1 phosphorylation was found to be due to the levels of ATR recruited to the
chromatin (Fig 2-21).

PALA treatment did not cause ATR recruitment to the chromatin,

explaining the lack of Chk1 phosphorylation; the upstream kinase was not recruited and
therefore, Chk1 could not become phosphorylated and activated. Interestingly, another S-phase
checkpoint protein, BLM, was also not at the chromatin after PALA treatment, while HU
treatment resulted in BLM recruitment. It is clear that PALA treatment did not activate the
signaling pathway involved in the S-phase checkpoint (Fig 2-5), but the question remains as to
why there is such a disparity between HU and PALA treatment? Why is ATR recruited to the
chromatin only after HU treatment? ATR recruitment was shown to be dependent on ATRIP
loading onto RPA coated ssDNA and that the long stretches of RPA-coated ssDNA is the
molecular trigger initiating the S-phase checkpoint (Zou and Elledge, 2003). It is possible that
PALA treatment does not result in long stretches of exposed ssDNA at replication forks. Since
the recruitment of ATRIP and ATR depends on RPA bound ssDNA, if this event is not
occurring, then the differences in ATR recruitment between HU and PALA treatment could be
explained be examining the RPA levels at stalled replication forks.

Why is PALA cytotoxic and HU is not?
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Cell kill was obvious early studies of PALA treatment. After cells were treated with
PALA for extended lengths of time (> 24 hours) the majority of the cells were falling off the
tissue culture dish and floating. Throughout the time course studies, it was difficult to obtain
enough cells at the later time points for flow cytometry or western blot analysis. The answer
became clear when I discovered that the HCT116 cell death after PALA was apoptotic (Fig 224). PALA induces apoptosis and HU does not at equivalent functional effects on S-phase
traverse. Interestingly, there appeared to be no lag time in the observed apoptosis. Within 6
hours of PALA treatment, 90% of the cells were unable to survive and by 36 hours no significant
cell survival was observed (Fig 2-23). This was not true for HU-treated cells; almost all plated
cells were still able to survive and form visible colonies after 48 hours of HU treatment. When
the dependency of cell survival on p53 was investigated, it was shown that at the working
concentration of PALA (100 M), 50% of HCT116 cells null for p53 could survive while cells
wild-type for p53 could not (Fig 2-22).
The mode of cell death was first suggested by analysis of the PTMs of p53 after HU and
PALA treatment. The PTMs of the accumulated p53 were completely opposite following HU or
PALA treatment (Fig 2-8). During HU treatment serines 15 and 20 were phosphorylated. ATR
is known to phosphorylate p53 at serine 15 and Chk1 is known to phosphorylate p53 at serine 20
(Shieh et al., 2000; Tibbetts et al., 1999); therefore these modifications correlate with the
observed activation of the S-phase checkpoint in HU but not in PALA. The modifications on
serines 37, 46 and 392 during PALA treatment are informative of the cellular activities of p53:
phosphorylation of serine 46 has been shown to favor p53-dependent apoptosis (Mayo et al.,
2005), serine 392 phosphorylation enhances p53 tetramerization and subsequent DNA binding
(Hupp et al., 1992; Keller et al., 2001; Sakaguchi et al., 1997), and phosphorylation of serine 37
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promotes sequence-specific DNA binding of p53 (Sakaguchi et al., 1998). During HU treatment
none of these sites were phosphorylated to the extent observed during PALA treatment,
suggesting that the p53 accumulated during PALA treatment was activated to bind to DNA and
promote apoptosis whereas the p53 in HU-treated cells was not. This was found to be true;
PALA-stabilized p53 was bound to all investigated pro-apoptotic promoters at levels greater than
that of the HU-stabilized p53 (Fig 2-25). It was later discovered that PALA induces apoptosis
which is dependent on p53; cleavage of PARP1 was not observed after PALA treatment in
HCT116 cells null for p53 (Fig 2-24).

The dependency on p53 for inducing apoptosis after

PALA treatment and the fact that HCT116 cells null for p53 are able to survive after 24 hours of
PALA treatment while HCT116 cells wild-type for p53 are not, indicated that the key factor in
this decision for apoptotic cell death appeared to be p53.

Does p53 determine cellular fate?
It appears that p53 is involved in the differing cellular responses to HU and PALA. The
total amount of accumulated p53 between the two treatments is significantly different and the
post-translational modifications of the accumulated p53 are completely opposite when
comparing drug treatments. Secondly, the apoptotic response was found to be p53-dependent
and the colony formation assays demonstrated that p53 null cells are better able to survive after
PALA treatment, all implicating the involvement of p53.
It was consistently observed that PALA treatment resulted in the accumulation of twice
as much p53 than seen after HU treatment (Figs 2-11, 2-13, 2-14, 2-15). This was observed in
synchronous cells, asynchronous cells and over a range of time points. Why is there a difference
in the p53 levels accumulated after HU and PALA treatment? It has been shown that the nuclear
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export sequence (NES) that is located at amino acids 340-351 within the oligomerization domain
is masked by p53 tetramerization resulting in nuclear retention of p53 (Stommel et al., 1999).
The PTMs of p53 after PALA treatment, specifically phosphorylation of serine 392, suggested
that after PALA treatment, the accumulated p53 forms tetramers more readily than the HUstabilized p53. If this is found to be true, then during PALA treatment the tetramerization of p53
may be masking the NES and therefore trapping p53 in the nucleus and protecting it from
degradation, while the p53 accumulated during HU treatment is not.

How do the differing levels of accumulated p53 ultimately determine the cellular fate of
PALA-treated cells?
Although the exact answer to this question remains to be elucidated, the experiments
presented throughout this chapter have led to some interesting hypotheses. The role of p53 in the
S-phase checkpoint is complex and there is no known required transcriptional role for p53 in the
S-phase checkpoint. It is thought that p53 interacts with BLM and Rad51, enhancing their
recruitment to stalled replication forks independent of transcriptional activation.

Previous

literature has suggested that the p53 stabilized during HU treatment has decreased transcriptional
activity when compared to IR-stabilized p53 as determined by northern blot analyses of RNA
levels of several p53 dependent genes including, p21, gadd45, hdm2 and cyclin G (Gottifredi et
al., 2001).

In this chapter, we showed that HU treatment activates a functional S-phase

checkpoint as shown by ATR recruitment to the chromatin and phosphorylation of Chk1. This
would suggest that the transactivating ability of p53 is dispensable for a functional S-phase
checkpoint. Furthermore, it appears that, during PALA treatment, promoters are enriched with
p53 to a greater extent than during HU treatment. In the ChIP assays described throughout this
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chapter, PALA-stabilized p53 was found to bind to large range of promoters, as observed in the
panel of pro-apoptotic promoters and the p21 promoter (Fig 2-7 & Fig 2-25). Conversely, during
HU treatment the upstream binding site of the p21 promoter, which is known to have the highest
affinity for p53 (Inga et al., 2002; Kaeser and Iggo, 2002; Weinberg et al., 2005), was the only
promoter that had significant levels of p53 enrichment. These data suggest that the PALAstabilized p53 is able to bind p53RE within promoters better than that of the HU-stabilized p53.
The PALA-stabilized p53 is capable of transactivating genes, as is evident from the robust
stimulation of Wip1 transcription (Fig 2-18). Therefore, these data raise the possibility that a
stabilized p53 that is able to bind and transactivate genes is capable of inducing apoptosis while
the p53 accumulated during HU treatment is not capable of activating the genes required for
apoptosis. However, stabilization of p53 caused by HU treatment may enhance the recruitment
of BLM and Rad51 to stalled replication forks in the S-phase checkpoint.

Is p53 differentially recruited to replication forks in HU and PALA treatment?
Although the levels of p53 recruited to the chromatin during HU and PALA treatment
appeared to be similar (Fig 2-21), the chromatin fractionation isolated all nuclear chromatin.
Replication forks as well as promoters of p53-dependent genes were both included in this
chromatin fraction, making it difficult to differentiate the levels of p53 recruited to the chromatin
from that of p53 bound to p53REs in promoters. The p53 accumulated after PALA treatment
was shown to be more capable of binding to promoters than the HU-stabilized p53 (Fig 2-25), so
it is logical to hypothesize that a large majority of the chromatin bound p53 is indeed p53 bound
to promoters, not p53 at replication forks.

To determine if HU and PALA treatment

differentially recruit p53 to replication forks, colocalization studies of p53 and BrdU in HU and
PALA treated cells could be performed. Treating cells with DNase after a brief pulse with BrdU
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has been shown to lead to BrdU incorporation at stalled replication forks (Kennedy et al., 2000).
This methodology would allow the identification of stalled replication forks by
immunofluorescence and colocalization of p53 with the replication forks could then be
determined.
Is the S-phase checkpoint activated by HU treatment cytoprotective?
It was clear that PALA treatment resulted in marked cytotoxicity, but did the S-phase
checkpoint activated by HU treatment protect the cells from nucleotide deficiencies? The data
presented within this chapter centrally proves that HCT116 cells are protected from cytotoxicity
during HU treatment. After 36 hours of HU treatment, cells were able to survive as well as the
untreated control and even after 72 hours of HU treatment, cells showed some toxicity but a
small percentage (~17%) of them still were able to survive and form colonies (Fig 2-23).
Interestingly, HCT116 cells null for p53 and HCT116 wild-type for p53, were able to survive to
the same extent when treated with HU at the working concentration of 1.5 mM for 24 hours (Fig
2-22). The p53 dependency of Chk1 phosphorylation during HU treatment also demonstrated
that Chk1 was phosphorylated at serine 345 and 317 in HCT116 p53 -/- cells to the same extent
as HCT116 cells containing wild-type p53 (Fig 2-14). Both observations suggest that p53 is not
required for a functional checkpoint and the resulting cytoprotectivity that the S-phase
checkpoint provides during HU treatment. The exact role of p53 during the S-phase checkpoint
activated by HU treatment remains to be elucidated and the cell line, which will be described in
the next section was generated to address this question.
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Chapter 3: Development and Characterization of an Endogenously TAP-tagged p53 Locus

Introduction
The p53 tumor suppressor is known to be involved in several cellular pathways that are in
place to protect the cell from tumorigenesis. p53 is one of the main regulators in cell cycle
control and apoptosis pathways yet it is mutated in half of all human cancers resulting in
dysregulation of the cell cycle and of apoptosis. For this reason, the cellular and molecular
functions of p53 have been thoroughly investigated to understand its cellular roles and to better
comprehend the changes that cancer cells undergo following mutation of p53.
p53 exerts its tumor suppressor activity through two main functions; by binding to gene
promoters recruiting transcriptional machinery activating (or repressing) transcription, and by
directly binding to and modulating protein functions. The transcriptional regulation activity of
p53 has been extensively investigated while the modulation of protein functions by p53 is less
well characterized.

There are examples in both cell cycle regulation and apoptosis pathways

where p53 exerts its tumor suppressor activity by both mechanisms.
p53 was first implicated in homologous recombination when p53 null mammalian cells
were shown to have elevated levels of spontaneous homologous recombination (Mekeel et al.,
1997). Since then, the proteins involved in homologous recombination have been identified and
the role of p53 in this pathway has been further elucidated. Rad51 is induced in late S-phase and
G2 and binds to single stranded DNA during the initial steps of homologous recombination
(Benson et al., 1994; Flygare et al., 1996). Rad51 possesses DNA-dependent ATPase activity
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which supplies the energy needed for the homologous pairing and strand exchange steps during
homologous recombination (Baumann et al., 1996). p53 was shown to inhibit homologous
recombination through binding to and modulating the function of Rad51 (Linke et al., 2003;
Sturzbecher et al., 1996). Rad51 and p53 co-localize to stalled replication forks induced by HU
and their interaction stabilizes the replication fork through inhibition of the Rad51-driven branch
migration (Sengupta et al., 2003; Yoon et al., 2004). During VP16-induced DNA damage, p53
binds to the Rad51 promoter inhibiting the transcription of this gene. Therefore, p53 controls
homologous recombination at two levels when the genome integrity is compromised; through
protein-protein interactions and through transcriptional repression (Arias-Lopez et al., 2006).
This duality of p53 in control of a cellular process also occurs during apoptosis. It was
shown that p53 had a role in apoptosis when p53 null tumor cells underwent spontaneous cell
death after the introduction of wild-type p53 (Yonish-Rouach et al., 1991). Bax has been welldefined as an apoptotic protein that inserts into the outer mitochondrial membrane to form a
pore, releasing cytochrome c and activating cytosolic events in the apoptotic pathway (Rosse et
al., 1998). The restoration of p53 in murine leukemia cells caused an increase of Bax mRNA and
protein levels (Selvakumaran et al., 1994). Bax was found to be a direct transcriptional target of
p53 and it was the first example of a proapoptotic gene that is directly regulated by p53
(Miyashita and Reed, 1995). Almost ten years after the discovery of the transcription activation
of Bax by p53, p53 was found to bind to Bax directly, promoting mitochondrial
permeabilization, a characteristic of apoptosis (Chipuk et al., 2004). Homologous recombination
and apoptosis are two examples of very different cellular processes in which p53 exerts tumor
suppressor activity through effects at both the level of transcriptional control and at the level of
protein-interactions.
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There are several examples where p53 exerts only one level of control by binding to and
modulating protein functions. One such example is the control of the function of the RecQ
helicase, BLM, the product of the gene responsible for causing Bloom‟s syndrome when
mutated.

Cells from Bloom Syndrome patients exhibit chromosomal instability due to an

elevated rate of sister-chromatid exchange, suggesting that a protein involved in recombination is
mutated in these cells (Chaganti et al., 1974). The sequence of BLM has high homology with the
RecQ family of helicases and was shown to have 3′-5′ helicase activity (Ellis et al., 1995; Karow
et al., 1997). BLM selectively recognizes Holliday junctions and promotes the branch migration
of these junctions, preventing homologous recombination events from occurring (Karow et al.,
2000). It has been hypothesized that when replication forks stall, Holliday junctions arise and
that resolution of these structures would result in a double-strand DNA break (Sharples et al.,
1999). p53 has been shown to bind directly to BLM, modulating the helicase activity. By
inhibiting the resolution of the Holliday junctions at stalled replication forks, modulation of
BLM by p53 prevents the collapse of replication forks, as well as further DNA damage and the
threat of tumorigenesis (Yang et al., 2002).

The problem addressed in this chapter
With the myriad mechanisms of action of p53 that occur, the question arises of how to
suitably study the binding of p53 to various proteins and promoters in the cell while also
conserving the ability to determine whether various PTMs drive p53 to these various nuclear,
cytosolic and mitochondrial compartments.

Specifically, the role of p53 in the S-phase

checkpoint has been recently proposed and the question arises whether p53 is binding to other
checkpoint proteins. In order to address this question, p53 has to be isolated at endogenous
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levels with all interacting proteins during nucleotide deficiencies to determine what proteins bind
p53. To address these questions, we have designed and created a HCT116 cell line in which a
tandem affinity purification tag has been inserted into one of the endogenous p53 alleles by
homologous recombination.

The use of TAP tag to study protein-protein interactions
Until recently, the methodology to ask non-biased questions about protein interactions
within mammalian cells has been limited. Co-immunoprecipitation experiments only provide
data answering specific questions such as, „does protein x interact with protein y?‟ and usually
are confined to analysis of such events in whole cell lysates. The ability to ask „what are all of
the proteins that interact with protein x?‟ has not been easily feasible until the introduction of the
tandem affinity purification (TAP) tag technology combined with mass spectrometry. This tag
was designed to allow the target protein to be purified with all interacting proteins using mild,
non-denaturing, purification conditions. The two step purification tag consists of a protein A tag
and a calmodulin binding peptide separated by a tobacco etch virus (TEV) protease cleavage site
(Fig 3-1) (Rigaut et al., 1999). This cleavage site was found to be advantageous over others
because the TEV nuclear inclusion A protein encoded by the tobacco etch virus is stable and
active over a range of pH, ionic strengths and temperatures and recognized a short peptide
sequence rarely found in mammalian tissues. The proteinase has stringent sequence specificity
for the TEV cleavage site, decreasing proteolysis of cryptic sites within mammalian proteins
(Parks et al., 1994).

IgG beads are used as the first affinity adsorption matrix to select any

protein bearing the protein A tag. The complex is removed from the beads by cleavage with the
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TEV protease. The complex is then subjected to the second affinity matrix absorption onto
beads covalently attached to calmodulin in the presence of Ca2+ which selectively binds to the
calmodulin binding peptide. The protein complex is eluted and isolated through chelation of the
Ca2+ with EGTA (See Figure 3-1) (Rigaut et al., 1999). The tandem purification approach is
superior to single purification tags for two reasons; the two purification steps allow for a purer
isolated product with less contaminants, and the design of the TAP tag allows for stringent, nondenaturing purification conditions making it possible to isolate protein binding partners.

Gene Targeting Allows Protein Interactions to be studied at endogenous levels
Protein interactions are driven by association constants (Ka) and therefore protein-protein
interactions should be studied at endogenous levels to rule out any false positives resulting from
the over expression of the target protein of interest. With the use of the TAP tag, isolation of
these interactions are now possible, and in combination with gene targeting, the TAP tag
sequence can be inserted by homologous recombination at the end of the endogenous gene locus
coding the protein of interest. This would result in the transcription and translation of the target
gene and the incorporated TAP tag in one contiguous transcript, allowing protein interactions to
be studied at natural endogenous levels. This was first achieved in yeast in 1999 and, in 2002,
Seraphin‟s group used the TAP tag to identify 234 multiprotein complexes and proposed new
roles for 344 of the proteins, 231 of which had no previously known function. Function could be
assigned for most of these unassigned open reading frame proteins by a “guilt-by-association”
logic, demonstrating the power of this technology (Gavin et al., 2002; Rigaut et al., 1999).
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Figure 3-1. Overview of Tandem Affinity Purification Procedure. Cellular lysates are
incubated with IgG beads that bind to protein A in the TAP tag. The target protein and binding
partners are eluted from the IgG beads with TEV protease. The eluate is then bound to
calmodulin beads in the presence of CaCl2, which will bind to the calmodulin binding peptide.
The target protein and binding partners are eluted by chelating the CaCl2 with EGTA.
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rAAV as the mode for gene delivery
For successful gene targeting events to occur, the targeting vector must pair up with the
homologous sequence in the chromosome. Considering that the human genome is three million
base pairs, the frequency of this occurring is exceptionally low (Vasileva and Jessberger, 2005).
Previous methodologies to introduce targeting vectors into mammalian somatic cells consisted of
lipid based transfections or electroporation of double-stranded DNA plasmid, which resulted in
frequencies of one cell out of a million transfected cells incorporating the targeting sequence into
their genomes by homologous recombination, but substantial frequencies of incorporation at
random locations within the genome occurred (Sedivy and Sharp, 1989). This low frequency of
correct insertion against a very high background made manipulating the endogenous genetic
locus of mammalian cells difficult, and required screening tens of thousands of cell clones to find
one clone in which correct sequence-specific integration had occurred. The introduction of
recombinant adeno-associated viruses (rAAV) as the mode of gene delivery greatly improved
these frequencies (Kohli et al., 2004). AAV were first used in the early 2000‟s as a method to
introduce genetic modifications into homologous human chromosomes. Vectors containing 1.5
kb of homologous sequence could be inserted into the correct location of the targeted gene at a
frequency of 1%, a vast improvement from previous methodologies (Hirata et al., 2002).
AAV is a single-stranded linear DNA virus with a 4.7 kb genome containing a rep gene
and a cap gene encoding proteins required for viral replication and encapsidation of the viral
genome. Inverted terminal repeats (ITR) are also required for replication. The ITR sequences
are 145 bp palindromic sequences which allow the virus to fold into a hairpin, these sequences
are required for integration into the host genome and viral replication. In recombinant rAAVs,
the rep and cap genes are replaced with homologous sequence to the gene to be targeted and the
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viral genes are supplied in trans through helper vectors during the viral packaging step. The
packaging limit of AAV is approximately 4.9 kbs and the ITR sequence is the only viral
sequence required to be provided in cis, providing space for 4.4 kb homologous sequence to be
cloned into the vector. These longer stretches of homologous sequences increase the frequency
of homologous recombination with the targeted genome (Reviewed in (Carter, 1992)).
It is not well understood why rAAV yield higher frequencies of gene targeting than
previous methodologies, but there are several hypotheses. Since a large number of intact viral
vectors are delivered to each cell, this increases the probability of homologous recombination
occurring. In addition, the single stranded viral genome is highly recombinogenic and is thought
to promote homologous pairing better than double stranded substrates similarly to homologous
recombination frequently seen with stretches of single-stranded DNA at replication forks and,
lastly, the hairpin structure of the genome may decrease random integration (Russell and Hirata,
1998).

Steps involved in generating human somatic knock-ins
Generating human somatic knock-ins consists of four steps: (i) designing and creating a
targeting vector containing homologous sequence to the gene to be targeted, (ii) delivery of the
targeting vector by rAAV to the cells, (iii) selecting for cells which underwent homologous
recombination with the targeting vector and (iv) screening cell clones for gene knock-in at the
correct location in the genome. Although this process is laborious, when compared to creating
cell lines where the sequence transfected randomly integrates into the genome, the advantages of
studying endogenously altered genes far outweighs the time involved in the creation of the cell
line.
110

To understand the function of p53 at the replication fork during nucleotide deficiencies
we have inserted a TAP tag into the p53 genomic locus at the C-terminus in human colon cancer
HCT116 cells. The protein product of this allele appears to be fully functional in comparison
with the wild-type p53 protein translated from the unaltered allele. We have used this cell line to
isolate p53 with its binding partners under the cellular stress of DNA damage induced by VP16
and nucleotide imbalances induced by HU and PALA.

This cell line is a powerful tool for

studying p53 in various cellular compartments, when combined with physical subfractionation of
the cell and/or immuno-selection of megacomplexes, as well as in studying the protein-protein
interactions of p53 during any form of cellular stress.

Materials & Methods
Prior to deciding to use the rAAV as the method of delivery of the TAP tag sequence into
the HCT116 cells, the sequence encoding the TAP tag and 3kb of the p53 coding sequence
directly upstream from the stop codon were cloned into the pIRES-neo2 vector. The cloning of
this vector will be explained first (Fig 3-2), and then the use of this vector as the template for
PCR in cloning the vector which was ultimately used in the gene targeting by rAAV will be
described. The final vector used for inserting the TAP tag sequence into the p53 genomic locus
was named pAAV-MCS p53 TAP (Fig 3-3).

Generating the template sequences used to clone the pAAV-MCS p53 TAP
Amplifying the TAP tag sequence and the 3 kb p53 coding sequence
The sequence encoding the calmodulin peptide, TEV cleavage site and protein A of the
TAP tag was amplified from the p-Zome-1-C plasmid using TAP tag pZome sense primer
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Figure 3-2. Overview of cloning the pIRES-TAP-p53 vector. A, The sequence encoding the
TAP tag peptide was amplified from the pZOME-1-C vector with a sense primer with a 5′- HpaI
restriction site and an antisense primer with a 3′-NotI restriction site. The amplified TAP tag
PCR product and the pIRES-neo2 vector were digested with HpaI and NotI and ligated,
generating the pIRES-TAP vector. B, The p53 coding sequence upstream from the stop codon
was amplified from genomic HCT116 DNA with a sense primer containing a 5′- AlfII site and an
antisense primer containing a HpaI site. The amplified p53 upstream PCR product and the
pIRES-TAP vector were digested with AlfII and HpaI and ligated generating the pIRES-TAPp53 vector. This vector was used as the PCR template in amplifying the left homology arm
required for the cloning of the vector required for rAAV gene targeting.
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Figure 3-3. Overview of the insertion of a TAP tag into the endogenous p53 locus by
homologous recombination. A, This figure shows the vector designed, cloned and transfected
in the generation of the cell line. The plasmid backbone is in rust, the right and left homology
sequences required for homologous recombination are in turquoise and the resistance cassettes
are in peach. B, The two p53 genomic loci after homologous recombination with the transducing
vector. Grey boxes indicate the endogenous exons and white indicates the exogenous sequence
inserted through homologous recombination.
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containing a HpaI restriction site and TAP tag pZome antisense primer containing a NotI
restriction site (Table 3-1, Fig. 3-2A) (Euroscarf, Frankfurt Germany). The 25 L PCR reaction
contained 20 mM Tris-HCl, 50 mM KCl (pH 8.4; MgCl2 Free 10x PCR Reaction Buffer), 200
M deoxynucleotides, 1.5 mM MgCl2, 0.6 M of each primer, 1 U Taq DNA Polymerase, 0.25
U PfuTurbo DNA Polymerase, 5% DMSO and 100 ng of p-Zome-1-C. The PCR program
consisted of a 10 minute incubation at 94ºC, followed by 35 cycles of 94ºC for 45 second, a
range of temperatures from 45ºC-42ºC to determine the optimal annealing temperature of the
primers for 45 seconds, and 72ºC for 3 minutes, and finished with a final extension at 72ºC for 5
minutes. PCR products were run on a 1% agarose gel with ethidium bromide and the 600 bp
product was extracted and purified using the Promega Wizard SV gel and PCR Clean-Up
System. The concentration of the purified product was determined by sample absorbance at 260
nm and the sequence of the purified product was checked.
A 3 kb fragment of the genomic p53 coding sequence was amplified from 50 ng genomic
DNA isolated from HCT116 cells by Fiona Turner with the Upstream p53 sense primer
containing a AlfII restriction site and the Upstream p53 antisense primer containing a HpaI
restriction site (Table 3-1).

The 25 L PCR reaction contained 12.5 L Hot StartTaq Master

Mix, 0.5 U PfuTurbo DNA Polymerase and 0.3M of each primer. The PCR program started
with a 15 minute incubation at 95ºC followed by a 10 cycles of 94ºC for 45 seconds, a range of
temperature from 70ºC -60ºC for 45 seconds to optimize the annealing temperature of the
primers and 72ºC for 3 minutes. This was followed with an additional 35 cycles of 94ºC for 45
seconds, 59.3ºC for 45 seconds and 72ºC for 3 minutes, and finished with an extension for 15
minutes at 72ºC (Fig 3-2B). The 3 kb band was purified as stated above and the sequence was
checked.
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Primer
TAP tag pZome sense
TAP tag pZome antisense
Upstream p53 sense
Upstream p53 antisense
Downstream p53 sense

Sequence
5′-AGTCTAGTTAACATGGAAAAGAGAAGATGG-3′
5′- TATTATGCGGCCGCATAACTTCGTATAATGTATGCTATACGAA
GTTATCTAATTAGCGTCTACTT-3′
5′-CACTACTTAAGTCCCAAGTTGCTTCAACTACAGGC-3′
5′-TAGATAGTTAACGTCTGAGTCAGGCCCTTCTGTC-3′

Downstream p53 antisense

5′-TAACTAGTCGACATAACTTCGTATAGCATACATTATACGAAGTT
ATCATTCTCCACTTCTTGTTCCCCACTG-3′
5′-GTCAATCAGCTGCTGAAGCCATGAGGAAATTGGG-3′

Left homology arm sense

5′-ATACATACGCGGCCGCCATGGTCAAAGGCAGCTG-3′

Left homol arm antisense
Right homology arm Sense

5′-GCTCCAGCTTTTGTTCCCTTTAGCTAATTAGCGTCTACTTT-3′
5′-CGCCCTATAGTGAGTCGTATTACCATTCTCCACTTCTTGTTC-3′

Right homol arm antisense
Left homol-Neo sense

5′-ATACATACGCGGCCGCTTGGCTGGCCATGGTGGCATGA-3′
5′-ATACATACGCGGCCGCCATGGTCAAAGGCAGCTG-3′

Left homol-Neo antisense

5′-GCGTAATACGACTCACTATAGGGCGAATTGGGTACC-3′

Neo-right homol sense

5′-CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGG-3′

Neo-right homol antisense
Exon 10 screening sense

5′-ATACATACGCGGCCGCTTGGCTGGCCATGGTGGCATGA-3′
5′-AGA GCTGAATGAGGCCTTGGAACT-3′

TAP screen antisense
3′-screening sense

5′-TAGCGCTTTGGCTTGGGTCATCTT-3′
5′-AGTCTAGTTAACATGGAAAAGAGAAGATGG-3′

3′-screening antisense

5′-CTTCCCAGCACCTCCTCACTCACCCCTG-3′

Table 3-1. The primers used in cloning the pAAV-MCS p53 TAP vector and in screening
for the correct insertion of the TAP tag into the p53 genomic locus by homologous
recombination.
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Cloning the sequence encoding the TAP tag and p53 sequence into the pIRES-neo2 vector
The TAP tag PCR product and pIRES-neo2 vector (Clontech) were digested with HpaI
and NotI at 37ºC for 1 hour in a 20 L reaction containing 50 mM NaCl 10 mM Tris-HCl, 10
mM MgCl2, 1 mM dithiothreitol (pH 7.9), 0.1 g/L BSA, 10 U of NotI and 10 U HpaI (Fig 32A).

Following the digestion the products were electrophoresed, purified and their

concentrations were determined as stated above. Ligation of 25 ng of the pIRES-neo2 vector
with 9.9 ng of the TAP tag PCR product (a 3:1 molar ratio) was carried out at 16ºC for 16 hours
in a 10 L volume reaction containing 66 mM Tris-HCl, 5 mM MgCl2 , 1 mM dithiothreitol, 1
mM ATP (pH 7.5) and 1 U T4 DNA ligase.
TOP10 chemically competent E. coli cells were transformed with the ligation product.
TOP10 cells were removed from the -80ºC and thawed on ice; 4 L of the ligation reaction was
added to the TOP10 cells and mixed gently. This mixture was incubated on ice for 15-30
minutes and then heat shocked at 42ºC for 30 seconds. S.O.C. medium (2% tryptone, 0.5 %
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose)
was warmed to 25ºC and 250 L was added to the tubes and the tubes were shaken vertically at
225 rpm at 37ºC for 1 hour in an orbital shaker. The transformed TOP10 cells were plated on
Luria-Bertani (LB) plates with 100 g/ml carbenicillin added and the plates were incubated at
37ºC for 16 hours. Only TOP10 cells which were successfully transformed would survive since
the pIRES-neo2 vector contained an ampicillin resistance cassette. Eight surviving colonies
were picked for expansion, inoculated into 4mL of LB medium containing carbenicillin and the
tubes were shaken vertically at 225 rpm at 37ºC for 16 hours in an orbital shaker. Bacterial cells
were pelleted by centrifugation at 4,000 x g and the plasmid DNA was isolated using a Promega
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Wizard Plus SV Miniprep kit. All purified plasmids were digested with NotI and HpaI as
described above to check for the appropriately sized insert.
The cloned pIRES-neo2 vector, now containing the TAP tag sequence was named
pIRES-TAP, and the purified p53 sequence were digested with HpaI and AflII for 1 hour at 37ºC
in a 20 L reaction containing 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM
magnesium acetate, 1 mM dithiothreitol (pH 7.9), 0.1 g/L BSA, 10 U AflII and 10 U HpaI.
Following the digest, the products were electrophoresed, purified and their concentrations were
determined as stated above. The pIRES-TAP plasmid and the purified p53 sequence insert were
ligated as stated above with 43.7 ng of the insert and 25 ng of the plasmid. The ligation was
transformed into TOP10 cells, surviving colonies were picked and mini-prepped as described
above. The eight purified plasmids were checked for the correct size insert with a digestion
including HpaI I and AflII as described above. This vector was named pIRES-TAP-p53 (Fig 32B).

Amplifying the 3kb p53 UTR fragment
A 3kb fragment of the p53 non-coding sequence directly after the stop codon was
amplified from 50 ng of genomic DNA isolated from HCT116 cells by Fiona Turner with the
Downstream p53 sense primer and the Downstream p53 Antisense primer (Table 3-1) in a 25 L
reaction containing 12.5 L Hot StartTaq Master Mix, 0.5 U PfuTurbo DNA Polymerase and 0.3
M of each primer. The PCR program started with a 15 minute incubation at 95ºC followed by
35 cycles of 94ºC for 45 seconds, 60ºC for 45 seconds and 72ºC for 3 minutes, and finished with
an extension for 15 minutes at 72ºC.

The product was electrophoresed, purified and the

concentration was determined as previously described and the sequence was checked.
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Cloning the pAAV-MCS p53 TAP vector
Homology Arm Amplification
The left homology arm was designed to contain 900 bp of p53 sequence upstream from
the stop codon and the sequence encoding the TAP tag which would provide sufficient
homologous sequence with the endogenous p53 allele to allow for homologous recombination to
occur with the vector. These sequences were amplified from the pIRES-TAP-p53 vector which
contained 3kb of p53 coding sequence upstream from the endogenous stop codon and the TAP
tag sequence. The primers used for this amplification contained a NotI restriction site in the Left
homology arm sense primer and a 23 bp sequence referred to as a linker sequence which is
required for subsequent PCR reactions in the Left homol. arm antisense primer (Fig 3-4, Table 31).

The right homology arm was designed to contain 900 bp of p53 sequence directly

downstream of the p53 stop codon to allow homologous recombination to occur with the
endogenous p53 genomic locus. This sequence was amplified from the purified PCR product
containing 3kb of p53 sequence directly after the stop codon.

The primers used for this

amplification contained a 23 bp sequence referred to as a linker sequence in the Right homol
sense primer and a NotI restriction site in the Right homol arm antisense primer (Fig 3-5, Table
3.1). Both PCR reactions contained 12.5 L Hot Start Taq Master Mix, 0.5 U PfuTurbo DNA
Polymerase and 0.3 M of each primer. The PCR program started with a 15 minute incubation
at 95ºC followed by 35 cycles of 94ºC for 45 seconds, a range of temperatures from 59ºC to 64ºC
for 45 seconds was used to optimize the annealing temperature of the primers and 72ºC for 1
minute, and finished with an extension for 15 minutes at 72ºC. A total of 25 PCR reactions were
done for each template to obtain sufficient PCR product for subsequent ligation steps. The
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Figure 3-4. Left Homology Arm Amplification. A, Left Panel, This figure shows an agarose
gel analysis of a digest of the 600 bp TAP tag sequence with NotI and HpaI from the pIRESTAP-p53 vector. Right Panel, This figure shows an agarose gel analysis of a digest with HpaI
and AflII of the 3 kb p53 upstream homologous sequence from the pIRES-TAP-p53 vector.
Clone 2 contained the insert of the correct size. Bottom panel, This figure is a depiction of the
PCR amplification step of the Left homology arm using the sequences cloned into pIRES-TAPp53 as template. Primer design included a sense primer with a 5′-Not1 restriction site and
antisense with the 3′-23 bp linker. B, This figure is a depiction of the amplification product and
agarose gel analysis of the amplified 1.5 kb product.
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Figure 3-5. Right Homology Arm Amplification. A, Top panel, This figure is an agarose gel
analysis of the 3 kb PCR product of the p53 3′-UTR sequence amplified from HCT116 genomic
DNA. Primer design included an antisense primer with a 3′-Not1 restriction site and the sense
primer with the 5′-23 bp linker. Bottom panel, This figure is a depiction of the PCR amplification
of the right homology arm using the 3 kb PCR product as the PCR template. B, This figure is a
depiction of the amplification product and agarose gel analysis of the amplified 900 bp product.
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products were pooled, electrophoresed, purified and the concentrations were determined as
previously described.

Digest Neomycin Cassette from pNeDaKO-Neo
The pNeDaKO-Neo vector (2 g) (Kohli et al., 2004) was digested with PvuI in a total
volume of 20 L containing 300 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM
dithiothreitol (pH 7.9), 5 U PvuI, and 0.1 g/L BSA for 1 hour at 37ºC. The digest reaction
was run on a 1% agarose gel with ethidium bromide and the 4 kb product was excised, purified
and the concentration was determined as previously described. This fragment carried sequence
complementary to the 23 bp linker sequence present in the primers used to amplify the homology
arms.

Fusion PCR of Homology Arms and Neomycin Cassette
Figure 3-6B depicts how the linker sequences in the homology arms and neomycin
cassette allowed for a 3-way PCR fusion. An equimolar PCR fusion with 30 ng of the left
homology arm product and 33 ng of the neomycin cassette were incubated with the Left homolneo sense primer designed to anneal to the 5′-end of the left homology arm sequence and the Left
Homol-Neo antisense primer to anneal to the 3′-end of the neomycin cassette (Table 3-1). The
23 bp linker sequences within the homology arm and neomycin cassette acted as primers and
annealed during the reaction (Fig 3-6C). The 25L PCR reaction contained 12.5 L Hot
StartTaq Master Mix, 0.5 U PfuTurbo DNA polymerase and 0.3 M of each primer. The PCR
program started with a 15 minute incubation at 95ºC followed by 35 cycles of 94ºC for 45
seconds, a range of temperatures from 61ºC to 64ºC for 45 seconds and 72ºC for 3.5 minutes, and
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Figure 3-6. Fusion PCR of the Homology Arms with the Neomycin Resistance Cassette. A,
This figure is an agarose gel analysis of a digest with PvuI of the 2.2 kb neomycin cassette from
the pNeDaKO-Neo vector. B, This figure is a depiction of the 3 way PCR fusion of the
homology arms with the neomycin cassette which was not successfully accomplished C, This
figure is a depiction of the separate PCR fusion reactions, the black rectangles depicts the 23 bp
linker sequences. The agarose gel analysis of each fusion reaction is below the respective
depiction.
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finished with an extension for 15 minutes at 72ºC. The PCR reaction was analyzed on an 1%
agarose gel, the 3.7 kb product was excised, purified and the concentration was determined as
previously described. The fusion between the neomycin cassette and the right homology arm
was performed in a similar fashion. The Neo-right homol sense primers were designed to anneal
to the 5′-end of the neomycin cassette and the Neo-right homol antisense primer was designed to
anneal to the 3′-end of the right homology arm (Table 3-1). The PCR reaction was set up as
described above and the PCR program was also the same with the exception of the range of
temperature used to optimize the primer annealing temperature, which was changed to 62ºC to
68ºC for this PCR fusion. The 3kb product was found to be efficiently amplified at an annealing
temperature of 63ºC, it was analyzed and purified as previously stated.

Both fusion products

were sequenced and the sequences were compared with the known sequences of p53, the
sequence encoding the TAP tag, and the known sequence of the neomycin resistance cassette.
Both resulting PCR fusions contained neomycin resistant cassettes and only one
neomycin cassette is required in the final vector needed for homologous recombination. Hence,
the neomycin cassette from the right homology arm was removed with a digest containing KpnI.
The left homology arm was also cut with KpnI to generate compatible sticky ends required for
the subsequent ligation with the right homology arm (Fig 3-7). The KpnI digestions were
performed for one hour at 37ºC in a reaction volume of 50 L containing 10 mM Tris HCl, 10
mM MgCl2, 1 mM dithiothreitol (pH 7.0), 10 U KpnI and 0.1 g/L BSA. The reaction were
analyzed on a 1% agarose gel and the 3.6 kb left homology arm and the 943 bp right homology
arm were gel purified and their concentrations were determined. The two purified homology
arms were ligated together for 16 hours at 16ºC in a solution contain T4 ligase and ligase buffer
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Figure 3-7. Generation of the Cloned Insert Necessary for Gene Targeting. The top half of
the figure demonstrates how the left homology arm was digested with KpnI to remove the 23 bp
linker and right homology arm was digested with KpnI to remove the neomycin cassette.
Analysis by agarose gel is the right of the depiction. The bottom half demonstrates the ligation of
the left and right homology arms creating the 4.5 kb insert necessary for gene targeting. Prior to
cloning the fragment into the pAAV MCS vector the insert was digested with NotI generating
compatible ends. Agarose gel analysis of the ligation is to the right of the figure, the total
volume of the ligation was loaded into the four lanes.
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as previously described. The ligation product was run on a 1% agarose gel and the 4.5 kb band
was excised and purified as described above.

Cloning the insert into the pAAV-MCS vector
The pAAV-MCS vector was digested with NotI for two hours at 37ºC in a 200 L
reaction containing 300 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol (pH
7.9), 40 U NotI, 0.1 g/L BSA and 2g of the vector. NotI was heat inactivated for 20 minutes
at 65ºC and the vector was dephosphorylated with 20 U calf intestinal alkaline phosphatase for
one hour at 37ºC. The vector was phenol:chloroform extracted by adding one volume of
phenol:chloroform (ratio 1:1) to the reaction, the tube was vortexed and centrifuged at 16,100 x g
for 15 minutes at 4ºC in a tabletop centrifuge. The top (aqueous) layer was recovered and 1/10
volume of 3 M NaOAc and 2 volumes of 100% ethanol were added, the tubes were vortexed and
incubated at -80ºC for one hour to precipitate the DNA. The sample was thawed and spun down
at 16,100 x g for 15 minutes at 4ºC to pellet the DNA. The supernatant was poured off and
washed with one volume of 70% ethanol. The DNA was pelleted by centrifugation at 16,100 x g
for 15 minutes at 4ºC. The supernatant was poured off and the pellet was dried for 5 minutes.
The pellet was resuspended in 20 L H2O and the dissolved cut plasmid was purified on a 1%
agarose gel and the 3 kb cut vector was isolated (Fig 3-8). The 4.5 kb insert containing the left
homology arm-TAP tag sequence-right homology arm was cut with NotI and gel-purified.
The insert and vector were ligated at a 3:1 molar ratio as described above. The ligation
reaction was transformed into TOP10 chemically competent E. coli cells and plated on LB
plates. Fifty colonies were picked, each was inoculated in LB containing 50 g/mL carbenicillin
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Figure 3-8. Cloning the Insert into the pAAV-MCS vector. A, This figure is an agarose gel
analysis of a digest with NotI of the pAAV-MCS vector. The 3kb vector backbone was gel
purified and used in the subsequent ligation. B, This figure is an agarose gel analysis of a digest
with NotI to verify the 4.5 kb insert after the ligation, transformation in TOP10 competent E. coli
cells and vector purification from the surviving colonies.
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and 40 g/ml zeocin and the cultures were incubated for 16 hours at 37ºC with shaking. Miniprepped plasmids were prepared from each culture. The purified plasmids were digested with
NotI to check for the correct size insert (Fig 3-8). The pAAV MCS p53TAP vectors were
sequenced.

Packaging and isolating the rAAV
HEK293 cells (ATCC) were grown in DMEM supplemented with 10% dFBS and 100
U/mL of penicillin and 100 mg/mL of streptomycin at 37ºC with 5% CO2. Cells were grown to
80% confluency in a T-75 flask prior the transfection. A mixture of 2.5 g of pAAV MCS
p53TAP and 2.5 g of each helper plasmid, pAAV-RC and pHelper was diluted in Opti-MEM
reduced serum medium to a total volume of 750L. Lipofectamine 2000 reagent (54g) was
mixed with Opti-MEM medium to a total volume of 750L. The two tubes were combined and
incubated at 25ºC for 15 minutes. The HEK293 cells were washed with 10 mL Hank‟s Balanced
Salt solution and 7.5 mL of Opti-MEM medium was added to the flask. The transfection mixture
was added drop-wise to the flask and incubated for four hours. The Opti-MEM medium was
removed and replaced with DMEM medium and the flask was incubated at 37ºC. Forty-eight
hours after the transfection, the packaged adeno-associated virus was collected from the HEK293
cells (Fig 3-9). The DMEM medium was aspirated and the cells were scraped off into 1.5 mL of
PBS. The cells were freeze thawed three times in a 70% ethanol and dry ice bath for 10 minutes
with intermediate thaws in a 37ºC water bath. The cells were pelleted at 12,000 x g at 25ºC for
10 minutes and the supernatant was stored in three 500 L aliquots at -80ºC.

Transducing HCT116 cells with the packaged rAAV
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Figure 3-9. The process of packaging the rAAV with the pAAV-MCS p53 TAP vector. The
cloned pAA-MCS p53 TAP vector, pHELPER and pAAV-RC helper vectors were cotransfected
into HEK 293 cells. The rAAV was extracted from the cells after 48 hours and an aliquot of the
isolated virus was used to transduce HCT116 cells.
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HCT116 cells (ATCC) were grown in RPMI 1640 supplemented with 10% dFBS and
100 U/mL of penicillin and 100 mg/mL of streptomycin at 37ºC with 5% CO2. A 75% confluent
culture in a T-75 flask was washed once with Hanks Balanced Salt Solution, an aliquot of the
isolated rAAV was thawed on ice and added to the culture mixed with 4 mL of RPMI 1640.
After two and a half hours, the virus mixture was removed and 8 mL of fresh RPMI 1640 was
added to the flask. The cells were plated out under 0.4 mg/mL geneticin (G418) selection in ten96 well plates at 200 L per well, 48 hours after transduction. The plates were wrapped with
parafilm to minimize evaporation and placed in the incubator for 10 days.

Wells clearly

containing only one cell clone were marked. The medium was aspirated and 100 L of trypsin
was added to each marked well and incubated at 37ºC for two minutes. Duplicate plates were
made with the trypsinized clones by adding 50 L of each cell suspension to 150L RPMI 1640
with 10% dFBS, 100 U/mL of penicillin and 100mg/mL of streptomycin and 0.4 mg/mL G418
(complete medium) in new 96-well plates. A total of 144 single cell clones were re-plated in
duplicate.

After four days the cells were expanded into duplicate 24-well plates by

trypsinization.

One set of 24 well plates were used for screen the clones for correct

recombination while the other duplicate plate was placed in -80ºC after addition of 300 L of
freezing medium (10% DMSO in dFBS).

Screening cell clones for correct insertion of the TAP tag into the endogenous p53 locus
The Exon 10 screening sense primer was designed to anneal to exon 10 in the
endogenous p53 genomic locus and the TAP screen antisense primer was designed to anneal to
TAP tag sequence within the insert (Fig 3-10, Table 3-1). The primer placement allowed for
screening for the correct orientation of the TAP tag insertion by homologous recombination
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Figure 3-10. PCR screening for the correct insertion of the TAP tag into the p53 genomic
locus by homologous recombination. The top of the figure depicts the screening process
including the strategic placement of the black screening primers with one primer located in the
genomic sequence outside of the cloned insert and the other placed inside the insert. The orange
primers denote the 3′ screening process. The bottom figure is the agarose gel analysis of 140
clones screened with the 5′-screening primers (black). The plus sign denotes the lanes
containing the positive control, the asterisks denote clones containing the correct location of
insertion as verified by the 1.4 kb PCR product of the insert and the X denotes a false positive
that was determined in subsequent PCR reactions.
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since one screening primer was located outside of the insert and the other was placed within the
insert. The pIRES-p53-TAP vector was used as the positive control for the screening process.
The PCR program was optimized with the positive control vector in a 25 L reaction volume
containing 12.5 L Hot StartTaq Master Mix and 0.6 M of each primer. The PCR program
started with a 15 minute incubation at 95ºC followed by 30 cycles of 94ºC for 45 seconds, 57ºC
for 45 seconds and 72ºC for 1.5 minutes, and finished with an extension for 10 minutes. The
reaction was analyzed on a 1% agarose gel containing ethidium bromide. Genomic DNA was
isolated from the 24-well plates using the Promega Wizard SV genomic DNA purification
system and the concentration was determined by sample absorbance at 260 nm. All genomic
DNA samples were diluted down to a concentration of 50 ng/mL with H2O; 1 L of each gDNA
sample was added to the previously described PCR reaction. A positive control and a blank
reaction containing water was including in all screening reactions. The PCR products were run
out on a 1% agarose gel and analyzed for a 1.4 kb product indicating correct homologous
recombination. The PCR product from the screening procedure from 4 clones containing the
TAP tag at the correct orientation were excised from the agarose gel and purified as previously
described. The purified PCR screening product was cloned into the pCR4-TOPO vector for
sequencing using the TOPO TA Cloning Kit for Sequencing (Invitrogen). A 6 L reaction
containing 0.2 M NaCl and 10 mM MgCl2 (Salt Solution), 4 L of purified DNA and 1 L
pCR4-TOPO was incubated at 25ºC for 30 minutes. TOP10 chemically competent E. coli cells
were transformed with 2 L of each reaction. Bacteria were plated, expanded and mini-prepped.
The purified plasmids were cut with EcoRI to check for the correct insert size. The reactions
were run on a 2% agarose gel containing ethidium bromide and one plasmid containing the
purified product from each of the four cell clones that containing the correct insert was
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sequenced. Clone number AA5 contained no mutations, the duplicate plate containing this well
was removed from the -80ºC and was thawed in a water bath. A volume of 2 mL of complete
medium was added to the well containing this clone and placed into a 15 mL conical tube and
spun down. The pellet was resuspended in 5 mL of complete medium and plated into a T-25
flask. This cell line was named AA5 TAP. The 3′-end of this clone was screened by PCR to
make sure that only the insert and no other parts of the vector homologously recombined with the
p53 locus. The 3′-screening sense primer was designed to anneal within the TAP tag and the 3′ screening antisense primer was designed to anneal within the 3′ UTR of p53 outside of the insert
(Fig 3-10, Table 3-1). The PCR reaction contained primers at a concentration of 0.3 M and
started with a 15 minute incubation at 95ºC followed by 35 cycles of 94ºC for 45 seconds,
53.9ºC for 45 seconds and 72ºC for 2 minutes, and finished with an extension for 10 minutes.
The PCR product was electrophoresed and the 1.3 Kb product was excised, purified and
sequenced.

Western Blotting
Cellular Lysate preparation
HCT116 and AA5 TAP cells were plated at 8 x 105 cells/10 cm dish and allowed to
adhere 24 hour prior to drug treatment. Etoposide (VP16, Sigma) was dissolved in DMSO
making a 10 mM stock and then diluted in PBS to 100 M prior to use. The 100 M solution of
VP16 was filter sterilized with a 0.22 Mfilter, 1 mL of it was added to 9 mL complete medium
added to the treatment plates. The no treatment plates received 9 mL complete medium with the
same dilution of DMSO used in the VP16 plates. Preparations of cellular lysates and Western
blotting were performed as described in Chapter 2. Briefly, 25 g of total cellular protein was
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resolved by electrophoresis on a 7.5% -polyacrylamide gel (BioRad) and transferred to a PVDF
membrane. Non-specific protein binding was blocked with Blotto solution containing 5% milk,
0.1% Tween 20, 0.01 M Tri, pH 7.4, 0.15 M NaCl for 1 hour at 25ºC with gently rocking.
Primary antibody was diluted in 5% milk in TBS-T and incubated with the membrane overnight
at 4ºC.

Primary antibodies used were p53 monoclonal Ab-6 (Calbiochem) at 1:100, p21

monoclonal Ab-1 (Calbiochem) at 1:100, TAP polyclonal (Open Biosystems CAB1001) at 1:500
and monoclonal beta Actin (Abcam) at 1:5000. Membranes were incubated with secondary
antibodies conjugated to horseradish peroxidase (Pierce) diluted in 5% milk in TBS-T for 1 hour
at 25ºC. Complexes were detected by enhanced chemiluminescence using the Supersignal West
Pico Chemiluminescent Substrate Kit (Pierce).

Removing the neomycin cassette with cre recombinase
Dr. Jolene Windle generously provided a plasmid, pMC1 CRE, in which the cre
recombinase can be expressed in mammalian cells under the control of a thymidine kinase
promoter. This plasmid was transformed into TOP10 chemically competent E. coli cells and
purified using with the Promega Pure Yield Plasmid Midiprep System and checked with a
digestion for one hour at 37ºC in a 20 L reaction containing 10 U EcoRV, 10 U SalI, NEB3,
and 0.1 g/L BSA. The reaction was run on a 1% agarose gel to check correct product size.
AA5 TAP cells were plated in a 60 mm dish with RPMI 1640 with 10% dFBS and allowed to
reach 90% confluency. A total of 8 g of pMCI CRE was diluted into 500L Opti-MEM
medium and 20 g of Lipofectamine 2000 was added to 480 L Opti-MEM medium; both
mixtures were incubated at 25ºC for 5 minutes, then combined, gently mixed and incubated for
20 minutes at 25ºC before adding the mixture to the cells. Twenty-four hours after transfection
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the transfected cells were trypsinzed and plated at 0.25 cell/well in five 96-well plates in RPMI
1640 with 10% dFBS and 100 U/mL of penicillin and 100 mg/mL of streptomycin. The plates
were wrapped in parafilm and placed in the incubator for 12 days. Wells containing only one
cell clone were marked and trypsinzed and split into duplicate sets of 24-well plates as
previously described. Cells were allowed to adhere for 24 hours, the medium was then replaced
on both sets of plates. One set received complete medium containing 0.4 mg/mL G418 while the
duplicate set received complete medium without G418. Five days after selection clones that
were not G418 sensitive were trypsinized and expanded in T-75 flasks with complete medium
not containing G418. This cell line was named CRE2 TAP.

Chromatin Immunoprecipitation
The ChIP assay was performed as described in Chapter 2. Briefly, 1 x 107 HCT116 cells
or CRE2 TAP cells per treatment were crosslinked at room temperature with 1% formaldehyde.
Aliquots of 2 x 106 washed cells were lysed and sonicated with the Diagenode bioruptor for a
total of 18 minutes in consecutive duty cycles of 30 seconds on, 30 seconds off (for a total of 3
cycles, each being 6 minutes). These conditions were found to yield DNA fragments less than
1000 bp in size. Lysate volumes corresponding to 2 x 106 cells were precleared and blocked with
8 g of BSA and 5 g of sonicated lambda DNA, then were incubated with 2 g of p53 Ab-6
(Calbiochem) antibody, 2 g TAP antibody directed against the calmodulin peptide (Open
Biosystems) or 2 g IgG (Millipore) antibody overnight. Antibody-protein-DNA complexes
were captured by the addition of 30 L of 50% protein G-Sepharose bead slurry. Beads were
extensively washed as previously described. Protein-DNA complexes were eluted with elution
buffer containing 2% SDS, 10 mM DTT, 0.1 M NaHCO3 and incubated at 65ºC overnight to
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reverse the crosslinks.

DNA was treated with RNase, Proteinase K, phenol-chloroform

extracted, ethanol-precipitated as previously described, and dissolved in 100L of TE.

Quantitative PCR
Q-PCR was performed with 1 L of input DNA or ChIP DNA per a 25 L reaction
containing 12.5 L Quantitect SYBR Green PCR Master Mix (Qiagen), 0.3 M of each primer.
The sequences of the primers for the upstream p53 consensus binding site on the p21 promoter
were

5′-CTTTCCACCTTTCACCATTCC-3′

(sense)

and

5′-

AAGGACAAAATAGCCACCAGC-3′ (antisense). The amplification conditions were 95ºC for
15 minutes, 40 cycles of 95ºC for 45 seconds, 53ºC for 45 seconds, 72ºC for 45 seconds with a
plate read between cycles followed by a 5 minute extension at 72ºC and a determination of the
melting curve from 45ºC to 100ºC. Quantities were calculated using a standard curve ranging
from 100 ng to 0.8 ng of input DNA.

Tandem Affinity Purification of p53
Cellular Lysate Preparation
Approximately 8 x 108 CRE2 TAP cells were used for each purification. CRE2 TAP
cells were plated at 4 x 106 cells/15 cm dish in forty dishes per drug treatment containing RPMI
1640 with 10% dFBS and allowed to adhere for 24 hours. Cells were treated for 24 hours with
either VP16, HU or PALA as previously described. Cells were trypsinzed, washed twice with
PBS containing 1x protease inhibitor complete cocktail (Roche) and resuspended in 8 mL
Tween-20 lysis buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM
EGTA 0.1% Tween-20.

All purification buffers contained 1 g/mL aprotinin, 1 g/mL
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leupeptin, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF. Lysates were sonicated on ice using the
Misonix Sonicator 3000 with the 1/16” microtip for 40 cycles of 1 second on, 5 seconds off at 4
ºC while on ice and then incubated on ice for 30 minutes.

IgG Purification and TEV Cleavage
Cell debris was spun down at 16,100 x g for 15 minutes at 4ºC. An aliquot (200 L) IgG
Sepharose 6 Fast Flow beads (GE Healthcare) that were washed with Tween-20 Lysis buffer and
a 50 % bead slurry was added to the clarified supernatant. The IgG bead suspension was
incubated at 4ºC for 4 hours while rotating end-over-end. The beads were pelleted at 2,500 x g
for 1 minute at 4ºC and washed three times with Tween-20 lysis buffer and three times with TEV
buffer containing 50 mM Tris pH 8.0, 0.5 mM EDTA. The p53 complex was cleaved from the
IgG beads in a 300 L reaction containing 50 mM Tris, pH 8.0, 0.5 mM EDTA, 1.0 mM DTT
and 100 U AcTEV Protease (Invitrogen) TEV protease cleavage proceeded for 16 hours at 4ºC
rotating end-over-end.

Calmodulin Purification
The IgG beads were pelleted at 2,500 x g for 2 minutes at 4ºC and the supernatant was
removed and added to 200 L of the 50% slurry of Calmodulin Sepharose 4B (GE Healthcare).
The IgG beads were washed three times with 300 L calmodulin binding buffer containing 10
mM Tris pH 8.0, 150 mM NaCl, 1 mM magnesium acetate, 1 mM imidazole, 0.1% NP-40, 2
mM EGTA, 10 mM 2-mercaptoethanol and each wash was added to the saved supernatant.
Aliquots of a concentrated stock of 1M CaCl2 was added to the lysate-calmodulin slurry to
achieve a final concentration of 4 mM and the mixture was incubated for 4 hours at 4ºC while
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rotating end-over-end. The beads were pelleted by centrifugation at 2,500 x g for 2 minutes at
4ºC and washed three times with calmodulin binding buffer. The p53 protein complex was
eluted in eight 200 L fractions with calmodulin eluting buffer (10 mM Tris pH 8.0, 150 mM
NaCl, 1 mM magnesium acetate, 1 mM imidazole, 0.1% NP-40, 2mM EGTA, 10 mM 2mercaptoethanol). Aliquots of IgG Beads and Calmodulin beads from this procedure were
resuspended in 100 L SDS sample buffer containing 62.5 mM Tris pH 6.8, 5% glycerol, 2%
SDS, 5% 2-mercaptoethanol, boiled for five minutes, pelleted and the supernatant was saved
along with samples from each step of the purification for further analysis. All samples were
stored at -80ºC for further analysis.

Analysis of Tandem Affinity Purification
The concentrations of the soluble and insoluble fractions after sonication were
quantitated with the Bradford assay as previously described. Samples collected throughout the
purification process and eluted fractions were resolved on a 4-15% gradient SDS polyacrylamide
gel. Soluble and insoluble starting materials (25 g) were used while the remaining samples
were loaded onto this gel based on estimations of their protein concentrations and equal volumes
of eluted fractions were added to each well. One set of gels underwent silver staining using the
Bio-Rad Silver Stain plus according to manufacturer‟s instructions (161-0449) while the other
set was immunoblotted for the presence of p53.

Results
The experiments in Chapter 3 describe the design, development, and characterization of a
HCT116-derived cell line in which one endogenous p53 locus has been manipulated to include
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the TAP tag sequence in frame at the 3′ end of the p53 coding sequence. This cell line was
created to allow a proteomic analysis of the molecular role of p53 during nucleotide pool
imbalances. Specifically, we wished to investigate how p53 is involved in the decision to
promote apoptosis or a cytostatic S-phase arrest.

Design and Molecular Cloning of the pAAV vector that will allow insertion of the TAP-tag
sequence in the p53 gene
The vector that was designed and constructed in order to insert the TAP tag into the
endogenous p53 locus is shown in Figure 3-3 and the strategy for construction of this targeting
vector is show in Figure 3-2. Two fragments of DNA identical to regions of the p53 genomic
sequence were amplified from HCT116 genomic DNA and inserted into a pAAV vector, one on
each side of a sequence encoding the TAP-tag peptides. To obtain high efficiencies of gene
targeting, a minimum of 900 bp of homologous sequence upstream and downstream from the
gene targeting site was previously shown to be required (Kohli et al., 2004). The TAP tag
sequence and approximately 3 kb of sequence upstream from the stop codon in the p53 genomic
sequence was isolated by PCR and ligated into the pIRES vector (See Methods, Fig 3-2),
including all of the coding sequence of exon 11 (79 nucleotides) and 2921 nucleotides of intron
10. The sequence encoding the TAP tag was excised from the pIRES-TAP vector with NotI and
HpaI to verify the correct size (Fig 3-4A, left panel). After the TAP tag sequence was ligated
into pIRES, the 3 kb of p53 sequence upstream from the stop codon in the p53 genomic sequence
was ligated into the vector upstream of the TAP tag sequence to create the pIRES-TAP-p53
vector (Fig 3-2). This 3 kb fragment was excised from pIRES-TAP-p53 vector with HpaI and
AflII to verify the correct size (Fig 3-4A, right panel). The pIRES-TAP-p53 vector was used as
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the template for amplifying the left homology arm needed for the targeting vector.

This

homology arm contained 900 bps of the upstream p53 coding sequence, which includes 79
nucleotides from exon 11 ending immediately upstream of the stop codon, 821 nucleotides of
intron 10 and the TAP tag sequence. The primers for this PCR reaction were designed to contain
a NotI restriction site on the 5′-end of the sense primer and to include a 23 bp linker sequence on
the 3′-end of the antisense primer that would be required for future cloning reactions. The
resulting 1.5 kb fragment amplified with these primers contained 900 bps of homologous p53
sequence followed by the TAP tag sequence, with a NotI site at the 5′-end and the linker
sequence at the 3′-end (3-4B). The right homology arm contained 900 bp of homologous
sequence from the p53 3′-untranslated region (UTR) sequence directly following the stop codon.
Previously, a 3 kb fragment was amplified from HCT116 genomic DNA with primers starting
after the stop codon and extending for 3 kb (Fig 3-5A). This PCR fragment was used as the
template for the amplification of the 900 bp needed for the right homology arm. New primers
were designed to include the 23 bp linker sequence and a NotI restriction site for this
amplification. The resulting PCR product was a 900 bp product with the linker sequence at the
5′-end and a NotI restriction site at the 3′-end (Fig 3-5B).

The neomycin selection cassette was

digested out of the pNeDaKO-Neo plasmid obtained from the Vogelstein group (Kohli et al.,
2004) with PvuI (Fig 3-6A). The resulting 2.2 kb fragment contained a mammalian neomycin
selection marker and a zeocin bacterial selection marker flanked with loxP sites and the 23 bp
linker sequence on both ends. The 23 bp linker sequences on each end of the neomycin cassette
and the complementary linker sequences on the left and right homology arms were designed to
allow for a three-way PCR fusion using primers designed to anneal at the 5′-end of the left
homology arm and at the 3′-end of the right homology arm (Fig 3-6B). Many variations of this

139

PCR fusion were attempted with several combinations of primer sets, yet the product was never
amplified, so two two-way fusions with the neomycin cassette were performed (Fig 3-6C). The
left homology arm was fused with the neomycin cassette with primers designed against the 5′terminus of the left homology arm and against the 3′-end of the neomycin cassette. The 3.7 kb
fusion product was amplified and purified (Fig 3-6B left). A similar reaction was performed
with the right homology arm and neomycin cassette. The 3.2 kb fusion product was amplified
and purified (3-6B, right panel). Each homology arm contained a neomycin cassette and only
one cassette was needed in the final product, so the neomycin cassette was digested off the right
homology arm fusion with KpnI (Fig 3-7, top panel). The left homology arm fusion also was
digested with KpnI to remove the 23 bp linker (Fig 3-7). As a result from the digest, the purified
products both contained complementary sticky ends and they were easily ligated together to form
the 4.5 kb insert necessary for the gene targeting (Fig 3-7, bottom panel). The insert was
digested with NotI as was the pAAV MCS vector (Fig 3-7, 3-8A). The 3 kb vector backbone
was mixed with an equimolar amount of the 4.5 kb insert and joined with DNA ligase. To verify
that the correct ligation took place, the insert was cut from the pAAV MCS vector with NotI and
sized on an agarose gel (Fig 3-8B). Four out of 50 screened clones contained the correct size
insert. The resultant vector was named pAAV MCS p53 TAP

Generation and Characterization of the p53 TAP-tagged Cells
The cloned pAAV MCS p53TAP vector in combination with two helper vectors were
transfected into HEK 293 cells for viral packaging. The virus was collected from the HEK 293
cells after 48 hours and used to transduce HCT116 cells (see methods and Fig 3-9). A total of
140 neomycin resistant cell clones were propagated and screened by PCR for correct integration
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of the TAP tag in the p53 locus. Two different primer sets were used for the PCR screening for
homologous recombinants; one set tested the 5′- insertion site and the other tested the 3′-insertion
site. Each set contained one primer corresponding to the TAP sequence and one outside of the
insert to verify insertion specifically into the p53 gene locus in the correct orientation (Fig 3-10).
Out of the 140 screened cell clones, 11 contained the TAP tag inserted into the correct location
within the p53 gene locus as is seen by the 1.4 kb product amplified for a 7.9% efficiency of
homologous recombination (Fig 3-10). Several clones containing the TAP tag were expanded
and then sequenced to ensure proper insertion and presence of all essential sequence elements.
Clone A-A5 was used for all subsequent experimentation (Fig 3-11).
The sequence that was inserted into the p53 genomic locus added about 25 kDa to the
mass of the expressed p53. Data from western blot experiments should show two bands when
probed for p53, a band at 53 kDa for the un-altered p53 allele and one band at 78 kDa for the
TAP-tagged allele. Initial experiments with the TAP tag cell line showed that the p53 that was
transcribed and translated from the TAP tagged allele, was able to be stabilized, following VP16induced DNA damage. However, the protein levels made from the TAP tagged p53 allele were
not comparable to the p53 protein transcribed and translated from the wild-type, un-altered allele
(Fig 3-12).
We hypothesized that insertion of the 2.2 kb neomycin resistance cassette moved the
polyadenylation tail further away from the p53 coding sequence thus altering the stability of the
mRNA. Since the neomycin resistance cassette had been designed to be flanked with loxP sites
in the case this happened, it was removed by a transient transfection of the pMC1 CRE vector
containing the cre recombinase gene. Duplicate plates of single cell transfected clones were
propagated. One set of plates was exposed to G418 while the other set contained no selection
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AAAATACAAAAGTAGCCGGGCGTGGTGATGCATGCCTGTAATCCCAGCTACCTACTCGGG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AAAATACAAAAGTAGCCGGGCGTGGTGATGCATGCCTGTAATCCCAGCTACCTACTCGGG
AGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCGGTGAGCTGAGATCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGGcTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCGGTGAGCTGAGATCT
CACCATTACACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTCAAAAAAGATAAATAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CACCATTACACTCCAGCCTGGGCAACAAGAGTGAAACTCCGTCTCAAAAAAGATAAATAA
AGTAAAATGGGGTAAGGGAAGATTACGAGACTAATACACACTAATACTCTGAGGTGCTCA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AGTAAAATGGGGTAAGGGAAGATTACGAGACTAATACACACTAATACTCTGAGGTGCTCA
GTAAACATATTTGCATGGGGTGTGGCCACCATCTTGATTTGAATTCCCGTTGTCCCAGCC
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GTAAACATATTTGCATGGGGTGTGGCCACCATCTTGATTTGAATTCCCGTTGTCCCAGCC
TTAGGCCCTTCAAAGCATTGGTCAGGGAAAAGGGGCACAGACCCTCTCACTCATGTGATG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTAGGCCCTTCAAAGCATTGGTCAGGGAAAAGGGGCACAGACCCTCTCACTCATGTGATG
TCATCTCTCCTCCCTGCTTCTGTCTCCTACAGCCACCTGAAGTCCAAAAAGGGTCAGTCT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TCATCTCTCCTCCCTGCTTCTGTCTCCTACAGCCACCTGAAGTCCAAAAAGGGTCAGTCT
ACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACGTTAACATG
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACGTTAACATG
GAAAAGAGAAGATGGAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAAAAGAGAAGATGGAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAA
ATCTCATCCTCCGGGGCACTTGATTATGATATTCCAACTACTGCTAGCGAGAATTTGTAT
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATCTCATCCTCCGGGGCACTTGATTATGATATTCCAACTACTGCTAGCGAGAATTTGTAT
TTTCAGGGTGAGCTCAAAACCGCGGCTCTTGCGCAACACGATGAAGCCGTGGACAACAAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTTCAGGGTGAGCTCAAAACCGCGGCTCTTGCGCAACACGATGAAGCCGTGGACAACAAA
TTCAACAAAGAACAACAAAACGCGTTCTATGAGATCTTACATTTACCTAACTTAAACGAA
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TTCAACAAAGAACAACAAAACGCGTTCTATGAGATCTTACATTTACCTAACTTAAACGAA
GAACAACGAAACGCCTTCATCCAAAGTTTAAAAGATGACCCAAGCCAAAGCGCTA
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
GAACAACGAAACGCCTTCATCCAAAGTTTAAAAGATGACCCAAGCCAAAGCGCTA

Figure 3-11. Sequence analysis of the PCR product from the screening process. The top
sequence is the reference sequence and the bottom is the sequence of the screened product. A
line between the two sequences indicates a match. The green highlighted sequence denotes exon
10 of p53, the non-colored sequence represents intron 10, blue denotes exon 11 of p53 and pink
denotes the TAP tag sequence.
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Figure 3-12. TAP tagged p53 accumulates in response to DNA damage levels lower than
that of untagged p53. This figure is a western blot analysis of p53 levels in HCT116 and AA5
TAP cells exposed to 10 M VP16 for24 hours. Total cell lysate protein (25 g) was subjected
to SDS-PAGE and immunoblotted with antibodies against p53 or the calmodulin peptide in the
TAP tag were used.
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(Fig 3-13). The cells which did not survive when exposed to G418 no longer contained the
neomycin resistance cassette and, hence, had excised the neomycin cassette and also not fixed
the pMCI CRE plasmid in the genome since this vector also carried the neomycin resistance
cassette. The corresponding wells in the duplicate set without selection, were grown for further
analysis. Following growth of neomycin sensitive single cell populations, p53 protein levels
were assessed by western blotting. The removal of the neomycin resistance cassette from the
TAP tag insert completely restored the TAP tag protein levels to wild-type p53 protein levels
both in unstressed cells and also in cells treated with the topoisomerase II inhibitor, VP16 (Fig 314). The equivalent levels of accumulated p53 from the TAP tagged allele and the wild-type
allele indicates that the TAP tag did not interfere with p53 stabilization and accumulation after
DNA damage. The levels of p21 activated upon DNA damage were similar to the untagged cells
suggesting that insertion of the TAP tag did not interfere with the transactivating ability of p53.
The functionality of the TAP tagged p53 was further investigated to determine whether
the tag interferes with the cellular functions of the p53 encoded by the tagged allele. To assess
the capability of the TAP tagged p53 to bind to gene promoters, the presence of p53 at the p21
promoter was investigated using ChIP. Two antibodies were used for the immunoprecipitation;
the DO-1 antibody to pull down all cellular p53, and an antibody against the calmodulin binding
peptide in the TAP tag to pull down only TAP tagged p53. Total p53 and TAP tagged p53 are
poised at the upstream p53 binding site on the p21 promoter under no drug conditions and after
VP16-induced DNA damage, the levels of both total and TAP-tagged p53 increase more than
threefold indicating that the TAP tag does not interfere with the ability of p53 to bind to DNA
(Figure 3-15).
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Figure 3-13. Selection of neomycin sensitive clones post transfection of a cre recombinase
containing vector. Cre2 TAP cells were plated in duplicate post transfection. The cells which
could not survive under G418 selection were propagated from the duplicate well in the no
selection plate.
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Figure 3-14. Removal of the neomycin cassette restores TAP tagged p53 levels to that of the
untagged p53. This figure is a western blot analysis of p53 and p21 levels in HCT116, AA5
TAP and CRE2 TAP cells exposed to 10 M VP16 for 24 hours. Total cell lysate protein (25
g) was subjected to SDS-PAGE and immunoblotted with antibodies against p53 or p21 were
used. Protein loading was assessed with-Actin.
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Figure 3-15. TAP tag does not interfere with the ability of p53 to bind to the p21 promoter.
This figure is a ChIP analysis of p53 enrichment at the Rad51 promoter in CRE2 TAP cells after
24 hours of drug treatment. p53-DNA complexes were immunoprecipitated from formaldehyde
crosslinked cells with either the DO-1 p53 or antibody against the calmodulin peptide in the
TAP tag and p21 promoter levels were quantitated with Q-PCR. Standard error is depicted by
the bars from two biological repeats each with triplicate Q-PCR samples. Non-specific binding
was estimated using immunoprecipitation with non-specific IgG. Vehicle was PBS, VP16 was
used at 10 M.
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Tandem Affinity Purification of p53
The ability of the TAP tag to pull down and isolate p53 binding partners through the
tandem affinity purification protocol was evaluated using an adapted version of the published
purification protocol (Bertwistle et al., 2004). TAP-tagged p53 was tandem affinity purified
from VP16-treated cells, along with it any associated proteins. An aliquot from each step in the
purification was saved to assess the efficiency of the protocol; the level of p53 in each fraction
was determined by western blot using the DO-1 p53 antibody (Fig 3-16). There was loss of p53
at both of the binding steps. TAP tagged p53 was found in samples from the lysates that did not
bind to the IgG beads. The majority of the TAP tagged p53 was lost after TEV cleavage as
observed by a significant amount of p53 remaining bound to IgG beads after TEV cleavage and
after the final elution from the calmodulin beads, suggesting the use of more TEV protease and
more calmodulin beads would result in a larger yield of p53 (Fig 3-16).
Western blot analysis of the eight eluted fractions from the purification, probed with the
DO-1 p53 antibody, resulted in two bands indicating that the TAP-tagged p53 is pulling down
the wild-type p53 as a protein binding partner, an interesting result since it implies that the
majority of p53 pre-exists as multimers of equal parts transcribed from each allele (Fig 3-17).
The purification functionally isolated a portion of the TAP-tagged p53. Silver staining analysis
of the eluted fractions revealed numerous proteins being pulled down with p53 during VP16induced DNA damage (Fig 3-17). This purification procedure was next performed on cells
which were exposed to HU to ask questions about the binding partners of p53 during nucleotide
pool imbalances in comparison to the binding partners during DNA damage. A control of nontagged HCT116 cells was also included to determine the background proteins being pulled down
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Figure 3-16. Recovery of p53 during tandem affinity purification. This figure shows a
western blot analysis of the steps of the TAP purification of p53 from CRE2 TAP cells treated
with VP16 for 24 hours and immunoblotted with DO-1 p53 antibody. Twenty-five g of total
protein was loaded for the insoluble fraction and soluble lysate, while the concentrations of the
other fractions were estimated. Off IgG Beads is the supernatant that resulted after the IgG
beads were boiled; the material remaining on IgG beads after TEV cleavage. VP16 was used at
10 M.
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Figure 3-17. TAP tag purifies p53 with several protein binding partners. This figure is a
western blot and silver stain analysis of 8 EGTA-eluted fractions from the TAP purification of
p53 from CRE2 TAP cells treated with VP16 for 24 hours. 18.75% of each eluted fraction was
subjected to SDS page: one polyacrylamide gel was immunoblotted with DO-1 p53 antibody
while the other was silver stained. VP16 was used at 10 M.
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by the purification protocol. The silver stain of the eluted fractions showed differential binding
patterns when comparing untreated cells to HU and VP16 treated cells (Fig 3-18). Although we
are unable to confirm that there are indeed different proteins by mass spectrometry binding to
p53 during nucleotide pools imbalances than during DNA damage, these data are encouraging.
A similar purification was performed from HU- and PALA-treated cells. This was performed to
investigate the different p53 binding partners during the observed S-phase arrest induced by HU
treatment and the apoptosis induced by PALA treatment. In the previous purification, an equal
number of cells were used in the purification, in contrast to using an equivalent amount of
protein, which was done in the HU and PALA purification. PALA treatment resulted in a fivefold increase in p53 purification over that of the HU treated cells while the silver stain of the
eluted fraction showed surprisingly similar protein banding patterns (Fig 3-19).

Discussion
The creation of this cell line marked the first time our lab has successfully manipulated a
mammalian genomic locus by homologous recombination in a cell line. Previous attempts were
made by Dr. Fiona Turner using different technologies but the screening process was laborious
and after screening thousands of clones, the attempts were abandoned.

This chapter

demonstrates that this powerful AAV technology is possible and, indeed, highly efficient; it is a
vast improvement over previous methodologies. From the cloning process to the completion of
the cell line, the most challenging aspect was the cloning process, specifically attempting the
three-way-fusion. This three-way fusion was never successfully accomplished in the cloning of
the pAAV MCS vector. Other methodologies were used without adding significant labor to the
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Figure 3-18. TAP tag purifies p53 with different protein binding partners after nucleotide
deficiencies than after DNA damage. This figure is a western blot and silver stain analysis of
the second eluted fraction from the TAP purification of p53 from CRE2 TAP cells treated with
VP16 or HU for 24 hours. Purification of p53 from nontagged, HCT116 cells were used as a
negative control for non specific proteins. 18.75% of each eluted fraction was subjected to SDS
PAGE one polyacrylamide gel was immunoblotted with DO-1 p53 antibody while the other one
was silver stained. VP16 was used at 10 M and HU was used at 1.5 mM
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Figure 3-19. TAP tag purifies p53 with protein binding partners after nucleotide
deficiencies induced by HU and PALA treatment. This figure is a western blot and silver
stain analysis of the second eluted fraction from the TAP purification of p53 from CRE2 TAP
cells treated with HU or PALA for 24 hours. 18.75% of each eluted fraction was subjected to
SDS PAGE: one polyacrylamide gel was immunoblotted with DO-1 p53 antibody while the
other was silver stained. HU was used at 1.5 mM and PALA was used at 100 M.
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process. The screening step which previously has caused the most problems was the least
problematic step. With a targeting efficiency of 7.9%, it would be theoretically possible to
screen fifteen clones and find one that was correct. This alone makes this methodology powerful
enough to allow questions to be asked which previously were not within reach.

Does the neomycin cassette interfere with the stability of the TAP tagged p53?
The initial analysis of the stability of the TAP tagged p53 AA5 cells by western blot
analysis showed for the first time that the tagged p53 is able to be stabilized and accumulated
after VP16-induced DNA damage, suggesting that the large 25 kDa TAP tag is not interfering
with the stabilization of p53 after genotoxic stress. The levels of accumulated p53 were not
equivalent between the tagged allele and the wild-type allele (Fig 3-12). If the protein produced
from a tagged allele does not reflect the behavior of the protein product from the wild-type allele,
it would be difficult to draw conclusions about the protein binding partners of p53. Hence, the
protein level disparity had to be addressed. Since insertion of the neomycin cassette moved the
endogenous polyadenylation tail 2.2 kb further away from the end of the coding sequence, we
suspected that the neomycin cassette was altering with the stability of the mRNA. Although the
function of the polyadenylation tail is somewhat complex, there are several hypotheses of how it
affects the stability of mRNA and the initiation of protein synthesis (reviewed in (Millevoi and
Vagner, 2010)).

Moving the polyadenylation tail over 2 kb downstream from its original

location most likely interfered with protein binding and subsequent signaling events involved in
the splicing, translocation and translation initiation of the p53-TAP mRNA. The pAAV MCS
vector was designed to have loxP sites flanking the neomycin resistance cassette allowing the
removal of the cassette from the endogenous p53 in the eventuality that this type of problem
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arose. After the pMCI CRE plasmid containing the cre recombinase gene was transfected into
the AA5 cells, cells were selected for the acquisition of sensitivity to G418 (Fig 3-13). In cell
lines which the cre excision removed the drug resistance cassette, the protein levels of the TAP
tagged p53 was restored to the endogenous levels of the wild-type protein, implying that the
hypothesis that the neomycin cassette was altering translation or mRNA stability was correct
(Fig 3-14).

Does the TAP tag interfere in the molecular properties of p53?
The ability of the TAP tagged p53 to accumulate after DNA damage was encouraging,
but to prove that the TAP tag did not interfere in the molecular properties of p53, further
experimentation was done. The ChIP analysis of the binding of both alleles of p53 at the p21
promoter demonstrated that the TAP tag did not interfere with the ability of p53 to bind to
promoters. Since different antibodies were used for the TAP- and p53-immunoprecipitates, we
cannot quantitatively determine the amount of TAP tagged p53 versus wild-type p53 that is at
the p21 promoter. To assess the ability of the tagged p53 to bind to and modulate proteins, both
BLM and HU-stabilized tagged p53 could be purified and the helicase activity of BLM could be
measured. To do so, both purified proteins would be incubated with a radiolabeled X-junctions
mimicking a Holliday junction where BLM is known to promote branch migration (Karow et al.,
2000). If the HU stabilized p53 is able to bind to and inhibit BLM, then the X-junction would
not be disrupted. If p53 does not inhibit BLM, then the X-junction would be disrupted, and two
products would result; a one armed product (single stranded DNA) and a two armed product
(half of the holiday junction) (Yang et al., 2002).
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Purification of TAP tagged p53 along with its binding partners
The purification of tagged p53 along with interacting proteins was successful and the
silver stain analysis showed that many proteins of various masses (Fig 3-18) are interacting with
p53 and that these interactions change depending on the genotoxic stressor. When the western
blot analysis of the eluted fraction was probed with the p53 antibody two bands resulted: the
TAP tagged p53, which after the TEV protease cleavage has a mass of 59 kDa, and the band
from wild-type p53. Since TAP tagged p53 is pulling down equimolar wild-type p53 in the
purification, this indicates that the tag does not interfere with p53 oligomerization.
A second TAP tag could have been inserted into the wild-type p53 locus through gene
targeting in the same manner as the other locus. This would have resulted in all cellular p53
being TAP tagged. Since p53 acts as a tetramer and we demonstrated that the tagged p53
interacts with the wild-type p53, there is no real desire to tag the other locus. Having an
unaltered locus is a useful internal control when determining the functionality of the tagged p53.

Possible Uses for the TAP tagged p53
Post-translational Modifications
p53 is a highly post translationally modified protein.

These modifications include

phosphorylation, methylation, acetylation, sumoylation, neddylation and ubiquitylation and are
thought to act as a barcode governing the activity of p53 (reviewed by (Murray-Zmijewski et al.,
2008) (Fig 2-2). Extensive research has been done to identify the upstream kinases responsible
for modifying p53 and how certain modifications impact the cellular activities of p53. The TAP
tag cell line could be used to purify p53 and through mass spectroscopy, all of the PTMs could
be identified under any given set of circumstances. Since the focus of this thesis is on the
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different cellular responses to HU and PALA treatment, the p53 purified from CRE2 TAP cells
treated with HU and PALA can be used to identify the PTMs of p53. As discussed in the
previous chapter, some of the modifications of p53 during HU and PALA treatment have been
investigated with western blots; the results are striking.

The PTMs were asymmetrically

opposed; if a specific serine was phosphorylated in HU treatment it was not phosphorylated in
PALA treatment (Fig 2-8). Using the nonbiased approach of mass spectroscopy, an all inclusive
PTM map of the p53 accumulated by HU- and PALA-treatment could be constructed. The
upstream kinases could be elucidated and possibly give direction to the next experiment needed
to understand the upstream cellular events promoting the oppositely modified p53 and
subsequent different cellular outcomes.

Protein Binding Partners
Mitochondrial Fractionation
Not only can p53 be isolated from whole cells to determine what is binding to p53 but it
could be purified from sub-cellular fractions to ask more specific questions. p53 has been found
in the mitochondria and is known to induce mitochondrial outer membrane permeabilization
triggering the release of pro-apoptotic molecules (Chipuk et al., 2004). Intact mitochondria
could be fractionated from drug-treated cells and the protein binding partners of p53 could be
identified. Previously, we found that PALA-treatment promoted p53-dependent apoptosis while
HU-treatment did not. Thus, it would be interesting to compare the mitochondrial binding
partners of p53 during these two treatments. Hypothetically, one would expect to find p53
associating with the pro-apoptotic Bcl2 family proteins during PALA treatment, such as Bax,
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Bak, Bad and Bid while during HU treatment p53 may be associated with anti-apoptotic
molecules Bcl-2 and Bcl-XL. The TAP tag cell line could be used to ask such questions.

Cytosolic Fractionation
The function of cytosolic p53 has recently been investigated and it has been linked to
both inhibition of autophagy and to energy conservation. During metabolic stress, it is thought
that AMPK phosphorylates and activates p53 (Feng et al., 2005). The accumulated p53 activates
the transcription of sestrin 1 and sestrin 2. Both sestrins preferentially activate AMPK towards
phosphorylating TSC2 which inhibits mTOR (Budanov and Karin, 2008). mTOR suppresses
autophagy, so through its inhibition, p53 has been linked to activating autophagy during
metabolic stress while basal levels of cytosolic p53 have been implicated in the inhibition of
autophagy (Tasdemir et al., 2008). Through inhibition of mTOR the cell is able to conserve
energy and prolong viability. This is fairly new and rapidly growing field, and with the TAP tag
cell line, the involvement of p53 could be further examined.

Questions about the direct

interactions between p53 and AMPK could be addressed, as well as identifying all proteins
which interact with p53 in the cytosol. Since cytosolic p53 has been associated with AMPK
signaling, one would imagine at least some of the proteins binding to p53 will have a role in this
signaling pathway.

Nuclear Fractionation
The majority of p53 research has been focused on the nuclear functions of the tumor
suppressor, specifically its functions as a transcription factor activating the transcription of cell
cycle and apoptosis regulatory proteins. The mechanism involved in determining which set of
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genes p53 activates is not fully understood. There are two theories: one is the p53-centric theory,
in which the cellular fate of the cell depends on the activities of p53 which are regulated by the
PTMs and protein interactions of p53. The other theory is the p53-autonomous model that states
that the cellular fate is determined independently of p53 activity and that, although p53 may be
found at the promoter, the activation of transcription is dependent on other transcription factors
(Gomes and Espinosa, 2010). TAP purification of nuclear p53 from cells undergoing apoptosis
(PALA-treated) versus cell cycle arrested cells (HU-treated) could be used to compare the PTMs
and protein interaction of p53 between both cellular fates. The similarities and differences may
lead to further understanding of how the cellular fate is decided and if indeed p53 is a key
regulator in the decision.

Transcriptional Regulation
The enrichment of p53 at promoters does not necessarily indicate that transcription is
activated. There are instances where p53 is found at the p21 promoter yet it is not activating
transcription. Previously in our lab, Julie Bronder identified one of these instances where, during
DDATHF treatment, p53 was found at the p21 promoter but due to the lack of PTMs of p53 and
the closed chromatin structure of the promoter, transcription was not activated (Bronder and
Moran, 2003). During this dissertation work, two more instances were found, both HU and
pemetrexed treatment resulted in a defect in significant p21 transcription even though p53 was
found at the p21 promoter (Heyer, Racanelli and Moran, unpublished results and (Gottifredi et
al., 2001), and Figs 2-6, 2-7). This was not found during PALA treatment. The hydroxyurea
observation was previously identified and thought to be due to a decrease in the phosphorylation
of RNA polymerase II which is required for transcriptional elongation (Mattia et al., 2007). The
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causative event for this defect was never identified. Prior to any cellular stress, basal levels of
p53 are at the p21 promoter and establish a gradient of paused RNA polymerase II at the
promoter. Upon stress, the RNA polymerase is converted to the elongation form via CTD
phosphorylation, resulting in gene transcription. This process requires the recruitment of several
elongation factors including P-TEFb, FACT, DSIP, TPIIF and TFIIH. This suggests that gene
transcription of p53-dependent promoters depends on the protein complexes recruited after
cellular stress (Espinosa et al., 2003; Gomes et al., 2006). Nuclear purified TAP tagged p53
from both HU- and PALA-treated cells would help to investigate the different protein complexes
associating with p53 at promoters where in one instance p21 transcription is activated and in the
other, it is not. Promoter complexes could first be isolated through immunoprecipitation of a
component of the preinitiation complex and then subjected to the TAP purification to isolate p53
binding proteins. With mass spectroscopy, the identities of the protein that are present or
missing in both treatments could be achieved. The PTMs of promoter bound p53 could also be
identified and may possibly lead to an understanding of the signaling events required for
transcriptional activation.

S-phase Checkpoint
Another nuclear role of p53 is the S-phase checkpoint, which was described in depth in
the previous chapter. Since the role of p53 is still to be elucidated in this pathway, the TAP tag
would be useful in expanding the knowledge in this field. It appears that p53 exerts its tumor
suppressor activity as a protein modulator in this pathway more than as a transcription factor. By
isolating p53 and all interacting proteins from nuclear extracts, or specifically from chromatin,
the protein complexes could be identified. To further enrich for stalled replication forks, an
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initial immunoprecipitation could be performed with an antibody against a specific replication
fork protein such as BLM, RPA or Rad51. Then this pool of proteins could be subjected to the
TAP purification resulting in isolation of the proteins which interact with p53 solely at stalled
replication forks.

Identification of these proteins may lead to discovering new proteins

previously not identified in the S-phase checkpoint, leading to further understanding of the
signaling events occurring after a replication fork stalls.

Modifications of the TAP tag
Since the development of the CRE2 TAP cell line, several other tandem affinity tags have
been developed. The weakness of the TAP tag was found to be the calmodulin binding peptide.
TAP tagged p53 was not completely captured by the calmodulin beads as it was found in all the
washes and a larger amount of protein remained on the calmodulin beads after the elution
(Calmodulin supernatant (unabsorbed) and Cal Wash #1 & #2, Fig 3-16). Since a large amount
of the purified protein complex was lost at this step, upwards of 800 million cells had to be used
to yield enough protein for analysis. Different versions of the TAP tag have been engineered.
The calmodulin peptide has been replaced with a FLAG tag or a streptavidin binding peptide.
Protein A has been replaced with Protein G which is thought to have a slightly higher binding
affinity for a broader range of IgGs (Sauer-Eriksson et al., 1995). The modified TAP tag where
the calmodulin binding peptide was replaced with the FLAG tag and the completely changed tag
where both protein G binding units replaced the protein A units and the streptavidin binding
peptide replaced the calmodulin peptide had a significant increase in purified protein yield
(Burckstummer et al., 2006; Tsai and Carstens, 2006). Recovery increased to 80% and 50
million cells were used to obtain protein yields similar to what were achieved in my studies with
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1 billion cells with the original TAP tag. Interestingly, the original TAP tag paper tested
combinations of calmodulin binding peptide, FLAG tag, histidine tag, streptavidin binding
peptide, and chitin-binding domain and found the protein A and protein calmodulin binding
peptide combination to yield the most efficiently recovered protein complexes in yeast cells
(Rigaut et al., 1999). Although there have been significant modifications in the TAP tag, the
CRE2 TAP cells still have endless possibilities, the starting cell number simply needs to be
adjusted to account for a lower efficiency of purification.
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Chapter 4: Perspectives

Through the course of this dissertation, I have identified that human colon carcinoma
cells respond differently to two nucleotide synthesis inhibitors, HU and PALA. The difference
lies at the level of activation of the S-phase checkpoint: whereas HU treatment activates the
checkpoint resulting in Chk1 phosphorylation, PALA treatment fails to, resulting in p53dependent apoptosis. Despite the wealth of information obtained regarding the molecular events
occurring after treatment with both antimetabolites, several fundamental questions remain
unanswered about why these differences exist. These questions will be addressed within this
chapter from a specific standpoint as well as from a global standpoint in regards to the clinical
utility of antimetabolites.

Why do colon carcinoma cells respond differently to an inhibitor of dNTP synthesis versus
an inhibitor of pyrimidine synthesis?
The nucleotide concentrations after drug treatment were not measured in the course of
this dissertation work. These concentrations may lead to a better understanding of why the
HCT116 cells responds in such different manners to HU and PALA treatment. There is some
evidence that nucleotide levels may affect the DNA binding capacity of p53 in that increased
levels of ADP and dADP stabilize p53-DNA complexes whereas ATP, dATP, GTP and dGTP
facilitate the release of p53 (Okorokov and Milner, 1999). Further investigation would be
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necessary to determine if the pyrimidine dNTPs would have an impact on the DNA binding
capacity of p53 as well as to determine the nucleotide levels in HCT116 cells after HU or PALA
treatment. The original suggestion that p53 is capable of sensing nucleotide levels concluded
that antimetabolites primarily affecting dNTP levels arrest early in S-phase, independent of p53
status, while CTP, UTP and GMP synthesis inhibitors induce a p53-dependent G1 arrest (Linke
et al., 1996). Therefore, the idea that p53 is able to detect nucleotide levels is not universal, and
is only relevant for some nucleotides. A more probable explanation is that p53 senses changes in
the signal transduction pathways rather than the direct changes in nucleotide levels. The changes
in the signal transduction pathways after treatment with nucleotide synthesis inhibitors ultimately
could determine the cellular fate. Interestingly, we observed a difference in phosphorylation of
p53 between HU, PALA and the DNA damaging agent VP16. p53 was phosphorylated at all
investigated serines when cells were treated with VP16, a topoisomerase II inhibitor, which does
not inhibit nucleotide synthesis. Only a fraction of these residues were phosphorylated after
either HU or PALA-induced nucleotide synthesis inhibition, suggesting that the signal
transduction pathways after nucleotide deficiencies were different than that after DNA damage.
Why during PALA treatment is there a greater level of stabilized p53 than during HU
treatment? The dissimilar PTMs of p53 after treatment with HU or PALA may help to gain
insight to as to why there is a difference in the total amount of accumulated p53.

During HU

treatment, p53 is modified at serines 15 and 20, the hallmark sites known to inhibit MDMinduced degradation of p53, while these residues are not modified during PALA treatment.
Serine 392 is phosphorylated in PALA-treated cells (Fig 2-8). This phosphorylation is known to
enhance tetramerization which masks the nuclear export signal, possibly trapping PALAstabilized p53 within the nucleus and therefore protecting it from degradation. If the level of p53
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is the causative event promoting apoptosis or S-phase arrest, then understanding why there is a
differing level is crucial for our understanding and the clinical implications of this dissertation
work.
To further address the differences observed between HU treatment and PALA treatment
in HCT116 cells, the question of how cells are traversing through S-phase with a limited pool of
nucleotides should be addressed. Are the cells accumulating DNA damage while synthesizing
DNA with limiting nucleotides? Does this DNA damage differ between drugs? If so, is this the
signal that causes the activation of the two different pathways?

The studies performed

throughout this dissertation work suggest that cells are progressing through S-phase at a much
reduced rate compared with the untreated cells. HU treatment does not completely exhaust the
nucleotide pools, but it is hard to imagine the small percentages remaining during treatment are
enough to provide the nucleotides required to progress through an entire S-phase (Koc et al.,
2004). If extensive DNA damage was occurring, the measured H2AX levels would be higher,
similar to what was observed during VP16 treatment. Also, during PALA treatment, if cells
were accumulating DNA damage, why did they bypass the G1 arrest and enter S-phase? Further
experimentation to address these questions will build on the observations made during this
dissertation, as well as understanding how drugs inhibiting enzymes within the nucleotide
synthesis pathway can have such dissimilar cellular consequences.
The events responsible for the differing responses to HU and PALA treatment remain to
be completely elucidated. It may be due to the levels of nucleotides within the cell, the differing
levels of accumulated p53, or it may be peculiar for HCT116 cells. Either way we discovered
that colon carcinoma cells do not respond equally to nucleotide synthesis inhibitors and the
clinical implications of these findings will now be discussed.
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Clinical Implications
The hypothesis that the level of accumulated p53 may cause the differential cellular
response to HU and PALA treatment could aid in targeted chemotherapy. PALA treatment
resulted in a p53-dependent apoptosis, a higher level of accumulated p53 and higher levels of
p53 bound to all investigated promoters compared to promoter residence after VP16 or HU
treatment. Conversely, HU treatment resulted in a cytostatic S-phase arrest, a lower level of
accumulated p53, and significant p53 enrichment only at high affinity promoters. Overall, it
appears that the high level of accumulated p53 during PALA treatment is able to bind specific
promoters and transactivate these genes, resulting in programmed cell death. Cancer in which
p53 is over expressed due to deletion of Mdm2, might be pushed towards apoptosis while the
normal stem cells would arrest in S-phase until treatment subsides. If it is true that the level of
accumulated p53 determines the cellular fate during nucleotide stress, then cancer cells over
expressing a wild-type form of p53 could be treated with a nucleotide synthesis inhibitor. Prior
to any treatment, p53 would be poised at proapoptotic promoters, and after nucleotide synthesis
is inhibited, p53 levels would increase activating the transcription of these genes causing
apoptosis. In the normal cells, p53 levels would be low prior to any treatment; after treatment,
p53 levels would increase, but not to the extent observed in the cancer cells, resulting in S-phase
arrest, similar to what we observed after HU treatment. This would result in cytotoxicity of the
cancer cells and a reversible cytostatic arrest in the normal cells.
In light of the current ability to sequence the cancer genome, identifying the upstream
pathways regulating p53 after inhibition of nucleotide synthesis would be very informative. The
genetics of cancer is exhaustively being studied in hopes of finding common mutational trends
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within cancer types. If the upstream modulators of p53 after HU and PALA treatment are
identified, then cancers known to contain mutations of these modulators perhaps will have a
higher response rate to nucleotide synthesis inhibitors. The PTMs of p53 after treatment with
either HU or PALA suggest different upstream signaling pathways are activated during the two
treatments, resulting in the diametrically opposed pattern of phosphorylation. If our hypothesis
is true that p53 does not directly sense nucleotide levels but does sense changes in signaling from
stalled replication intermediates, then the identification of the specific p53 activating pathway
being activated would be beneficial. Specifically, in the case of PALA treatment, where the
PTMs of p53 stimulate sequence-specific DNA binding and transcription of apoptotic genes, the
upstream kinases responsible for phosphorylated serines 37, 46 and 392 would advance our
understanding of the resulting apoptotic response. CK2 is thought to be a cancer driver since it
was found at elevated levels in a number of cancers and cells containing elevated CK2 have a
selective advantage for oncogenesis (reviewed in (Ruzzene and Pinna, 2010)). CK2 is known to
phosphorylate p53 at serine 392 and this phosphorylation was found to enhance p53 tetramer
stability, increase DNA binding and transcriptional activity of p53 (Meek et al., 1990). In cancer
cells that have an elevated level of CK2, it is logical to think that CK2 is readily available to
phosphorylate p53 at serine 392 after nucleotide deficiencies, promoting DNA binding and
transcription, and in the case of PALA treatment, apoptosis. This concept can be extended to
inactive mutant forms of ATR or Chk1; treatment with HU would hypothetically drive cells to
apoptosis since the S-phase cell cycle checkpoint would not be intact, while normal surrounding
cells would reversibly arrest in S-phase.

Through sequencing of the cancer genome, the

knowledge of probable mutations within cancer types will be available, thus allowing for
chemotherapies to be designed according to the genetics of an individual cancer case,
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significantly improving the treatment of cancer. Therefore, the signaling pathways involved in
the cellular responses to HU and PALA need to be identified, as well as the proteins
phosphorylating p53, to better understand how inhibitors of nucleotide synthesis can be used in
the treatment of cancer. With the use of the TAP tagged p53 cell line generated during this
dissertation work, this may now be possible.
The p53 TAP tagged cell line can also be used to identify S-phase specific p53 binding
partners. A large part of the function of the S-phase checkpoint is to modulate homologous
recombination proteins to ensure DNA repair does not occur in times of replicative stress. With
the use of the TAP tag, new proteins can be identified which may have a high incidence of
mutations within human cancers. Cancers containing mutation in S-phase proteins would be
more sensitive to S-phase specific drugs since the checkpoint would not be intact. Constitutively
active mutants of pro-recombinogenic proteins would result in the S-phase checkpoint losing
control of DNA repair activity. If these cancer cells are treated with HU, or another S-phase
specific drug, apoptosis would be induced due to increased homologous recombination at a time
of genomic instability. The homologous recombination protein Rad51 has been implicated in
cancer. Decreased Rad51 expression was found in 30% of the investigated 179 breast cancer
cases and in sporadic invasive ductal breast cancer. In pancreatic adenocarcinoma, Rad51 was
found to be over expressed (reviewed in (Thacker, 2005)). Together with the finding that cells
containing a Rad51 mutant preventing phosphorylation by Chk1 are more sensitive to HU
treatment, suggests that targeted therapeutics in cancers containing Rad51 mutations is possible
(Sorensen et al., 2005). It is also likely that there are other proteins involved in the S-phase
checkpoint which still remain to be identified and with the use of the p53 TAP tagged cell line,
these

multi-protein

complexes

can
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be

isolated

and

identified.
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